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ABSTRACT
Protein Conformational Stability Enhancement Through
PEGylation and Macrocyclization
Qiang Xiao
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
PEGylation can improve the pharmacokinetic properties of protein therapeutics via decreasing
renal clearance and shielding the protein surface from proteases, antibody neutrailization, and
aggregation. Conformational stability enhancement can provide criteria for the identification of optimal
sites for PEGylation, but how PEG influence the noncovalent interactions from the surface of proteins
has not been well illustrated. Macrocyclization can effectively enhance the conformational stability of
small peptides and large proteins. Combination of PEG-based conformational stability enhancement and
macrocyclization-based conformational constraint has not been explored. Macrocycliziation has been
employed to stabilize protein tertiary structures, but there are no general guidelines for interhelical staple
to stabilize coiled-coil motifs of proteins.
Chapter 1 is an introduction to peptide stapling and macrocyclization of proteins. Chapter 2
describes our test of the hypothesis that PEG increases the conformational stability of proteins by
desolvating nearby salt bridges. In chapter 3, we explore the combination of PEG-based conformational
stability enhancement with macrocyclization on WW domain, and find that the most important criteria
for PEG stapling is ensuring the side chains cross-linked by PEG are distant in primary sequence but
close in tertiary structure. In chapter 4, we further apply this macrocyclization criteria to another βsheet-based protein, SH3 domain of the chicken Src protein, and to a disulfide-bonded parallel coiledcoil heterodimer derived from the yeast transcription factor GCN4. In chapter 5, we explore the
determinants of PEG-staple-based stabilization by changing the distance of the staple to the terminal
interhelical disulfide bond, varying the length of staple, exploring different solvent exposed positions for
stapling and employing heterochiral residues for stapling. We further apply the interhelical PEG staple
to a HER-2 affibody, and find that PEG-stapling increases the conformational stability and proteolytic
resistance of the stapled affibody relative to its non-stapled counterpart and to the native unmodified
affibody.

Keywords: PEGylation, macrocyclization, salt bridge desolvation, conformational stability, proteolytic
stability, interhelical staple, PEG staple, staple guidelines, protein therapeutics
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1. Conformational Constraint of Peptides and Proteins via Macrocyclization
1.1 Introduction
Protein-protein interactions (PPIs) play critical roles in signaling pathways that maintain the
normal cellular functions. Around 650,000 different types of PPIs are present in the human body;1
Modulating (i.e., stabilizing or inhibiting) these PPIs is an important goal in drug discovery for many
diseases.2 Protein-protein interaction interfaces (1500-3000Å2) are generally much larger and flatter than
the typical interface between a small molecule and its receptor (300-1000Å2)3, 4 and have many more
points of contact.5 Therefore, only a few PPIs have been amenable to modulation by small molecules,
usually with only moderate binding affinity.6, 7 Alternatively, peptides and proteins can modulate PPIs
with high binding affinity and selectively due to their potential to display functional groups with distinct
structural and electronic characteristics over a large surface area. Accordingly, interest in peptide/protein
drugs has experienced a surge over the past two decades, with many peptide/protein drugs approved or in
clinical development.8, 9 However, suboptimal pharmacokinetic properties have hindered the development
of peptide/protein drugs. Their limited proteolytic resistance and poor cell membrane permeability can
lead to short serum half-life and negligible oral bioavailability; in many cases, successful therapy requires
subcutaneous injection or intravenous infusion and frequent dosing regimens, which can decrease patient
compliance.9 The high immunogenicity of some protein therapeutics can cause life-threatening immune
responses.10 Additionally, many therapeutic proteins can aggregate during storage, transportation, and/or
administration to patients;11 even a small amount of protein aggregation can increase protein
immunogenicity, which may cause serious safety issues.12
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The conformational stability of a peptide or protein directly impacts its aggregation propensity,13,
14

immunogenicity,15-18 and resistance to proteolysis.19-24 Strategies that can improve peptide/protein

conformational stability could therefore increase proteolytic stability, and decrease aggregation propensity
and immunogenicity. These strategies include β-hairpin nucleation,25-32 N-glycosylation,33-35
PEGylation36-38 and macrocyclization. Macrocyclization can enhance peptide/protein conformational
stability by preorganizing an unfolded peptide into a conformation that resembles the folded or bound
state, thereby prepaying the energetic cost of folding or binding.39-42 In this chapter, we focus on how
macrocyclization affects peptide/proteins conformational stability in different secondary and tertiary
structural contexts, along with related properties including proteolytic resistance, target binding affinity,
and enzymatic activity under unnatural conditions. This will generally involve comparing the properties
of the cyclized products with their linear precursors; accordingly, we will not discuss the structural features
or biological functions of many naturally occurring cyclic peptides/proteins (e.g., cyclosporin,
vancomycin, etc.), which have been reviewed in detail elsewhere.43, 44 We will describe in detail the
macrocyclization strategy used in each example we consider, but we refer the reader to several excellent
reviews for a more comprehensive overview of the chemoselective ligation reactions available for
peptide/protein macrocyclization.44-46
1.2 Macrocyclization for Stabilizing Protein/Peptide Secondary Structure
1.2.1 Side-chain cross-linking on α-helices
Macrocyclization of α-helical peptides through side-chain crosslinking has also been called
peptide stapling. A canonical α-helix has 3.6 residues per turn, with the carbonyl oxygen of the i-position
residue engaged in a hydrogen bond with the amide proton of the i+4-position residue. Each turn of the
2

helix is 5.4 Å from the previous turn along the helical axis, such that the side-chain β carbons (Cβs) of the
i-, i+3-, and i+4- positions are ~6 Å apart. Similarly, the i- and i+7-position Cβ’s are ~11 Å apart; and the
i- and i+11-position Cβ’s are ~16 Å apart. These positions are located along the same face on the helix
(one, two, or three helical turns apart; Figure 1A), which provides optimal geometry for stapling. Taylor’s
group reported that three i-to-i+4 lactam bridges (Lys3-Glu7, Lys10-Glu14, and Lys17-Glu21; Figure
1B) within the peptide H-[KLKELKE]3-NH2 induces high α-helical content in the presence of 50%
trifluoroethanol (TFE), whereas the linear counterpart adopted a disordered conformation.47, 48 Although
the ability of lactam bridge to enhance the α-helicity is limited in this case (TFE was required to observe
increased helicity), this work was an important early proof of concept. With the same lactam-based
stapling strategy, Rosenblatt and coworkers later reported that cyclization via an i-to-i+4 lactam bridge
(Lys13-Asp17) increased the potency of parathyroid hormone related protein (7-34) by 5-10 times relative
to its linear counterpart.49 The limitation of this lactam stapling approach is that orthogonal protecting
groups are required and the modified proteins have to be prepared by solid phase peptide synthesis, which
are not realistic for large proteins.
Schultz and coworkers50 used molecular modeling to explore the possibility of introducing a
disulfide bridge between the i- and i+7-positions of an α-helix. Presumably the distance between these
positions within an α-helix (~11 Å) is too large to be spanned by two Cys residues; accordingly, they
turned to the ε-thiol derivative of Lys (i.e., 2-amino-6-mercaptohexanoic acid, abbreviated as thioLys),
which is much longer than Cys (Figure 1C). Interestingly, molecular modeling suggested that
compatibility of an i-to-i+7 intramolecular disulfide bridge with α-helical secondary structure would
depend on the stereochemistry of the thioLys residues at the i- and i+7 positions. Within a right-handed
α-helix, side chains with L-stereochemistry are oriented toward the N-terminus of the helix, whereas side
3

chains with D-stereochemistry are oriented toward the C-terminus. Presumably the orientation of the iposition

D-thioLys

toward the i+7-position

L-thioLys

would facilitate disulfide formation without

disrupting the α-helix. Experimental observations verified this prediction: an eight-residue peptide with a
heterochiral disulfide bridge between an i-position

D-thioLys

and an i+7-position

L-thioLys

is

substantially more helical than its reduced acyclic counterpart, even at 60 °C. In contrast, the diastereomer
with the L,L-disulfide is only marginally more helical than its linear counterpart, whereas the diastereomer
with the L,D-disulfide is not α-helical at all. However, the application of heterochiral bridge is limited to
peptides that can be synthesized on solid phase, since the current method for incorporating unnatural
amino acids with in proteins do not tolerate D-amino acids.
Similarly, Spatola and co-workers used molecular dynamic simulations to calculate the distances
between sulfur atoms of two D- vs. L-Cys residues with i-to-i+3 spacing in an α-helix, and found the
distance is shortest (3.8 Å) when D-Cys is located at i position and L-Cys is located at i+3 position
(compared to the D/D, L/L, L/D combinations). Accordingly, they placed an i-position D-Cys and an i+3position L-Cys (Figure 1D) within an estrogen receptor modulator analog; the resulting stapled peptide
H-Lys-c(D-Cys-Ile-Leu-Cys)-Arg-Leu-Leu-Gln-NH2 binds to estrogen receptor α ~9 times more tightly
than an i-to-i+4-lactam-bridged variant.51 Disulfide-based stapling is easier to do than lactam-based
stapling on unprotected peptides owing to the lower frequency of Cys than Lys, Glu, and Asp in peptides
and proteins and to the high chemoselectivity of disulfide formation. However, disulfide-stapled peptides
are sensitive to the reducing environment of cytosol, whichs limits their application to extracellular targets.
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Figure 1. A) Positions on the same face of α-helix structure B) Lactam bridge
between Lys and Glu/Asp with i-to-i+4-spacing; C) Disulfide bond formed
by D- and L-ThioLys with i-to-i+7-spacing; D) Disulfide bond formed by Dand L-Cys with i-to-i+3-spacing.

To explore the side-chain crosslinking strategies based on orthogonal chemistry, Blackwell and
Grubbs successfully carried out an olefin metathesis reaction between two O-allyl serine/homoserine
(Ser/Hse) residues (Figure 2A) with i-to-i+4-spacing on a well folded short helical peptide Boc-Val-X(i)Leu-Aib-V-X(i+4)-Leu-OMe. CD spectra suggested that the unstapled peptide already adopted a helical
conformation (presumably due to the α,α-disubustituted Aib residue); therefore no obvious α-helicity
enhancement was observed upon stapling.52 However, this proof-of-principle report demonstrated the
compatibility of metathesis-based hydrocarbon stapling with α-helical secondary structure, and led to the
innovations in hydrocarbon stapling described below.
Verdine and colleagues adapted this metathesis-based stapling approach by using amino acids with
side-chain terminal olefins that are connected to the backbone via a hydrocarbon tether (Figure 2B). They
varied α-carbon substitution and stereochemistry; hydrocarbon tether length; and staple spacing and
assessed the impact of the resulting staples on α-helicity. Optimal staples featured α-methyl, α-alkyl
disubstituted amino acids with i-to-i+7 spacing; R configuration of the i-position vs. S configuration of
5

the i+4- or i+7-position; and tether lengths such that the final staple comprises eleven carbons. An αhelical peptide stapled via this method was 44% more helical and 41 times more resistant to trypsin
digestion than its non-stapled counterpart.53 These design principles take advantage of the known helixinducing properties of α,α-disubstituted amino acids and the heterochiral staples discovered previously.
Verdine and coworkers applied this approach to an α-helical peptide derived from the BID BH3 domain,
which can bind to BCL-2, a key protein in the cellular apoptosis pathway. The hydrocarbon-stapled BID
BH3 variant was nine times more resistant to proteolysis, bound BCL-2 seven times stronger, and had
better cellular uptake than its non-stapled counterpart.54, 55 Subsequent work found that hydrocarbon
stapling better increases peptide cellular uptake when the staple is placed at boundary between polar and
non-polar residues on the surface of modified peptide, though the mechanistic origin of this increased cell
membrane permeability still needs to be further explored.56 Owing to its ability to enhance helicity as well
as potential cell membrane permeability, hydrocarbon stapling is currently the most investigated
macrocyclization strategy in the context of α-helical peptides; currently, a p53-derived peptide with
hydrocarbon staple is in clinic trails.57

Figure 2. Olefin-metathesis based crosslinkers: A) O-allyl serine crosslinked bridge
between Ser/Hse with i-to-i+4-spacing; B) All hydrocarbon staple crossing positions
with i-to-i+4-or i-to-i+7-spacing.

Thiol alkylation chemistry takes advantage of the high nucleophilicity and chemoselectivity of the
Cys thiol for specific electrophiles; the resulting thioethers are stable to the the reducing environment of
6

the cytosol. For example, Dawson’s group used thiol alkylation to develop a more convenient way of
installing i-to-i+3-or i-to-i+4 lactam bridges (Figure 3), by reacting cysteine with an α-bromoamide group
in the presence of 6M GdnHCl where the peptide is cleaved and deprotected.58 Qualitative analysis of the
CD spectrum indicated this i-to-i+3-thioether-containing lactam bridge enhanced the α-helicity of a
modified gp41 epitope H-Asn-Trp-Phe-c(Cys-Ile-Thr-Orn)-Trp-Leu-Trp-Lys-Lys-Lys-Lys-NH2 [c(CysIle-Thr-Orn) indicates the presence of a bridge linking the sidechains of Cys and Ornithine (Orn)].
Moreover, gp41-specific antibody 4E10 thioether cyclized gp41 and gp41with four-fold greater affinity
than its non-cyclized counterpart.59 Compared with conventional lactam bridges, this thioether-containing
lactam bridge formation does not need orthogonal side chain protection and on-resin cyclization.

Figure 3. Thiol alkylation between residues with i-to-i+3-or i-to-i+4-spacing.

Woolley and coworkers used a two-component stapling strategy based on Cys thiol alkylation.60
They used an azobenzene derivative to crosslink two cysteines (with i-to-i+7-60 or i-to-i+11-61 spacing)
within an α-helical peptide Ac-Glu-Ala-c(Cys-Ala-Arg-Val-Aib-Ala-Ala-Cys)-Glu-Ala-Ala-Ala-ArgGln-NH2 (Figure 4A). Azobenzene readily isomerizes from trans to cis under UV light;
photoisomerization to the cis stereoisomer increases the α-helicity by a factor of 2-4 in water. Similarly,
Lin’s group used a biaryl bis-methylene bromide (Figure 4B) to crosslink two cysteines at i- and i+7positions within p53. The rigid biarylmethylene-crosslinked p53 derived H-Leu-Thr-Phe-c(D-Cys-His-

7

Tyr-Trp-Ala-Gln-Leu-D-Cys)-Ser-NH2 is 20% more α-helical and 70% more membrane permeable than
its non-stapled counterpart and binds to MDM2/MDMX with three-fold greater affinity.62
Chou and colleagues successfully carried out a thiol-ene coupling reaction between a diene and
two cysteine residues with i-to-i+4 or i-to-i+7 spacing within p53 (Figure 4C); qualitative analysis of the
CD spectrum indicated that staples with i-to-i+7 spacing and comprising 8-9 carbons led to enhanced
helicity. A stapled p53 variant generated via their approach, Ac-Gln-Ser-Gln-Gln-Thr-Phe-c(Cys-AsnLeu-Trp-Arg-Leu-Leu-Cys)-Gln-Asn-NH2, blocks the p53-MDM2 interaction and kills p53 wild-type
colorectal carcinoma HCT-116 cells, whereas the unstapled counterpart did not adopt an α-helical
structure and was unable to block the interaction.63 Their approach introduced a more convenient way of
incorporating hydrocarbon chain as side-chain crosslinker compared to olefin metathesis-based stapling.

8

Figure 4. Cys-based two-component stapling strategies: A) Photoisomerizable azobenzene
crosslinker crossing residues with i-to-i+7-or i-to-i+11-spacing; B) Rigid biarylmethylene
crosslinker crossing residues with i-to-i+4-or i-to-i+7-spacing; C) Thiol-ene reaction based
hydrocarbon staple between Cys with i-to-i+4-or i-to-i+7-spacing; D) m-Xylene-based
crosslinker between residues with i-to-i+4-spacing; E) Perfluoroaryl-cysteine based
crosslinker between positions with i-to-i+4-spacing.

DeGrado and Greenbaum rigidify an unstructured peptide into an α-helical conformation by
stapling two Cys residues with i-to-i+4 spacing; their goal was to develope a peptide inhibitor of the
protease calpain. They screened 24 different crosslinkers including alkyl and allyl bromides, alkyl iodides,
benzyl bromides, maleimides, and a diflurobenzene. Analysis of the CD spectra of the stapled peptides
revealed that structurally rigid cross-linkers, especially the m-xylene-based crosslinker (Figure 4D), were
best at stabilizing α-helices. The m-xylene cross-linked variant Ac-Ile-Pro-Pro-Lys-Tyr-c(Cys-Glu-LeuLeu-Cys)-NH2 was also a better inhibitor of calpain than parent peptide cathepsin L by a factor of four.64
Pentelute and co-workers used a perfluoroaryl-cysteine SNAr reaction to selectively crosslink two
Cys residues with i-to-i+4 spacing within an unprotected peptide (Figure 4E). The stapled peptide H-IleThr-Phe-c(Cys-Asp-Leu-Leu-Cys)-Tyr-Tyr-Gly-Lys-Lys-Lys-NH2 was 37% more α-helical than its
9

unstapled counterpart and also benefitted from increased cell permeability and proteolytic stability. This
SNAr reaction based stapling strategy can selectively crosslink Cys residues in the presence of other
nucleophilic side chains.65 More interestingly, an α-helical BIM BH3 peptide stapled via their approach
has increased penetration of the blood-brain barrier in a mouse model.66
Inouye and colleagues used a similar two-component stapling strategy for helical peptides by
exploiting nucleophilicity of amines from Ornithine(Orn) residues instead of thiols from Cys side chains.
They reacted acetylenic crosslinking agents (Figure 5) with Orn sidechains with i-to- i+7 spacing from
DNA-binding protein HNF-3γ derived peptide TG-Ala-Ala-Gln-Arg-Ala-c(Orn-Asn-Ser-Ala-Arg-HisOrn)-Ser-Phe-Asn-Gly-Ala-Arg-Arg-Arg-Ala-NH2, from which TG (Tokyo Green derivative) is attached
for the purpose of fluorescence resonance energy transfer analysis. The crosslinked peptide showed 50%
greater helicity, 142 times enhanced DNA binding affinity, and four-fold greater half-life in the presence
of trypsin than its non-stapled counterpart.67, 68 The limitation of this approach is the crosslinking agents
is not selective for Orn residues over Lys or for one Orn residue vs. another.

Figure 5. Lysine based two-component stapling strategy with rigid acetylenic linker crosslinking two Orn with
i-to-i+4-or i-to-i+7-spacing.

The widely used copper-catalyzed Alkyne-Azide Cycloaddition (CuAAC)69 has also been applied
to peptide side-chain crosslinking. Meldal and colleagues reported the first cyclization of a peptide on
resin via CuAAC, though the secondary structure of the cyclized peptide was not characterized.70 Chorev
10

and co-workers crosslinked Nle(ε-N3) (L-norleucine derivative bearing azido group) and Lpropargylglycine (Pra) with i-to-i+4-spacing from parathyroid hormone-related peptide Ac-Lys-GlyNle(ε-N3)-Ser-Ile-Gln-Pra-Leu-Arg-NH2 via CuAAC (Figure 6A).71 CD spectra indicated that CuAACbased macrocyclization can increase α-helicity by 50% in water/hexafluoroacetone (50:50, v/v). NMR
data revealed that the conformation of CuAAC-stapled peptide containing a triazolyl bridge resembles
one with a conventional Lys-Glu lactam linkage, which is consistent with other observations that the
triazole is a reasonable amide isostere. To further optimize this stapling strategy, Wang and co-workers72
varied the length and stereochemistry for azido and alkynyl residues necessary for stapling BCL9 helices.
They found that a BCL9 variant with a triazole staple between an i-position L-Nle(ε-N3) and an i+4position D-propargylglycine is more helical (90% vs. 45%) and binds β-catenin 38 times more tightly than
its linear counterpart. The L/D stereochemistry of this i-to-i+4 triazole staple is opposite of the optimal D/L
stereochemistry described above for disulfide and hydrocarbon staples. However, staple stereochemistry
appears not to matter as much for BCL9 as for the other helical peptides described above: the variant with
the L/L i-to-i+4 triazole staple is still more helical (66% vs. 44%) and binds β-catenin 4.2 times more
tightly than its linear counterpart. Interestingly, a BCL9 variant with two triazole staples did not have
substantially improved binding affinity for β-catenin than the variant with one triazole staple, though it
was slightly more helical. The double-stapled variant was much more stable in cell media than the linear
parent BCL9, though the authors did not assess the stability of the singly stapled variant in cell media.
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Figure 6. Click-chemistry based crosslinkers: A) Triazole bridge formed between Pra and
Nle(ε-N3) with i-to-i+4-spacing; B) CuAAC-based two component stapling strategy between
two Nle(ε-N3) with i-to-i+7-spacing; C) SPAAC-based two-component stapling strategy
between two Nle(ε-N3) with i-to-i+4-spacing.

Through the use of two tandem CuAAC reactions, Spring’s team reported the stapling of two
Nle(ε-N3) with i-to-i+7-spacing with a 1,3-dialkynyl benzene linker within a peptide derived from p53:
Ac-Glu-Thr-Phe-Nle(ε-N3)-Asp-Leu-Trp-Arg-Leu-Leu- Nle(ε-N3)-Glu-Asp-NH2 (Figure 6B).73 The
resulting stapled p53 variant via this method showed 35% increased α-helicity and up to 66 times greater
MDM2 binding affinity relative to its non-stapled counterpart. They also showed that 79% of stapled p53
remained intact after 30h incubation in mouse serum at 37 ºC vs. only 18% for the non-stapled variant.
Interestingly, Spring and coworkers also introduced an amine or a carboxylate at the 5-position of the
benzene ring, which allows for incorporation of various functional motifs (e.g. fluorescent labels, polyArg
tags, etc.) into the linker via amide-bond-forming chemistry prior to the stapling reaction. The stapling
reaction then becomes a labelling reaction as well. Spring and co-workers then combined this twocomponent strategy with the strain-promoted alkyne-azide cycloaddition (SPAAC) in the context of the
p53 peptide. They showed that SPAAC reaction can be used for in situ stapling in cell culture medium
12

through reacting two azido groups from p53 derived peptide with a constrained di-alkyne molecule
(Figure 6C). The top-ranked stapled peptide showed significantly improved proteolytic stability in a
chymotrypsin assay and low nanomolar binding affinity to MDM2.74

Figure 7. Reversible crosslinkers: A) Cyclic oxime bridge crossing positions
with i-to-i+4-spacing; B) Thiol-labile maleimide bridge crossing two Cys/HCy
with i-to-i+4-spacing.

Reversible stapling strategies can stabilize peptides upon stapling, and release the constraint under
certain conditions, which allows for dynamic control of peptide folding and potentially more facile
delivery of a peptide-based reagent to the cell. Horne and colleagues reported side-chain crosslinking via
oxime formation (Figure 7A) with i-to-i+3-or i-to-i+4-spacing on a short helical peptide Ac-Tyr-Glu-AlaAla-Xaa-Lys-Glu-Ala-Zaa-Ala-Lys-Glu-Ala-Ala-Ala-Lys-Ala-NH2 (Xaa and Zaa represents the
unnatural amino acids for oxime formation as shown in Figure 7A): the melting temperature for oxime
crosslinked peptide is 15 ºC higher than that of its non-stapled counterpart.75 One interesting aspect of this
approach is that the resulting cyclic oxime is capable of dynamic covalent exchange with an aminooxyfunctionalized small molecule, allowing for dynamically control of peptide folding via release of the
conformational constraint. Wilson and colleagues used dibromomaleimide to crosslink two Cys or two
13

homocysteines (HCy) with i-to-i+4-spacing on a Bcl-2 family peptide BID, Ac-Glu-Asp-Ile-Ile-Arg-AsnIle-Ala-Arg-His-Leu-Ala-Cys/HCy-Val-Gly-Asp-Cys/HCy-Asn-Asp-Arg-Arg-Ser-Ile-Trp-NH2. (Figure
7B). Comparing to the non-stapled counterpart, the stapled BID peptide showed 14% α-helicity increase
and significantly superior inhibition of BAK/Bcl-xL. The constraint from staple can then be removed by
replacement of maleimide with excess amount of thiol.76

Figure 8. Glaser reaction based stapling crossing two propargyl serine with i-to-i+4-spacing.

Recently, additional organic reactions have been explored for side chain cross-linking on αhelices. Dawson and colleagues reported on-resin peptide macrocyclization via the Glaser reaction, which
is carried out between two propargyl serine (PrS) residues with i-to-i+4, i-to-i+5, i-to-i+6, or i-to-i+7
spacing within an α-helical peptide derived from Bcl-9 (Figure 8). Among the resulting macrocyclic
diynes, the i-to-i+4 and i-to-i+7 staples enhanced the α-helicity by up to 56% whereas the i-to-i+5 and ito-i+6 staples ablated α-helicity.77 The limitation of this method is that the intensive synthetic effort might
be needed to vary the length of the alkyne-bearing side chains to enable optimal conformational constraint
in different structural contexts.
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Figure 9. Ugi reaction-based two-component stapling between Lys and Glu with i-to-i+4-spacing.

Rivera and colleagues successfully installed a lactam bridge between Lys and Glu with i-to-i+4
spacing wthin peptide Ac-Ala-Leu-Lys-Ala-(Lys)i-Leu-Trp-Ala-(Glu)i+4-Leu-Lys-Ala-NH2 via on-resin
Ugi reaction. Their Ugi multicomponent stapling protocol allows for the incorporation of lipids, sugars,
polyethylene glycol, fluorescent labels and reactive handles into the lactam linkage (Figure 9).
Interestingly, the identity of the N-functionality introduced by the isocyanide has an impact on the
conformation and stability of the stapled peptide. CD spectra suggest that a peptide adopts an α-helical
conformation when stapled with a lipid-containing isocyanide, but adopts a 310-helical conformation when
stapled with a carboxylate-containing isocyanide. In contrast, the stapled peptide has decreased helical
content when the isocyanide bears peraccetylated D-glucose or PEG, though no detailed explanation for
this observation was given.78 However, the limited extent of helicity enhancement gained from the Ugi
staple could be an obstacle for the further application of this approach.

Figure 10. Petasis reaction based stapling between two Nε-MeLys with i-to-i+4- or i-to-i+7-spacing.
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The Rivera group reported another novel multicomponent peptide stapling strategy based on the
Petasis reaction between carbonyl and boronic acid components and a peptide amino group (e.g. the Nterminal amine or the Lys or MeLys ε-amines). Two MeLys side chains with i-to-i+7-spacing within the
peptide Ac-Leu-MeLys-Phe-Gln-Ala-Leu-Ala-Tyr-MeLys-Ala-NH2 positions can be bridged by tandem
Petasis reactions with p-diphenylene bis-boronic acids and dihydroxyacetone (Figure 10).79 Qualitive
analysis of CD spectrum indicated the cyclized peptide is more helical than its non-stapled counterpart.
This Petasis stapling approach is capable of installing rigid aryl tethers and also allows for further
functionalization via the diversity arising from the carbonyl component. The resulting alkylated amines
should still be charged at physiological pH such that stapling via the Petasis approach does not change the
overall charge of the modified peptide relative to its non-stapled precursor.

Figure 11. Diels-Alder reaction based stapling crossing residues with i-to-i+4- or i-to-i+7-spacing.

Moellering and colleagues80 reported crosslinking via Diels-Alder [4+2] cycloaddition (DAC)
reaction in aqueous phase or on solid-phase between a diene and a dienophile with i-to-i+4- or i-to-i+7spacing within a peptide derived from the coactivator protein SRC2 (Figure 11). This led to higher αhelicity for the stapled endo isomer and four-times greater target binding affinity compared to the stapled
exo adduct isomer. One compelling aspect of this DAC stapling strategy is that the macrocyclization
reaction happens spontaneously, which is also essentially “reagentless”. However, the structurally
complicated non-natural amino acids for DAC might limit its further application to large proteins.
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1.2.2 Backbone cross-linking on α-helixes
In α-helices, hydrogen bonds between mainchain-carbonyl groups and hydrogens from mainchainamide groups with i-to-i+4-spacing stabilize and nucleate the helical structures. By replacing the Nterminal main-chain hydrogen bond with a covalent hydrazone linkage, Satterthwait and colleagues
showed that backbone cyclization at the N-terminus (Figure 12A) in place of the original hydrogen bond
is sufficient to convert a short disordered peptide Ac-Gly-Leu-Ala-Gly-Ala-Glu-Ala-Ala-Lys-Ala-NH2 to
a full-length α-helix in water.81 Arora’s group further optimized this strategy by applying the olefin
metathesis reaction to N-terminal backbone crosslinking, which yields a more stable carbon-carbon bond
(Figure 12B) to mimic the hydrogen bond at the N-terminus. Analysis of CD spectra indicated that the
peptide c(Gly-Glu-Ala-Ala)-Ala-Ala-Glu-Ala-OMe constrained by this metathesis-based hydrogen bond
surrogate (HBS) approach adopted an α-helical conformation, whereas no helical character was observed
for its linear counterpart.82 Arora’s group further applied this HBS approach to several biologically
relevant peptides, such as Bak BH3 domain derived peptide;83 gp41-derived peptide;84 hypoxia-inducible
factor 1α derived peptide;85 and p53 derived peptide.86

Figure 12. N-terminal hydrogen bond surrogates (HBS): A) Hydrazone based HBS at the N-terminus
of α-helix; B) Olefin-matathesis based HBS at the N-terminus of α-helix.

1.2.3 Side-chain cross-linking on β-sheets
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Similar macrocyclization strategies have been applied to the β-sheet peptides and proteins.
Cowburn and colleagues cyclized a FcεRI α-chain-derived peptide via disulfide bond formation between
two Cys at the N- and C-termini. NMR analysis indicated the disulfide bond cyclized peptide adopted a
well-defined antiparallel β-hairpin structure.87 Gellman and colleagues engineered a disulfide bond at the
C-termini of a designed parallel β-hairpin whose sequence is shown in Figure 13. NMR analysis indicated
the interstrand disulfide bond can stabilize parallel β-sheet peptide by 1.1 kcal/mol.88

Figure 13. Macrocyclization of parallel β-hairpin via interstrand sidechain disulfide bond formation.

D’Andrea and colleagues applied CuAAC-based triazole stapling to an antiparallel β-hairpin
peptide, whose sequence is shown in Figure 14. Analysis of CD spectra suggested that the short peptide
adopted the β-hairpin conformation to the most extent when m=1, n=2 (Figure 14).89 Waters and
colleagues further investigated the positional effect of CuAAC-based triazole stapling for β-hairpin
peptide conformation enhancement. They found that the triazole bridge can effectively “lock” the peptides
that contain either type I’ turn or type II’ turn to a β-hairpin structure. They tried to place the triazole
bridge at hydrogen bonded sites, non-hydrogen bonded sites, or the peptide termini, and found that the
stapled β-hairpins showed enhanced thermodynamic stability and proteolytic stability compared to their
non-stapled counterpart, regardless of where the triazole bridge is placed.90
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Figure 14. Macrocyclization of β-hairpin via interstrand triazole bridge.

Chapter 3 describes our lab’s work in RCM-based macrocyclization of a β-sheet protein WW via
combing conformational constraint with PEG-based desolvation effect.
1.2.4 Mainchain macrocyclization of β-hairpins
The development of mainchain macrocyclization of β-hairpins largely relied on the development
of β-hairpin nucleators, since either one or two of the β-turn nucleators were placed at either one or both
ends of hairpin to make a macrocycle. Extensive study has revealed a number of templates that are strong
nucleators of β-hairpin structure (Figure 15). These include dipeptide template D -Pro-L-Pro,29, 30, 91-93 D Pro-Gly,31, 94-96 Aib-Gly,97 Asn-Gly95 and small rigid cyclic molecules25-28, 98, 99 for antiparallel β-hairpins;
and D -Pro-DADME and , cis-CHDA-Gly for parallel β-hairpins.100, 101
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Figure 15. β-Turn nucleators including dipeptide templates and small-molecule templates.

Robinson and colleagues employed D-Pro-L-Pro template for β-hairpin macrocyclization to mimic
short protein epitopes that play critical roles at the interfaces of PPIs. They grafted a twelve-residue βhairpin loop from the extracellular interferon γ receptor onto the D-Pro-L-Pro template. NMR analysis
suggests that the resulting 14-residue cyclic peptide (Figure 16) structurally mimics corresponding
residues from the original antiparallel β-strands within the interferon γ receptor.102 Robinson’s group also
employed the heterochiral diproline-templated cyclic β-hairpins to mimic epitopes featured as helices that
are involved in protein-protein and protein-nucleic acid interactions.103, 104 For example, they showed that
a short cyclic eight-residue β-hairpin with the diproline template can mimic a p53 derived helix to bind to
HDM2,105 with KD value ~40 nM after optimization.106
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Figure 16. D-Pro-L-Pro dipeptide templated head-to-tail macrocyclization of IFNγR-derived β-turn.

Gellman and collegues evaluated the β-turn nucleators that promote parallel β-sheet formation in
the context of backbone cyclization. Their previous research showed that cis-1,2-cyclohexanedicarboxylic
acid and glycine (cis-CHDA-Gly) promotes the formation of parallel β-sheet when attached at the Ntermini of two β-strands, and that

D-proline

and 1,2-diamino-1,1-dimethylethane (D-Pro-DADME)

promote parallel β-sheet formation when attahced at the C-termini.107-109 They placed those two nucleators
at both the N- and C-termini of two parallel β-strands, to form a cyclic β-hairpin (Figure 17). They
investigated how those β-turn nucleators would promote the formoation of cyclic β-hairpin by abolishing
the templating effect from the one β-turn nucleator at a time and then in combination. They found only
one of the β-turn nucleators is required to enforce a high level of parallel β-sheet folding in a cyclic
content.110, 111

Figure 17. D-Pro-DADME and cis-CHDA-Gly templated head-to-head and tail-to-tail macrocyclization β-hairpin.
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Nowick and colleagues used macrocyclic β-hairpin peptides to mimic protein quaternary structure
through intermolecular β-sheet interactions.112 The cyclic peptide contains an extended heptapeptide βstrand, an unnatural β-strand mimic called Hao,113,

114

and two δ-linked ornithine (Orn) as β-turn

nucleators (Figure 18).32 NMR studies and analytical ultracentrifugation studies indicated the cyclic βhairpin peptide oligomerized as a tetramer in aqueous solution.112 They took advantage of the
oligomerization property of this cyclic β-sheet peptide by grafting a short tau protein (Tau)-derived
peptide VQIVY onto the cyclic peptide. Tau is a β-sheet rich protein that aggregates and forms
neurofibrillary tangles in patients with Alzheimer Disease (AD); Tau-derived peptide Ac-VQIVYK-NH2
(AcPHF6) aggregates in solution via β-sheet interactions. The cyclic β-sheet peptide mimic carrying the
VQIVY motif showed weak inhibition of the growth of AcPHF6 β-sheet aggregates, presumably by
capping elongating fibrils.115,

116

Amyloid-β (Aβ) also plays essential role in AD by forming Aβ

oligomers, which further form Aβ fibrils and plaques in AD patients. And yet the structures of smaller Aβ
oligomers are not well characterized. Nowick grafted the Aβ15-23 nonapeptide into their cyclic β-sheet
mimic, which stabilizes smaller oligomers and facilitates structural elucidation via X-ray crystallography.
The crystallographic structures of those cyclic Aβ15-23 -containing β-sheet peptide oligomers as well as the
toxicity of those oligomers towards neuronally derived cells provide some insights in understanding the
molecular basis of amyloid diseases.117-120
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Figure 18. Orn templated macrocyclization of β-hairpin with Tau-derived peptide VQIVY grafted.

Recently, Arora’s group reported that an antiparallel β-hairpin can be stabilized via
macrocyclization with a hydrogen bond surrogate (HBS). They replaced the interstrand hydrogen bond at
the open end of the hairpin with a metathesis-based staple (Figure 19). Qualitative analysis of CD spectra
suggested that the cyclized β-hairpin had more β-sheet character than its non-cyclized counterpart and
twenty-fold greater resistance to proteinase K.121 Macrocyclization via this HBS approach introduces
stabilizing linkage as replacement of interior hydrogen bond, while retaining all side chains for potential
function. However, the flexible nature of their HBS might limit the extent of conformational enhancement
from this macrocyclization approach.

Figure 19. Head-to-tail macrocyclization of β-hairpin with olefin-metathesis
based crosslinker as hydrogen bond surrogate.

1.3 Application of macrocyclization to stabilize tertiary structure
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Protein stabilization against thermal and chemical denaturation has been presented as a longstanding goal in enzyme design and engineering over the past few decades. Especially the development
of directed evolution122 and rational protein design by computation,123,

124

largely facilitated the

development of proteins with high thermal and chemical stability. Muir and colleagues reported the
chemical synthesis of cyclic WW domain of human Yes kinase-associated protein (YAP) via a
intramolecular native chemical ligation (NCL), invented by Kent and colleagues.125 They showed that the
rate of backbone cyclization via NCL is related to the folded state of the protein.126 They further cyclized
the N-terminal SH3 domain from the c-Crk adaptor protein via NCL and showed the cyclic SH3 had 7fold higher ligand binding affinity compared to its non-cyclized counterpart.127 The limitation of this headto-tail cyclization is the dependence on the close proximity of C- and N-termini of proteins; however,
approximately 50% of single-domain proteins in the PDB have C- and N-terminal structural elements
within 5 Å.128
Other than intramolecular NCL for backbone cyclization of proteins, natural enzymes can also
facilitate the backbone cyclization of proteins. Tam and colleagues identified that butelase 1 as a ligase
can macrocyclize proteins ranging in sizes from 26 to >200 residues. They cyclized green fluorescence
protein (GFP), interleukin-1 receptor antagonist (IL-1Ra), and human growth hormone (somatropin) with
butelase 1, and showed the cyclized IL-1Ra had similar inhibitory activities on IL-1β induced ICAM-1
expression compared to its non-cyclized counterpart but the melting temperature of the cyclized variant is
4-degree higher than its non-cyclized counterpart.129 The limitation of this butelase 1-based cyclization is
the requirement of tripeptide motif Asn/Asp-His-Val from the C-terminus and an N-terminal Gly or GlyIle for recognition and ligation. Ploegh and colleagues reported cyclization of Cre recombinase, a
derivative of GFP, and ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCHL3) with Sortase A,
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another ligase from Staphylococcus aureus. The limitation of this Sortase A-based protein
macrocyclization is the requirement for the N-terminal pentapeptide LPXTG as sorting signal and Gly at
the C-terminus.130 Another limitation is that the protein has to be long enough for Sortase A to cyclize.
With short peptides, Sortase A-mediated intermolecular ligation happens first, followed by intramolecular
cyclization.131
Howarth and colleagues reported macrocyclization of β-lactamase by lactam formation between
an Asp side chain from a short peptide called SpyTag and a Lys from SpyTag’s protein partner
SpyCatcher, which were fused at the N-terminus and C-terminus of the β-lactamase respectively. They
showed that the cyclic β-lactamase is soluble after heating at 100 ºC, and the catalytic activity can be
restored after cooling; in contrast the non-cyclic counterpart aggregates above 37 ºC. The distinguishing
aspect of this macrocyclization approach is that the lactam formation between the two partners occurs
spontaneously.132 The limitation is also obvious, which is the N- and C-terminal fusion of those SpyTag
and SpyCatcher, respectively. Another limitation of this approach is that its impact on conformational
stability is not well-characterized: elastin-like peptides can be cyclized successfully with the
SpyTag/SpyCatcher tags, but no functional effect of cyclization was established.133
Schultz and colleagues used amber suppression to randomly incorporate a series of tyrosine
derivatives with para-substituted aliphatic thiols that can form extended disulfide bond with Cys on the
surface of a truncated β-lactamase (Figure 20A). They used growth-based selection of a library of
truncated β-lactamase mutants under non-permissive temperatures to identify a mutant β-lactamase with
an extended disulfide bond that is 9 ºC more stable than the wild type enzyme.134 The advantage of this
approach is the thiol-containing tyrosine derivatives can form a disulfide bond across longer distances
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than can the natural Cys-Cys disulfides; this allows for constraint of residues that are far away from each
other. One obvious limitation of this approach is that the thiol-containing Tyr derivative may cause
disulfide scrambling, complicating the folding process. Disulfides are also not stable to reducing
environment. Finally, random incorporation of thiol-containing Tyr derivative combining with conditional
screening is quite labor intensive. Guidelines for the selection of sites for crosslinking are needed to
improve this approach.

Figure 20. A) Genetically encoded tyrosine derivatives with para-substituted aliphatic thiols
forming prolonged disulfide bond with natural cysteines on the surface of truncated β-lactamase
(PDB code: 1fqg). B) Genetically encoded O-2-bromoethyl tyrosine forming thioether with
natural cysteines on the surface of myoglobin-derived biocatalyst (PDB code: 1jp9).

Fasan and colleagues reported a similar approach for protein cyclization, but with the assistance
of computation. Instead of incorporating of a thiol-containing Tyr derivative to form disulfide with natural
Cys, they used O-2-bromoethyl Tyr (O2beY) to form a thioether with Cys (Figure 20B). Among the
calculated optimal sites for stapling, one myoglobin derivative with both G5O2beY-D126C and
H36ObeY-E109C stapled by their approach is 18 ºC more stable than the non-crosslinked counterpart,
and tolerates chemical denaturant [∆Cm (GndHCl) = 0.53 M] and high concentrations of organic
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cosolvents.135 The limitation of this approach is that not all the calculated optimal sites turned out to be
actual stabilizing sites for crosslinking.

Figure 21. A) Novel CovCore topology enabled by 3 cysteines cross-link with trielectrophile (PDB code: 5v2g).
B) Bicyclic Sortase A and Bicyclic transcriptional coactivator domain KIX via flexible trielectophile cross-link
with cysteines.

Baker and DeGrado designed a bicyclic protein (termed the CovCore) with predictable and welldefined tertiary fold by de novo computation (Figure 21A). An interesting aspect of this approach is that
the folding of the designed CovCore is enabled by constraint from tris-electrophile-based covalent linkage,
instead of hydrophobic core formation for natural protein folding.136 Analogously, Grossmann and
colleagues designed a bicyclic version of Staphylococcus aureus Sortase A and transcriptional coactivator
domain KIX (Figure 21B) by a tris-electrophile reacting with three surface-exposed Cys on the surface
of modified proteins. The resulting bicyclic Sortase A showed increased tolerance towards thermal and
chemical denaturation compared to the non-cyclized counterpart and efficient enzymatic activity under
denaturing conditions. The resulting bicyclic KIX domain is 24 ºC more stable than its non-cyclic
counterpart.137
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Figure 22. Thioether crosslinkers between loops and helices termini of albumin-binding domain (PDB code: 1gjt).

Karlstrom and colleagues applied macrocyclization to albumin-binding domain (ABD), derived
from streptococcal protein G, via thioether formation between Cys and chloroacetyl group that was
attached to the side chain of Lys (CALys) (Figure 22). Different from the macrocyclization of myoglobin
derivative by Fasan and coworkers, as mentioned above, Karlstrom incorporated the CALys into the
sequence of ABD by chemical synthesis, and the sites for crosslinking are arbitrarily chosen between the
ends of helices and loops that connect the adjacent two helices. The crosslinked ABD by their approach
is 5 ºC more stable, 17 times more resistant to pepsin digesting compared to its non-crosslinked
counterpart.138

Figure 23. Triazole based interhelical crosslinker enable the formation of: A) short
helical dimer; B) short helical trimer as coiled-coil mimics.
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Macrocyclization has also been applied for the development of small protein motifs to mimic
coiled coils for mediating the protein-protein interactions. Arora and colleagues reported that the
formation of a minimal helical dimer containing two nine-amino-acid peptides was enabled by a triazolebased inter helical covalent linkage (Figure 23A). Analysis of CD spectra suggested that the crosslinked
dimer adopted a helical conformation whereas the non-crosslinked counterpart appeared to be random
coil. The crosslinked short coiled-coil motif binds to its target more efficiently (up to 6-fold) compared to
its non-crosslinked counterpart.139 They further applied this interhelical crosslinking strategy to stabilize
parallel or antiparallel dimer or trimer (Figure 23B).140 A coiled-coil mimic of NF-κB essential modulator
(NEMO) crosslinked via their approach can disrupt the NF-κB signal pathway, induce cell death and delay
tumor growth in a primary effusion lymphoma xenograft model.141 Analogously, Liu and coworkers
reported a trimeric coiled coil derived from the N-terminus of HIV-1 gp41. The replacement of interhelical
salt bridge with covalent lactam bridge made the helical trimer resistant to thermal denaturation at 90 ºC.
The stapled variant remained intact after 24 hours incubation in rat plasma whereas the non-stapled form
was completely degraded within eight hours.142
Chapter 4 and Chapter 5 describe our lab’s effort in macrocyclization of small beta-sheet protein
SH3; the development of guidelines for PEG stapling on a heterodimeric coiled coil derived from the yeast
transcription factor GCN4; and further application of PEG staple to a therapeutic relevant protein affibody.
1.4 Summaries and conclusions
We summarized different strategies for peptide and protein macrocyclization and reviewed those
approaches from a perspective of the conformational change of secondary and tertiary structures enabled
by macrocyclization. We also addressed other properties associated with conformational stability, such as
29

proteolytic stability and target binding affinity. The most investigated macrocyclization strategies on
helices include olefin metathesis-derived hydrocarbon cross-linkers, cystine based two-component crosslinkages, and CuAAC-derived cross-linkages. Although it is almost clear that optimal sites for crosslinking on a helical peptide are sites with i-to-i+4- or i-to-i+7-spacing, screening of multiple sites with
various length of linkers are often required to yield cyclized peptide with the most thermodynamic
enhancement. We also summarized the multiple-component macrocyclization strategies73, 78 with the
potential to expand the application of the constrained peptides and proteins, such as cell membrane
permeability,73 prolonged serum half-life,143, 144 altered conformational stability,78 and peptide labeling.76,
145, 146

We also reviewed the macrocyclization of large functional proteins by chemical or chemical

engineering approaches. With the development of directed evolution and computation together with bioengineering techniques, and the development of bioconjugation strategies, macrocyclization of large
proteins may draw much more research attention in the future.
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2. Influence of PEGylation on the Strength of Protein Surface Salt Bridges
Reproduced with permission from ACS Chem. Biol. 2019, 14, 1652–1659 Copyright 2019 American Chemical Society.
Qiang Xiao and Steven R. E. Draper are equal co-first authors in this publication and both contributed to the work in
this chapter. Steven R. E. Draper contributed to the synthesis, purification, and thermodynamic data collection of WW variants
β-23-EA; β-23-AR; β-23-AA; pβ-23-EA; pβ-23-AR; pβ-23-AA; as well as the crystallography data collection of GCN4
variant 2α18 and p2α18. Natalie A. B. Pugmire contributed to the synthesis of GCN4 variants 2α18-EA; 2α18-AR; 2α18-AA;
p2α18-EA; p2α18-AR; p2α18-AA; Eliza E. K. Lawrence contributed to the synthesis, purification, thermodynamic data
collection of WW variant β-18.

2.1 Introduction
Conjugation of polyethylene glycol (PEGylation) to proteins is a well-known strategy for
enhancing the pharmacokinetic properties of many protein pharmaceuticals.2-5 The large hydrodynamic
radius of the PEG conjugate shields the protein from proteases and neutralizing antibodies, and decreases
its clearance from serum via renal filtration (a major clearance route for many drugs, excluding those like
elotuzumab, which is cleared primarily via receptor-mediated endocytosis).6-8 Traditionally, PEG-protein
conjugates were prepared by reacting a non-selective PEG-electrophile with surface nucleophiles,
resulting in a heterogeneous mixture of PEGylated proteins differing in both number and location of the
attached PEGs.4, 5 The resulting population of non-specifically PEGylated protein isoforms often exhibits
decreased in vitro activity, presumably because PEG also interferes with the binding events that are
essential for protein-protein interactions and/or catalysis; the extended serum half-life frequently
compensates for this loss of in-vitro bioactivity.9
Advances in chemoselective biorthogonal reactions now allow chemists to install PEG sitespecifically at any arbitrary position within a protein.10-22 Using these reactions, chemists can choose
surface PEGylation sites that are far from enzyme active sites and from substrate binding interfaces. The
resulting PEG-protein conjugates often retain more in vitro activity than did their randomly conjugated
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counterparts, relative to the non-PEGylated protein.13,17, 23 However, aside from these simple and intuitive
guidelines, finding a PEGylation site that provides an optimal balance between increased proteolytic
stability, lengthened serum half-life, and retained biological activity is often an empirical matter of trial
and error.24, 25
We have previously hypothesized that such optimal PEGylation sites will be characterized by the
increased conformational stability of the PEG-protein conjugate relative to its non-PEGylated
counterpart.26,

27

The rationale for this hypothesis is that proteolysis, aggregation, and

recognition/neutralization by antibodies are generally more severe for unfolded proteins than folded
proteins,28-31 especially when the protein is not of human origin32-34. Consequently, we have explored the
impact of PEGylation on the conformational stability of peptide and protein model systems in search of
structure- or sequence-based criteria for identifying conformationally stabilizing PEGylation sites. We
found previously that PEG can increase conformational stability, but the extent of stabilization depends
strongly on the location of the PEGylation site27 and the chemistry used to connect PEG and protein.35, 36
Detailed thermodynamic analyses and computational simulations suggest that the stabilizing impact of
PEGylation derives from an entropic effect, likely because PEG allows some first-shell water molecules
to be released to bulk solvent.27 We wondered whether such localized desolvation might increase the
strength of non-covalent interactions in the immediate vicinity of the PEGylation site; this possibility
seemed reasonable in light of several recent reports linking the strength of a salt bridge or of a hydrogen
bond to the polarity of its immediate microenvironment and its exposure to solvent.37-41
2.2 Results and Discussion
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We explored this possibility in the context of dimeric helix-bundle peptide GCN4-p1 (Figure
1A).42 As with other helix bundles, the primary sequence of GCN4-p1 is characterized by a seven-residue
repeating pattern in which non-polar residues occupy positions a and d of an abcdefg heptad, with polar
and/or charged residues predominantly occupying the other positions. Such an arrangement aligns the
non-polar a- and d-positions along the same side of the peptide in the α-helical conformation; burial of
these residues at the interface between the two helices provides the driving force for helix-bundle
formation.43 In contrast, residues at the other five positions are solvent-exposed and are therefore ideal
locations for probing the impact of PEG-based desolvation on the strength of non-covalent interactions at
the protein surface. Accordingly, we prepared GCN4-p1 variants p2α1, p2α3, p2α4, p2α6, p2α7, p2α10,
p2α14, p2α18, p2α21, p2α25, and p2α28, in which we incorporated an asparagine-linked monomethoxyPEG (i.e., AsnPEG, comprised of four ethylene oxide units; Figure 1B) at solvent exposed positions 1, 3,
4, 6, 7, 10, 14, 18, 21, 25, and 28, respectively (Figure 1, Table 1). We also prepared their Asn-containing
sequence-matched non-PEGylated counterparts 2α1, 2α3, 2α4, 2α6, 2α7, 2α10, 2α14, 2α18, 2α21, 2α25,
and 2α28. We used variable temperature circular dichroism (CD) experiments to obtain the apparent
melting temperatures (Tm) and folding free energies (ΔGf) of each variant listed in Table 1, along with the
impact of PEGylation on the conformational stability of each PEGylated variant relative to its nonPEGylated counterpart (ΔΔGf). GCN4-p1 is a homodimeric helix bundle; therefore, PEGylated GCN4-p1
variants contain two PEGylation sites: one on each monomer in the helix-bundle dimer. Subtracting the
ΔGf value of a non-PEGylated protein from that of its PEGylated counterpart results in a ΔΔGf value that
represents the impact of two PEGylation events on conformational stability. To facilitate comparison of
these ΔΔGf values with those derived from other protein model systems with distinct oligomerization
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states, Table 1 reports ΔΔGf / n where n is the number of monomers in the folded state of the protein (in
this case, two); these ΔΔGf / n values represent the change in folding free energy in kcal/mol per monomer.

Figure 1. (A) Ribbon diagram of dimeric helix bundle formed by peptide GCN4-p1 (PDB ID: 2ZTA) with side chains shown
as sticks. Positions where we incorporated Asn vs. AsnPEG are numbered and highlighted in gray. (B) Structures of Asn vs.
AsnPEG; Gln vs. GlnPEG; and PrF vs. PrFPEG. (C)–(H) Summary of triple mutant box analysis of PEGylation sites and
nearby salt bridges (highlighted in orange and gray, respectively) within peptides based on α-helical coiled-coil dimer GCN4
(PDB ID: 2ZTA): (C) 2α4 vs. p2α4 and (D) 2α18 vs. p2α18; α-helical coiled-coil trimer 1CW (PDB ID: 1COI): (E) 3α1 vs
p3α1 and (F) 3α6 vs. p3α6; and two closely related variants of β-sheet protein WW (PDB IDs: 2F21 and 1PIN): (G) β18 vs.
pβ18 and (H) β23 vs. pβ23. Impact of PEGylation on salt bridge strength (ΔΔΔΔGf / n) is indicated below each figure ±
standard error in kcal/mol per monomer (n = 2 for Figures 1C,D; n = 3 for Figures 1E,F; n = 1 for Figures 1G,H)

Asn-PEGylation has a minimal effect at positions 1, 3, 14 within GCN4-p1; is destabilizing at
positions 4, 6, 7, 10, 21, and 25; and is slightly stabilizing at positions 18 and 28 (Table 1). We examined
the structural context of each of these PEGylation sites to explore whether their proximity to any nearby
non-covalent interactions was related to the overall impact of PEGylation on the helix bundle.
Interestingly, positions 4 and 18 share a similar structural context: they each occupy the i–4 position
relative to an i to i+3 salt bridge: Lys8–Glu11 in p2α4 (Figure 1C) and Glu22–Arg25 in p2α18 (Figure
1D). However, PEGylation has opposite effects at these positions: p2α4 is less stable than 2α4, whereas
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p2α18 is more stable than 2α18. We wondered whether these differences might be reflected in the impact
of PEG on the strength of the Lys8–Glu11 salt bridge in p2α4 vs. the Glu22–Arg25 salt bridge in p2α18.
Table 1. Sequences, melting temperatures and folding free energies of GCN4-p1 variants 2α1, 2α3, 2α4,
2α6, 2α7, 2α10, 2α14, 2α18, 2α21, 2α25, 2α28 and their PEGylated counterparts.a
Peptide

Sequence
gabcdefgabcdefgabcdefgabcdefgab

Tm (°C)

ΔGf
(kcal/mol)

ΔΔGf
(kcal/mol)

ΔΔGf / nb
(kcal/mol
per
monomer)

2α1 NMKQLEDKVEELLSKNYHLENEVARLKKLVG 48.8 -7.08 ± 0.02
p2α1
N••••••••••••••••••••••••••••••
47.7 -6.92 ± 0.02 0.16 ± 0.04
0.08 ± 0.02
2α3
••N••••••••••••••••••••••••••••
39.0 -5.83 ± 0.02
p2α3
••N••••••••••••••••••••••••••••
37.1 -5.60 ± 0.03 0.24 ± 0.04
0.12 ± 0.02
2α4
•••N•••••••••••••••••••••••••••
43.8 -6.39 ± 0.02
p2α4
•••N•••••••••••••••••••••••••••
37.1 -5.70 ± 0.02
0.70 ±
0.35 ± 0.02*
2α6
•••••N•••••••••••••••••••••••••
36.4 -5.60 ± 0.01
p2α6
•••••N•••••••••••••••••••••••••
32.8 -5.14 ± 0.03
0.46 ±
0.23 ± 0.01*
2α7
••••••N••••••••••••••••••••••••
48.1 -7.00 ± 0.02
p2α7
••••••N••••••••••••••••••••••••
43.0 -6.27 ± 0.02
0.72 ±
0.36 ± 0.01*
2α10
•••••••••N•••••••••••••••••••••
55.4 -8.06 ± 0.02
p2α10
•••••••••N•••••••••••••••••••••
46.4 -6.72 ± 0.02
1.34 ±
0.67 ± 0.02*
2α14
•••••••••••••N•••••••••••••••••
51.9 -7.65 ± 0.02
p2α14
•••••••••••••N•••••••••••••••••
52.1 -7.72 ± 0.02 -0.14 ± 0.06 -0.07 ± 0.03
2α18
•••••••••••••••••N•••••••••••••
45.8 -6.67 ± 0.01
p2α18
•••••••••••••••••N•••••••••••••
47.3 -6.90 ± 0.01
-0.22 ±
-0.11 ± 0.01*
2α21
••••••••••••••••••••N••••••••••
52.6 -7.75 ± 0.02
p2α21
••••••••••••••••••••N••••••••••
49.7 -7.27 ± 0.02
0.48 ±
0.24 ± 0.01*
2α25
••••••••••••••••••••••••N••••••
47.8 -6.97 ± 0.02
p2α25
••••••••••••••••••••••••N••••••
45.6 -6.62 ± 0.02
0.34 ±
0.17 ± 0.01*
2α28
•••••••••••••••••••••••••••N•••
45.0 -6.53 ± 0.01
p2α28
•••••••••••••••••••••••••••N•••
46.6 -6.79 ± 0.02
-0.26 ±
-0.13 ± 0.01*
a
Folding free energies are given ± standard error in kcal/mol at 30 µM protein concentration in 20 mM sodium phosphate buffer
(pH 7) at the average melting temperature of variants 2α1, 2α3, 2α4, 2α6, 2α7, 2α10, 2α14, 2α18, 2α21, 2α25, 2α28 and their
PEGylated counterparts (318.5 K). ΔΔGf = ΔGf (PEGylated variant) – ΔGf (non-PEGylated variant), with error propagated as
described in the supporting information. b n = 2 for dimeric GCN4-p1 variants; ΔΔGf / 2 gives the impact of PEGylation in
kcal/mol per monomer. Αsterisks indicate ΔΔGf or ΔΔGf / n values for which p < 0.10 in a two-tailed t-test.

We explored this possibility using triple mutant cycle analysis as we have done previously.13 We
prepared six additional variants of 2α4 and p2α4 in which we replaced Lys8 and Glu11 with Ala,
individually (2α4-ΚΑ, 2α4-AE, p2α4-ΚΑ, p2α4-AE) and in combination (2α4-AΑ, p2α4-AA). For the
non-PEGylated variants, comparing the impact of the Lys8 to Ala8 mutation in the presence of Ala11
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(2α4-KΑ vs. 2α4-AΑ, ΔΔGf / 2 = 0.03 ± 0.02 kcal/mol per monomer) vs. Glu11 (2α4 vs. 2α4-AE, ΔΔGf
/ 2 = -0.03 ± 0.02 kcal/mol per monomer) reveals that the Lys8–Glu11 salt bridge does not contribute
substantially to the stability of 2α4 (ΔΔΔGf / 2= -0.06 ± 0.02 kcal/mol per monomer). Comparing the
analogous PEGylated variants (p2α4-KA vs. p2α4-AA, ΔΔGf / 2 = 0.36 ± 0.01 kcal/mol per monomer;
2α4 vs. 2α4-AE, ΔΔGf / 2 = 0.41 ± 0.01 kcal/mol per monomer) reveals that the Lys8-Glu11 salt bridge
has a similarly small impact on the stability of p2α4 (ΔΔΔGf / 2 = 0.05 ± 0.02 kcal/mol per monomer),
indicating that PEG has a minimal impact on the strength of the Lys8–Glu11 salt bridge (ΔΔΔΔGf / 2 =
0.11 ± 0.03 kcal/mol per monomer).
We performed analogous experiments with 2α18 and p2α18 and their six sequence mutants (2α18EΑ, 2α18-AR, 2α18-AA, p2α18-EΑ, p2α18-AR, p2α18-AA). When Asn occupies position 18, the
Glu22–Arg25 salt bridge contributes -0.45 ± 0.02 kcal/mol per monomer to the stability of 2α18; in
contrast, when AsnPEG occupies position 18, the Glu22–Arg25 salt bridge contributes -1.14 ± 0.03
kcal/mol per monomer to the stability of p2α18, indicating that PEG stabilizes the Glu22–Arg25 salt
bridge by -0.69 ± 0.03 kcal/mol per monomer. We wondered whether other stabilizing PEGylation sites
might be similarly characterized by their ability to increase the strength of nearby salt bridges. To test this
hypothesis, we explored PEGylation sites near salt bridges within a second α-helical model system (i.e.,
the trimeric helix bundle 1CW)44-46 and within a β-sheet model protein (the WW domain of the human
protein Pin1).47, 48 The variants and positions we explored are summarized in Figure 1E–H and in Table
2.
Position 1 within 1CW is oriented toward a nearby i to i+4 salt bridge comprised of Glu3 and Lys7
on an adjacent helix within the trimer (Figure 1E). We generated variant 3α1 and its PEGylated
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counterpart p3α1 by incorporating Gln vs. GlnPEG (Figure 1B) at position 1 within 1CW (Table 2). We
chose to use Gln vs. GlnPEG because they more closely resemble the residue that occupies position 1 (i.e.
Glu) within the parent 1CW peptide from which these variants were derived. GlnPEGylation slightly
destabilizes p3α1 and relative to 3α1. Comparing ΔGf values for p3α1 and 3α1 with those of their
sequence variants (3α1-EA, 3α1-AK, 3α1-AA, p3α1-EA, p3α1-AK, and p3α1-AA) reveals that
PEGylation at Gln1 does not substantially change the strength of the Glu3–Lys7 salt bridge in the 1CW
trimer (ΔΔΔΔGf / 3 = -0.05 ± 0.02 kcal/mol per monomer), which contributes favorably to helix bundle
stability whether or not PEG is present (Table 2).
Table 2. Triple mutant box analysis of the impact of PEGylation on salt-bridge strength within p2α4,
p2α18, p3α1, p3α6, pβ18 and pβ23.a
Peptide

Sequence

Tm
(°C)

ΔGf
(kcal/mol)

ΔΔGf / nb
(kcal/mol
per
monomer)

ΔΔΔGf / nc ΔΔΔΔGf / nd
(kcal/mol
(kcal/mol
per
per
monomer) monomer)
-0.06 ± 0.03

2α4
RMKNLEDKVEELLSKNYHLENEVARLK 43.8 -6.80 ± 0.03
2α4-KA
•••NLEDKVEA••••••••••••••••••••
39.1 -6.23 ± 0.02
2α4-AE
•••NLEDAVEE••••••••••••••••••••
43.6 -6.74 ± 0.03
2α4-AA
•••NLEDAVEA••••••••••••••••••••
39.6 -6.29 ± 0.03
p2α4
•••NLEDKVEE••••••••••••••••••••
37.1 -6.03 ± 0.03 0.38 ± 0.02* 0.04 ± 0.02 0.11 ± 0.03
p2α4-KA
•••NLEDKVEA••••••••••••••••••••
39.6 -6.27 ± 0.02 -0.02 ± 0.01
p2α4-AE
•••NLEDAVEE••••••••••••••••••••
44.3 -6.85 ± 0.03 -0.06 ± 0.02
p2α4-AA
•••NLEDAVEA••••••••••••••••••••
45.2 -7.00 ± 0.02 -0.35 ± 0.02*
2α18
RMKQLEDKVEELLSKNYNLENEVARLK 45.8 -7.74 ± 0.02
-0.46 ± 0.02*
2α18-EA
•••••••••••••••••NLENEVAA••••••
42.1 -7.07 ± 0.03
2α18-AR
•••••••••••••••••NLENAVAR••••••
31.1 -5.59 ± 0.02
2α18-AA
•••••••••••••••••NLENAVAA••••••
33.7 -5.84 ± 0.02
p2α18
•••••••••••••••••NLENEVAR••••••
47.3 -7.93 ± 0.02 -0.10 ± 0.01* -1.14 ± 0.03* -0.69 ± 0.03*
p2α18-EA
•••••••••••••••••NLENEVAA••••••
38.3 -6.51 ± 0.04 0.28 ± 0.02*
p2α18-AR
•••••••••••••••••NLENAVAR••••••
28.7 -5.30 ± 0.02 0.14 ± 0.01*
p2α18-AA
•••••••••••••••••NLENAVAA••••••
35.9 -6.17 ± 0.02 -0.16 ± 0.01*
3α1
QVEALEKKVEALESKVQKLEKKVEALE 77.4 -15.24 ± 0.02
-0.35 ± 0.01*
3α1-EA
QVEALEA••••••••••••••••••••••••••
76.0 -14.90 ± 0.02
3α1-AK
QVAALEK••••••••••••••••••••••••••
73.2 -14.23 ± 0.02
3α1-AA
QVAALEA••••••••••••••••••••••••••
76.1 -14.92 ± 0.03
p3α1
QVEALEK••••••••••••••••••••••••••
75.4 -14.76 ± 0.02 0.16 ± 0.01* -0.40 ± 0.01* -0.05 ± 0.02
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p3α1-EA
QVEALEA••••••••••••••••••••••••••
73.9 -14.40 ± 0.02 0.17 ± 0.01*
p3α1-AK
QVAALEK••••••••••••••••••••••••••
71.2 -13.76 ± 0.01 0.15 ± 0.01*
p3α1-AA
QVAALEA••••••••••••••••••••••••••
74.7 -14.59 ± 0.02 0.11 ± 0.01*
3α6
EVEALQKKVAALESKVQKLEKKVEALE 77.2 -15.71 ± 0.02
-0.99 ± 0.01*
3α6-KA
•••••QKKVAALA••••••••••••••••••••
67.4 -13.48 ± 0.02
3α6-AE
•••••QKAVAALE••••••••••••••••••••
72.4 -14.51 ± 0.02
3α6-AA
•••••QKAVAALA••••••••••••••••••••
75.5 -15.25 ± 0.02
p3α6
•••••QKKVAALE••••••••••••••••••••
73.3 -14.73 ± 0.02 0.32 ± 0.01* -1.10 ± 0.01* -0.11 ± 0.02
p3α6-KA
•••••QKKVAALA••••••••••••••••••••
64.9 -13.08 ± 0.01 0.13 ± 0.01*
p3α6-AE
•••••QKAVAALE••••••••••••••••••••
70.7 -14.10 ± 0.01 0.14 ± 0.01*
p3α6-AA
•••••QKAVAALA••••••••••••••••••••
77.7 -15.76 ± 0.03 -0.17 ± 0.01*
β18
KLPPGWEKRMDANGRVYFNHITNASQFE 77.7 -0.53 ± 0.02
-0.50 ± 0.03*
β18-DA
••••••••••DANGA•••••••••••••••••
68.7 0.37 ± 0.01
β18-SR
••••••••••SANGR•••••••••••••••••
69.5 0.30 ± 0.01
β18-SA
••••••••••SANGA•••••••••••••••••
65.7 0.70 ± 0.01
pβ18
••••••••••DANGR•••••••••••••••••
80.4 -0.78 ± 0.02 -0.25 ± 0.02* -0.54 ± 0.02* -0.03 ± 0.04
pβ18-DA
••••••••••DANGA•••••••••••••••••
71.3 0.09 ± 0.01 -0.28 ± 0.01*
pβ18-SR
••••••••••SANGR•••••••••••••••••
74.3 -0.21 ± 0.01 -0.51 ± 0.01*
pβ18-SA
••••••••••SANGA•••••••••••••••••
70.8 0.13 ± 0.01 -0.57 ± 0.02*
β23
KLPPGWEKRMSRSSGRVXFNHITNASQF 51.9 -0.35 ± 0.02
-0.35 ± 0.03
β23-EA
••••••EKAMSRSSGRVX•••••••••••••••
42.5 0.42 ± 0.01
β23-AR
••••••AKRMSRSSGRVX•••••••••••••••
48.0 -0.04 ± 0.01
β23-AA
••••••AKAMSRSSGRVX•••••••••••••••
42.8 0.38 ± 0.02
pβ23
••••••EKRMSRSSGRVX•••••••••••••••
55.6 -0.64 ± 0.02 -0.28 ± 0.03* -0.79 ± 0.03* -0.44 ± 0.04*
pβ23-EA
••••••EKAMSRSSGRVX•••••••••••••••
43.4 0.31 ± 0.01 -0.11 ± 0.02
pβ23-AR
••••••AKRMSRSSGRVX•••••••••••••••
48.6 -0.09 ± 0.02 -0.05 ± 0.02
pβ23-AA
••••••AKAMSRSSGRVX•••••••••••••••
46.5 0.08 ± 0.01 -0.30 ± 0.02*
a
N = AsnPEG; X = propargyloxyphenylalanine (PrF); X = PrFPEG; Q = GlnPEG. Variable temperature CD experiments were
performed in 20 mM phosphate buffer (pH 7) at 30 μM protein concentration except for the WW variants β18 and β23 and
their derivatives, which were characterized at 50 μΜ. ΔGf values are given ± standard error in kcal/mol. ΔGf values for each
of the eight peptides within the same triple mutant cycle were calculated at their average melting temperature: 314.7 K for 2α4
and its derivatives; 311.0 K for 2α18 and its derivatives; 347.9 K for 3α1 and its derivatives; 345.5 K for 3α6 and its derivatives;
345.4 K for β18 and its derivatives; 320.6 K for β23 and its derivatives. bImpact of PEGylation on peptide/protein
conformational stability in kcal/mol per monomer. For example, ΔΔGf = ΔGf (p2α4) – ΔGf (2α4), with n = 2 for homodimeric
GCN4-p1 variants (2α4, 2α18 and their derivatives); n = 3 for homotrimeric 1CW variants (3α1, 3α6 and their derivatives); n
= 1 for monomeric WW variants (β18, β23 and their derivatives). cStrength of salt-bridge interaction per monomer. For
example, ΔΔΔGf = ΔGf (2α4) – ΔGf (2α4-AE) – ΔGf (2α4-KA) + ΔGf (2α4-AA), with n as described above. dImpact of
PEGylation on salt-bridge strength per monomer. For example, ΔΔΔΔGf = ΔGf (p2α4) – ΔGf (p2α4-AE) – ΔGf (p2α4-KA) +
ΔGf (p2α4-AA) – ΔGf (2α4) + ΔGf (2α4-AE) + ΔGf (2α4-KA) – ΔGf (2α4-AA), with n as described above. Αsterisks indicate
ΔΔGf / n, ΔΔΔGf / n, and ΔΔΔΔGf / n values for which p < 0.10 in a two-tailed t-test.

Position 6 within 1CW is oriented toward a salt bridge between Lys8 on an adjacent helix and
Glu13 within the same helix (Figure 1F). Accordingly, we prepared 1CW variant 3α6 and its PEGylated
counterpart p3α6, in which we incorporated Gln vs. GlnPEG, respectively at position 6 (as with position
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1 above, the residue that occupies this position in the parent 1CW is Glu). GlnPEGylation destabilizes
p3α6 by 0.32 ± 0.01 kcal/mol per monomer relative to 3α6 (Table 2). Triple mutant cycle analysis of
p3α6, 3α6, and their sequence variants at positions 8 and 13 (p3α6-KA, p3α6-AE, p3α6-AA, 3α6-KA,
3α6-AE, and 3α6-AA) indicates that the Lys8–Glu13 salt bridge contributes strongly to helix bundle
conformational stability (ΔΔΔGf / 3 = -0.99 ± 0.01 kcal/mol) with PEGylation of Gln6 only slightly
increasing salt bridge strength (ΔΔΔΔGf / 3 = -0.11 ± 0.02 kcal/mol per monomer).
Position 18 within monomeric β-sheet protein WW (normally occupied by Asp) occupies the same
reverse turn as nearby positions 16 and 21, which are normally occupied by Ser and Arg, respectively
(Figure 1G). Side chains at these three positions occupy the same face of the reverse turn. We envisioned
that incorporating AsnPEG vs. Asn at position 18 and Asp at position 16 might allow PEG to stabilize a
salt bridge between Asp16 and Arg21. Accordingly, we prepared WW variants β18 and pβ18, with Asp
at position 16, Asn vs. AsnPEG at position 18, respectively, and Arg at position 21. PEGylation modestly
stabilizes pβ18 relative to β18 (ΔΔGf = -0.25 ± 0.02 kcal/mol per monomer). Triple mutant cycle analysis
of pβ18, β18, and their sequence variants (pβ18-DA, pβ18-SR, pβ18-SA, β18-DA, β18-SR, and β18-SA)
indicates that the Asp16-Arg21 salt bridge is stabilizing (ΔΔΔGf = -0.50 ± 0.03 kcal/mol per monomer),
but that PEGylation at position 18 does not affect its strength (ΔΔΔΔGf = -0.03 ± 0.04 kcal/mol per
monomer).
Finally, we recently found that conjugating an azido-functionalized four-unit PEG to a
propargyloxyphenylalanine residue (PrF, Figure 1H) at position 23 within WW increases the
conformational stability of the PEGylated protein (pβ23) relative to its non-PEGylated counterpart β23
(Table 2; ΔΔGf = -0.28 ± 0.03 kcal/mol per monomer). Position 23 within WW (normally occupied by
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Tyr) is oriented toward a salt bridge between Glu12 and Arg14 on an adjacent β-strand (Figure 1H), and
we wondered whether PEG-based stabilization of the Glu12–Arg14 salt bridge might partially account for
the increased stability of pβ23 relative to β23. Triple mutant cycle analysis of pβ23 and β23 and their
sequence variants pβ23-EA, pβ23-AR, pβ23-AA, β23-EA, β23-AR, and β23-AA indicates that the
Glu12–Arg14 salt bridge contributes -0.35 ± 0.03 kcal/mol per monomer to WW conformational stability,
with PEGylation increasing the strength of the salt bridge by an additional -0.43 ± 0.04 kcal/mol per
monomer.
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Figure 2. Plot of salt-bridge strength (ΔΔΔGf / n in kcal/mol per monomer) within PEGylated variants p2α4 and p2α18 (n =
2); p3α1, p3α1-ER and p3α6 (n = 3); and pβ18 and pβ23 (n = 1) vs. salt-bridge strength (ΔΔΔGf / n in kcal/mol per monomer)
within the corresponding non-PEGylated variants 2α4 and 2α18 (n = 2); 3α1, p3α1-ER, and 3α6 (n = 3); and β18 and β23 (n
= 1). Data for p2α18 vs. 2α18 and pβ23 vs. β23 are highlighted in orange; at these positions salt bridges are stronger in the
presence of PEG than without PEG. Dotted line represents linear regression of the data for p2α4 vs. 2α4, p3α1 vs. 3α1, p3α1ER vs. 3α1-ER, p3α6 vs. 3α6, and pβ18 vs. β18 (points highlighted in blue), where PEGylation does not substantially change
salt-bridge strength.

These results are summarized in Figure 2, which plots salt-bridge strength per monomer (ΔΔΔGf
/ n) within non-PEGylated variants 2α4, 2α18, 3α1, 3α6, β18, and β23 (x-axis) vs. salt-bridge strength per
monomer (ΔΔΔGf / n) within PEGylated variants p2α4, p2α18, p3α1, p3α6, pβ18, and pβ23 (y-axis).
PEGylation data points for 2α4, 3α1, 3α6, and β18 fit readily to a line with slope = 1.2 ± 0.01 (p = 0.001),
indicating that PEG has no substantial impact on salt-bridge strength for these variants. In contrast, data
points for 2α18 and β23 are exceptions to this trend: the salt bridges we investigated are stronger within
PEGylated p2α18 and pβ23 than in non-PEGylated 2α18 and β23. We wondered whether p2α18 and
pβ23 had any common features that might explain this observation. We noticed that both p2α18 and pβ23
contained a Glu–Arg salt bridge; whereas, p2α4, p3α1, p3α6 contain a Glu–Lys salt bridge and pβ18
contains an Asp–Arg salt bridge. To explore whether Glu–Arg salt bridges are uniquely subject to PEGbased stabilization, we prepared 1CW variants 3α1-ER, 3α1-AR, p3α1-ER, p3α1-AR, in which Arg
occupies position 7 rather than Lys. Comparing folding free energies of these variants (see supporting
52

information) vs. those of previously characterized 3α1-EA, 3α1-AA, p3α1-EA, and p3α1-AA reveals that
PEGylation does not substantially change the strength of the Glu3–Arg7 salt bridge (although the Glu3–
Arg7 salt bridge in 3α1-ER is stronger than the corresponding Glu3–Lys7 salt bridge in 3α1). It appears
from this observation that salt-bridge residue identity alone is not a sufficient predictor of the impact of
PEGylation on salt bridge strength.
To gain structural insight into how PEG affects the Glu22–Arg25 salt bridge in 2α18 vs p2α18,
we crystallized these variants, obtained x-ray diffraction data, and solved their structures via molecular
replacement (Figure 3A-B, respectively). The structures for 2α18 (PDB ID: 6O2E) and p2α18 (PDB ID:
6O2F) are extremely similar overall (rmsd = 0.113 Å) with identical distances between Glu22 and Arg25,
suggesting that the increased strength of the Glu22–Arg25 salt bridge in the presence of PEG does not
come from increased proximity of these charged groups. However, differences in the crystallographic data
become more apparent upon close inspection of the electron density maps of 2α18 vs. p2α18: the area
immediately surrounding Asn18, Glu22 and Arg25 in PEGylated p2α18 contains substantially more
electron density than the corresponding area in non-PEGylated 2α18 (Figure 3A–B). Indeed, electron
density for the Asn18 side chain in p2α18 continues to extend outward from the side-chain amide nitrogen,
which is consistent with the presence of an Asn-linked PEG at position 18 (as confirmed by mass
spectrometry; see supporting information). Including an explicit PEG connected to Asn18 in our
crystallographic model for p2α18 allowed us to account for some of this extra electron density and led to
modest improvements in the statistical quality of the model. However, no single conformation of PEG
accounted for all of the observed extra electron density; similar improvements in the statistical quality of
the model resulted from including explicit crystallographic water molecules in the place of PEG. Based
on these observations, we speculate that the Asn-linked PEG at position 18 in the crystalline state of p2α18
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is disordered but likely occupies the space between Asn18, Glu22 and Arg25. Though these observations
apply specifically to the crystalline state, it is tempting to extrapolate them to the solution behavior of
p2α18; it is possible that PEG occupies space in the immediate vicinity of the Glu22–Arg25 salt bridge
and partially desolvates it, thereby increasing its strength.

Figure 3. (A)–(B) Ribbon diagram of α-helical coiled-coil dimers formed by GCN4-p1 variant 2α18 (PDB ID: 6O2E) and its
PEGylated counterpart p2α18 (PDB ID: 6O2F), respectively, with side chains shown as sticks. Asn18 is highlighted in gray,
with the Glu22-Arg25 salt bridge highlighted in orange. Also shown are close up views of Asn18, Glu22, and Arg25 within a
single helix (yellow) within the crystalline lattices formed by variants 2α18 and p2α18, respectively. Gray mesh represents
electron density contoured at 0.5 σ.

Here we have shown that a short PEG oligomer can increase protein conformational stability by
increasing the strength of a nearby salt bridge in two distinct secondary structural contexts, including an i
to i+4 Glu-Arg salt bridge within an α-helix and an intra-strand i to i+2 Glu-Arg salt bridge within a βsheet. High-resolution crystallography data supports the possibility that PEG adopts a disordered
conformation near the Glu22–Arg25 salt bridge within GCN4 variant p2α18, occupying space that would
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normally be occupied by water. It is possible that this effect is partially responsible for the PEG-based
stabilization of the Glu22–Arg25 salt bridge. However, the structural prerequisites for this effect are not
a simple function of secondary structural context, orientation and distance of the PEGylation site with
respect to the salt bridge, or of salt-bridge residue identity; PEGylation did not increase the strength of
some salt-bridges, for reasons that remain unclear. Previous work showed that the structure of the PEGprotein linkage is a major determinant of PEG-based stabilization at a given PEGylation site.35,
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Moreover, a short PEG oligomer comprised of three ethylene oxide units can almost entirely recapitulate
the PEG-based stabilization associated with a longer 45-unit PEG.26, 27 These observations suggest that
the impact of PEG-based protein stabilization derives primarily from the PEG-protein linker and the first
few atoms of the attached PEG, which perturb the microenvironment in the immediate vicinity of the
PEGylation site, including nearby side-chain and backbone groups, along with water molecules in the first
solvent shell). If so, the minimal impact of PEG on the stability of nearby salt bridges within p2α4, p3α1,
p3α6, and pβ18 could reflect our choice of suboptimal linkers at these positions (AsnPEG, GlnPEG,
GlnPEG, and AsnPEG, respectively) vs. serendipitously optimal linkers at corresponding positions within
p2α18 and pβ23 (AsnPEG and PrFPEG, respectively). More broadly, our results also highlight the
importance of considering the extent to which side-chain functionalization (e.g. with a fluorophore, an
affinity tag, a post-translational modification, etc.) perturbs interactions with and among water molecules
and side-chain or backbone groups in the localized microenvironment and hydration sphere of the
conjugation site.
2.3 Methods
2.3.1 Peptide Synthesis
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Peptides were synthesized via solid phase synthesis using a standard Fmoc strategy, described in
detail in the Supporting Information. Fmoc-protected and PEGylated derivatives of L-asparagine and

L

-

glutamine were synthesized as reported previously.27, 35 Fmoc-protected propargyloxyphenylalanine (PrF)
was synthesized as reported previously. 49 A previously described PEG-azide was conjugated to PrF via
copper(I)-catalyzed azide-alkyne cycloaddition as we described recently.27, 35 Following cleaving from
resin, peptides were purified by HPLC with a reverse phase C18 column and a linear gradient of water
and acetonitrile with 0.1% v/v TFA. The mass of each peptide was confirmed by matrix-assisted laser
desorption/ionization time-of-flight spectrometry, and purity was evaluated by analytical HPLC. Mass
spectra and analytical HPLC chromatograms for all peptides are available in the supporting information.
2.3.2 CD Measurements
CD spectra and variable temperature CD data were collected using an Aviv 420
spectropolarimeter. Data were collected in triplicate by making a single sample and dividing it amongst
three cuvettes. We used nonlinear least-squares regression to fit the three individual variable temperature
CD data sets globally to equations derived from a two-state folding model for each variant to obtain Tm
and ΔGf values for each peptide, as described in detail the Supporting Information. Statistics for the fits
of all the compounds, including R2, sum of the squared are given in the supporting information, along
with a description of the error propagation used to generate the uncertainties shown in Tables 1 and 2.
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2.5 Supporting Information
2.5.1 Protein Synthesis, Purification and Characterization
All peptide variants were synthesized as C-terminal acids by Fmoc-based solid-phase peptide
synthesis as described previously.1 β18, pβ18, β18-SR, pβ18-SR and β23 and pβ23 were synthesized
previously.1,

2

Peptides with carboxyl termini were synthesized on Fmoc-Gly-Wang resin (EMD

Biosciences) and those with amidated termini were synthesized on Rink amide resin (Advanced Chem
Tech). We used standard Fmoc-protected amino acids with acid-labile sidechain protecting groups. We
used previously synthesized Fmoc-L-GlnPEG4-OH [18-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)15-oxo-2,5,8,11-tetraoxa-14-azanonadecan-19-oic acid],1 previously synthesized Fmoc-L-PrF-OH N[(9H-Fluoren-9-ylmethoxy)-O-2-propyn-1yl-L-tyrosine,3 and previously synthesized PEG-azide 13azido-2,5,8,11-tetraoxatridecane4 for PEGylating the PrF peptides via the copper (I) catalyzed azidealkyne cycloaddition.1 For the asparagine PEG peptides we used previously synthesized Fmoc-L(AsnPEG4)2-OH

[(S)-17-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-15-oxo-14-(2,5,8,11-

tetraoxatridecan-13-yl)-2,5,8,11-tetraoxa-14-azaoctadecan-18-oic acid].1 Other reagents we used were: 2(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate

(HBTU)

and

N-

hydroxybenzotriazole hydrate (HOBt) from Advanced ChemTech for amino acid activation; 20%
piperidine in N,N-dimethylformamide for removal of the Fmoc protecting group from the N-terminal αamine; a solution of a solution of phenol (0.0625 g), water (62.5 μL), thioanisole (62.5 μL), ethanedithiol
(31 μL) and triisopropylsilane (12.5 μL) in trifluoroacetic acid (TFA, 1 mL) for cleaving the protein from
resin and globally removing acid-labile side-chain protecting groups. Proteins were precipitated from the
TFA solution by addition of diethyl ether (~40 mL). Following centrifugation, the ether was decanted, and
61

the pellet was dissolved in ~40mL 1:1 H2O/MeCN, then flash frozen over dry ice in acetone and
lyophilized to remove volatile impurities. The resulting powder was stored at -20°C until purification.
Proteins were purified by preparative reverse-phase high performance liquid chromatography
(HPLC) on a C18 column using a linear gradient of water in acetonitrile with 0.1% v/v TFA. Fractions
containing the desired protein product were pooled, frozen, and lyophilized. Proteins were identified by
electrospray ionization time of flight mass spectrometry (ESI-TOF); expected and observed exact masses
mass spectra appear in Table S1, S2 and S3 and spectra appear in Figures S1-S63. Protein purity was
assessed by Analytical HPLC (Figures S64-S127).
Table S1. Sequences, molecular formulas, expected and observed m/z ratios for GCN4 variants.
Peptide
2α1
p2α1
2α3
p2α3
2α4
2α4-KA
2α4-AE
2α4-AA
p2α4
2α4-KA
2α4-AE
2α4-AA
2α6
p2α6
2α7
p2α7
2α10
p2α10
2α14
p2α14
2α18
2α18-EA

Sequence

Molecular
Formula

z

Expected
[M+z∙H]/z

Observed
[M+z∙H]/z

Ac-NMKQLEDKVEELLSKNYHLENEVARLKKLVGAc-N••••••••••••••••••••••••••••••-NH2
Ac-RMNQLEDKVEELLSKNYHLENEVARLKKLVG Ac-••N••••••••••••••••••••••••••••-NH2
Ac-RMKNLEDKVEELLSKNYHLENEVARLKKLVGAc-•••NLEDKVEA••••••••••••••••••••-NH2
Ac-•••NLEDAVEE••••••••••••••••••••-NH2
Ac-•••NLEDAVEA••••••••••••••••••••-NH2
Ac-•••NLEDKVEE••••••••••••••••••••-NH2
Ac-•••NLEDKVEA••••••••••••••••••••-NH2
Ac-•••NLEDAVEE••••••••••••••••••••-NH2
Ac-•••NLEDAVEA••••••••••••••••••••-NH2
Ac-RMKQLNDKVEELLSKNYHLENEVARLKKLVGAc-•••••N•••••••••••••••••••••••••-NH2
Ac-RMKQLENKVEELLSKNYHLENEVARLKKLVGAc-••••••N••••••••••••••••••••••••-NH2
Ac-RMKQLEDKVNELLSKNYHLENEVARLKKLVGAc-•••••••••N•••••••••••••••••••••-NH2
Ac-RMKQLEDKVEELLNKNYHLENEVARLKKLVGAc-•••••••••••••N•••••••••••••••••-NH2
Ac-RMKQLEDKVEELLSKNYNLENEVARLKKLVGAc-•••••••••••••••••NLENEVAA••••••-NH2

C163H274N46O50
C172H292N46O54
C163H274N48O50
C172H292N48O54
C164H278N48O49
C162H276N48O47
C161H271N47O49
C159H269N47O47
C173H296N48O53
C171H294N48O51
C170H289N47O53
C168H287N47O51
C164H279N49O48
C173H297N49O52
C165H281N49O48
C185H318N54O56
C164H279N49O48
C173H297N49O52
C166H281N49O49
C175H299N49O53
C163H279N47O50
C160H272N44O50

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

928.009
975.539
935.010
982.541
935.020
920.518
920.755
906.254
982.550
968.051
968.285
953.787
934.774
982.304
938.277
985.808
934.774
982.304
945.276
992.806
932.769
911.503

927.987
975.539
935.015
982.535
935.016
920.522
920.759
906.257
982.550
968.051
968.289
953.787
934.765
982.298
938.273
985.802
934.770
982.302
945.268
992.806
932.762
911.505

62

2α18-AR
2α18-AA
p2α18
p2α18-EA
p2α18-AR
p2α18-AA
2α21
p2α21
2α25
p2α25
2α28
p2α28

Ac-•••••••••••••••••NLENAVAR••••••-NH2
Ac-•••••••••••••••••NLENAVAA••••••-NH2
Ac-•••••••••••••••••NLENEVAR••••••-NH2
Ac-•••••••••••••••••NLENEVAA••••••-NH2
Ac-•••••••••••••••••NLENAVAR••••••-NH2
Ac-•••••••••••••••••NLENAVAA••••••-NH2
Ac-RMKQLEDKVEELLSKNYHLENEVARLKKLVGAc-••••••••••••••••••••N••••••••••-NH2
Ac-RMKQLEDKVEELLSKNYHLENEVNRLKKLVGAc-•••••••••••••••••••••••N•••••••-NH2
Ac-RMKQLEDKVEELLSKNYHLENEVARLKNLVGAc-•••••••••••••••••••••••••••N•••-NH2

C161H277N47O48
C158H270N44O48
C172H297N47O54
C169H290N44O54
C170H295N47O52
C167H288N44O52
C165H280N48O49
C174H298N48O53
C166H281N49O50
C175H299N49O54
C163H274N48O50
C172H292N48O54

4
4
4
4
4
4
4
4
4
4
4
4

918.268
897.002
980.300
959.034
965.798
944.532
938.523
986.054
949.275
996.805
935.010
982.541

918.271
897.006
980.298
959.036
965.802
944.536
938.516
986.053
949.268
996.805
935.013
982.541

Table S2. Sequences, molecular formulas, expected and observed m/z ratios for 1CW variants.
Name

Sequence

Molecular
Formula

z

Expected
[M+z∙H]/z

Observed
[M+z∙H]/z

3α1
3α1-ER
3α1-EA
3α1-AK
3α1-AR
3α1-AA

Ac-QVEALEKKVAALESKVQALEKKVEALEY-NH2
Ac-QVEALER•••••••••••••••••••••-NH2
Ac-QVEALEA•••••••••••••••••••••-NH2
Ac-QVAALEK•••••••••••••••••••••-NH2
Ac-QVAALER•••••••••••••••••••••-NH2
Ac-QVAALEA•••••••••••••••••••••-NH2

C143H242N36O45
C143H242N38O45
C140H235N35O45
C141H240N36O43
C141H240N38O43
C138H233N35O43

3
3
3
3
3
3

1062.267
1071.602
1043.247
1042.931
1052.267
1023.912

1062.264
1071.615
1043.245
1042.929
1052.280
1023.908

p3α1
Ac-QVEALEK•••••••••••••••••••••-NH2
p3α1-ER
Ac-QVEALER•••••••••••••••••••••-NH2
p3α1-EA
Ac-QVEALEA•••••••••••••••••••••-NH2
p3α1-AK
Ac-QVAALEK•••••••••••••••••••••-NH2
p3α1-AR
Ac-QVAALER•••••••••••••••••••••-NH2
p3α1-AA
Ac-QVAALEA•••••••••••••••••••••-NH2
3α6
Ac-EVEALQKKVAALESKVQALEKKVEALEY-NH2
3α6-KA
Ac-•••••QKKVAALA•••••••••••••••-NH2
3α6-AE
Ac-•••••QKAVAALE•••••••••••••••-NH2
3α6-AA
Ac-•••••QKAVAALA•••••••••••••••-NH2
p3α6
Ac-•••••QKKVAALA•••••••••••••••-NH2
p3α6-KA
Ac-•••••QKAVAALE•••••••••••••••-NH2
p3α6-AE
Ac-•••••QKAVAALA•••••••••••••••-NH2
p3α6-AA
Ac-•••••QKKVAALA•••••••••••••••-NH2

C152H260N36O49
C152H260N38O49
C149H253N35O49
C150H258N36O47
C150H258N38O47
C147H251N35O47
C143H242N36O45
C141H240N36O43
C140H235N35O45
C138H233N35O43
C152H260N36O49
C150H258N36O47
C149H253N35O49
C147H251N35O47

3
3
3
3
3
3
3
3
3
3
3
3
3
3

1125.640
1134.976
1106.621
1106.305
1115.640
1087.286
1062.267
1042.931
1043.247
1023.912
1125.640
1106.305
1106.621
1087.286

1125.636
1134.986
1106.616
1106.301
1115.653
1087.284
1062.260
1042.933
1043.241
1023.914
1125.633
1106.290
1106.620
1087.287

Table S3. Sequences, molecular formulas, expected and observed m/z ratios for WW variants.
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Name
β18

Molecular
Formula

Sequence

z

H2N-KLPPGWEKRMDANGRVYYFNHITNASQFERPSGC173H257N51O49S 4
OH

Expected
[M+z∙H]/z

Observed
[M+z∙H]/z

967.231

967.226

β18-DA

H2N-••••••••••DANGA••••••••••••••••••-OH

C170H250N48O49S 4

945.965

945.948

β18-SR

H2N-••••••••••SANGR••••••••••••••••••-OH

C172H257N51O48S 3

1279.973

1279.973

β18-SA

H2N-••••••••••SANGA••••••••••••••••••-OH

C169H250N48O48S 3

1251.619

1251.607

pβ18

H2N-••••••••••DANGR••••••••••••••••••-OH

C182H275N51O53S 4

1014.761

1014.747

pβ18-DA

H2N-••••••••••DANGA••••••••••••••••••-OH

C179H268N48O53S 4

993.495

993.483

pβ18-SR

H2N-••••••••••SANGR••••••••••••••••••-OH

C181H275N51O52S 4

1007.762

1007.751

pβ18-SA

H2N-••••••••••SANGA••••••••••••••••••-OH

C178H268N48O52S 4

986.496

986.482

---

---

β23

H2N-KLPPGWEKRMSRSSGRVXYFNHITNASQFERPSGOH

---

---

β23-EA

H2N-••••••EKAMSRSSGRVX••••••••••••••••-OH

C177H263N51O50S 4

984.741

984.735

β23-AR

H2N-••••••AKRMSRSSGRVX••••••••••••••••-OH

C178H268N54O48S 4

991.506

991.503

β23-AA

H2N-••••••AKAMSRSSGRVX••••••••••••••••-OH

C175H261N51O48S 4

970.240

970.232

pβ23

H2N-••••••EKRMSRSSGRVX••••••••••••••••-OH

---

---

pβ23-EA

H2N-••••••EKAMSRSSGRVX••••••••••••••••-OH

C186H282N54O54S 4

1043.026

1043.020

pβ23-AR

H2N-••••••AKRMSRSSGRVX••••••••••••••••-OH

C187H287N57O52S 4

1049.790

1049.787

pβ23-AA

H2N-••••••AKAMSRSSGRVX••••••••••••••••-OH

C184H280N54O52S 4

1028.524

1028.517

---

Figure S1. ESI-TOF MS data for 2α1 (QX108111). Expected [M+4H+]/4 = 928.009.
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---

Figure S2. ESI-TOF MS data for p2α1 (QX108111p). Expected [M+4H+]/4 = 975.539.

Figure S3. ESI-TOF MS data for 2α3 (QX108110). Expected [M+4H+]/4 = 935.010.
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Figure S4. ESI-TOF MS data for p2α3 (QX108110p). Expected [M+4H+]/4 = 982.541.

Figure S5. ESI-TOF MS data for 2α4 (QX10819). Expected [M+4H+]/4 = 935.020.

Figure S6. ESI-TOF MS data for 2α4-KA (QX11192). Expected [M+4H+]/4 = 920.518.
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Figure S7. ESI-TOF MS data for 2α4-AE (QX11193). Expected [M+4H+]/4 = 920.755.

Figure S8. ESI-TOF MS data for 2α4-AA (QX11191). Expected [M+4H+]/4 = 906.254.
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Figure S9. ESI-TOF MS data for p2α4 (QX10819p). Expected [M+4H+]/4 = 982.550.

Figure S10. ESI-TOF MS data for p2α4-KA (QX11195). Expected [M+4H+]/4 = 968.051.

Figure S11. ESI-TOF MS data for p2α4-AE (QX11196). Expected [M+4H+]/4 = 968.285.
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Figure S12. ESI-TOF MS data for p2α4-AA (QX11194). Expected [M+4H+]/4 = 953.787.

Figure S13. ESI-TOF MS data for 2α6 (QX10818). Expected [M+4H+]/4 = 934.774.
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Figure S14. ESI-TOF MS data for p2α6 (QX10818p). Expected [M+4H+]/4 = 982.304.

Figure S15. ESI-TOF MS data for 2α7 (QX10817). Expected [M+4H+]/4 = 938.277.

Figure S16. ESI-TOF MS data for p2α7 (QX10817p). Expected [M+4H+]/4 = 985.808.
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Figure S17. ESI-TOF MS data for 2α10 (QX10816). Expected [M+4H+]/4 = 934.774.

Figure S18. ESI-TOF MS data for p2α10 (QX10816p). Expected [M+4H+]/4 = 982.304.

Figure S19. ESI-TOF MS data for 2α14 (QX10815). Expected [M+4H+]/4 = 945.276.
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Figure S20. ESI-TOF MS data for p2α14 (QX10815p). Expected [M+4H+]/4 = 992.806.

Figure S21. ESI-TOF MS data for 2α18 (QX10814). Expected [M+4H+]/4 = 932.769.

72

Figure S22. ESI-TOF MS data for 2α18-EA (NAB10212). Expected [M+4H+]/4 = 911.503.

Figure S23. ESI-TOF MS data for 2α18-AR (NAB10211). Expected [M+4H+]/4 = 918.268.
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Figure S24. ESI-TOF MS data for 2α18-AA (NAB10213). Expected [M+4H+]/4 = 897.002.

Figure S25. ESI-TOF MS data for p2α18 (QX10814p). Expected [M+4H+]/4 = 980.300.

Figure S26. ESI-TOF MS data for p2α18-EA (NAB10215). Expected [M+4H+]/4 = 959.034.
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Figure S27. ESI-TOF MS data for p2α18-AR (NAB10214). Expected [M+4H+]/4 = 965.798.

Figure S28. ESI-TOF MS data for p2α18-AA (NAB10216). Expected [M+4H+]/4 = 944.532.

Figure S29. ESI-TOF MS data for 2α21 (QX10813). Expected [M+4H+]/4 = 938.523.
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Figure S30. ESI-TOF MS data for p2α21 (QX10813p). Expected [M+4H+]/4 = 986.054.

Figure S31. ESI-TOF MS data for 2α25 (QX10812). Expected [M+4H+]/4 = 949.275.
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Figure S32. ESI-TOF MS data for p2α25 (QX10812p). Expected [M+4H+]/4 = 996.805.

Figure S33. ESI-TOF MS data for 2α28 (QX10811). Expected [M+4H+]/4 = 935.010.
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Figure S34. ESI-TOF MS data for p2α28 (QX10811p). Expected [M+4H+]/4 = 982.541.

Figure S35. ESI-TOF MS data for 3α1 (QX10714). Expected [M+3H+]/3 = 1062.267.

Figure S36. ESI-TOF MS data for 3α1-ER (QX21532). Expected [M+3H+]/3 =1071.602.
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Figure S37. ESI-TOF MS data for 3α1-EA (QX10713). Expected [M+3H+]/3 = 1043.247.

Figure S38. ESI-TOF MS data for 3α1-AK (QX10712). Expected [M+3H+]/3 = 1042.931.
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Figure S39. ESI-TOF MS data for 3α1-AR (QX21531). Expected [M+3H+]/3 =1052.267.

Figure S40. ESI-TOF MS data for 3α1-AA (QX10711). Expected [M+3H+]/3 = 1023.912.

Figure S41. ESI-TOF MS data for p3α1 (QX10718). Expected [M+3H+]/3 = 1125.640.
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Figure S42. ESI-TOF MS data for p3α1-ER (QX21534). Expected [M+3H+]/3 =1134.976.

Figure S43. ESI-TOF MS data for p3α1-EA (QX10717). Expected [M+3H+]/3 = 1106.621.
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Figure S44. ESI-TOF MS data for p3α1-AK (QX10716). Expected [M+3H+]/3 = 1106.305.

Figure S45. ESI-TOF MS data for p3α1-AR (QX21533). Expected [M+3H+]/3 =1115.640.

Figure S46. ESI-TOF MS data for p3α1-AA (QX10715). Expected [M+3H+]/3 = 1087.286.
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Figure S47. ESI-TOF MS data for 3α6 (QX10511). Expected [M+3H+]/3 = 1062.267.

Figure S48. ESI-TOF MS data for 3α6-KA (QX10512). Expected [M+3H+]/3 = 1042.931.
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Figure S49. ESI-TOF MS data for 3α6-AE (QX10513). Expected [M+3H+]/3 = 1043.247.

Figure S50. ESI-TOF MS data for 3α6-AA (QX10514). Expected [M+3H+]/3 = 1023.912.

Figure S51. ESI-TOF MS data for p3α6 (QX10515). Expected [M+3H+]/3 = 1125.640.
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Figure S52. ESI-TOF MS data for p3α6-KA (QX10516). Expected [M+3H+]/3 = 1106.305.

Figure S53. ESI-TOF MS data for p3α6-AE (QX10517). Expected [M+3H+]/3 = 1106.621.
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Figure S54. ESI-TOF MS data for p3α6-AA (QX10518). Expected [M+3H+]/3 = 1087.286.

Figure S55. ESI-TOF MS data for β18 (EL1101). Expected [M+4H+]/4 = 967.231.

Figure S56. ESI-TOF MS data for β18-DA. Expected [M+4H+]/4 = 945.965.
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Figure S57. ESI-TOF MS data for β18-SR (ML1006). Expected [M+4H+]/3 = 1279.973.

Figure S58. ESI-TOF MS data for β18-SA. Expected [M+4H+]/3 = 1251.619.
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Figure S59. ESI-TOF MS data for pβ18 (QX10492). Expected [M+4H+]/4 = 1014.747.

Figure S60. ESI-TOF MS data for pβ18-DA (QX10494). Expected [M+4H+]/4 = 993.495.

Figure S61. ESI-TOF MS data for pβ18-SR (QX10491). Expected [M+4H+]/4 = 1007.762.
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Figure S62. ESI-TOF MS data for pβ18-SA (QX10493). Expected [M+4H+]/4 = 986.496.

Figure S63. ESI-TOF MS data for β23-EA (SD2006#2). Expected [M+4H+]/4 = 984.741.

Figure S64. ESI-TOF MS data for β23-AR (SD2018). Expected [M+4H+]/4 = 991.506.
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Figure S65. ESI-TOF MS data for β23-AA (SD2006#1). Expected [M+4H+]/4 = 970.240.

Figure S66. ESI-TOF MS data for pβ23-EA (SD2006#2C). Expected [M+4H+]/4 = 1043.026.
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Figure S67. ESI-TOF MS data for pβ23-AR (SD2018C). Expected [M+4H+]/4 = 1049.790.

Figure S68. ESI-TOF MS data for pβ23-AA (SD2006#1C). Expected [M+4H+]/4 = 1028.524
Peptide solution was injected onto a C18 analytical column and eluted with a linear gradient of 10-60% B (A = H2O,
0.1% TFA; B= MeCN, 0.1% TFA) over 50 min.; 10-min. rinse (95% B); and 10-min. column re-equilibration.

Figure S69. Analytical HPLC data for 2α1 (QX108111). Retention time = 36.042 minutes.
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Figure S70. Analytical HPLC data for p2α1 (QX108111p). Retention time = 37.750 minutes.

Figure S71. Analytical HPLC data for 2α3 (QX108110). Retention time = 36.625 minutes.

Figure S72. Analytical HPLC data for p2α3 (QX108110p). Retention time = 37.233 minutes.
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Figure S73. Analytical HPLC data for 2α4 (QX10819). Retention time = 35.683 minutes.

Figure S74. Analytical HPLC data for 2α4-KA (QX11192). Retention time = 49.983 minutes.

Figure S75. Analytical HPLC data for 2α4-AE (QX11193). Retention time = 52.491 minutes.
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Figure S76. Analytical HPLC data for 2α4-AA (QX11191). Retention time = 51.358 minutes.

Figure S77. Analytical HPLC data for p2α4 (QX10819p). Retention time = 41.625 minutes.
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Figure S78. Analytical HPLC data for p2α4-KA (QX11195). Retention time = 53.067 minutes.

Figure S79. Analytical HPLC data for p2α4-AE (QX11196). Retention time = 60.617 minutes.

Figure S80. Analytical HPLC data for p2α4-AA (QX11194). Retention time = 54.008 minutes.

95

Figure S81. Analytical HPLC data for 2α6 (QX10818). Retention time = 33.617 minutes.

Figure S82. Analytical HPLC data for p2α6 (QX10818p). Retention time = 34.450 minutes.

Figure S83. Analytical HPLC data for 2α7 (QX10817). Retention time = 35.750 minutes.

Figure S84. Analytical HPLC data for p2α7 (QX10817p). Retention time = 35.900 minutes.
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Figure S85. Analytical HPLC data for 2α10 (QX10816). Retention time = 34.525 minutes.

Figure S86. Analytical HPLC data for p2α10 (QX10816p). Retention time = 41.600 minutes.

Figure S87. Analytical HPLC data for 2α14 (QX10815). Retention time = 41.525 minutes.

97

Figure S88. Analytical HPLC data for p2α14 (QX10815p). Retention time = 36.100 minutes.

Figure S89. Analytical HPLC data for 2α18 (QX10814). Retention time = 42.958 minutes.

Figure S90. Analytical HPLC data for 2α18-EA (NAB10212). Retention time = 44.467 minutes.
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Figure S91. Analytical HPLC data for 2α18-AR (NAB10211). Retention time = 38.275 minutes.

Figure S92. Analytical HPLC data for 2α18-AA (NAB10213). Retention time = 39.775 minutes.

Figure S93. Analytical HPLC data for p2α18 (QX10814p). Retention time = 38.117 minutes.
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Figure S94. Analytical HPLC data for p2α18-EA (NAB10215). Retention time = 45.283 minutes.

Figure S95. Analytical HPLC data for p2α18-AR (NAB10214). Retention time = 36.842 minutes.

Figure S96. Analytical HPLC data for p2α18-AA (NAB10216). Retention time = 47.250 minutes.
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Figure S97. Analytical HPLC data for 2α21 (QX10813). Retention time = 41.825 minutes.

Figure S98. Analytical HPLC data for p2α21 (QX10813p). Retention time = 36.450 minutes.

Figure S99. Analytical HPLC data for 2α25 (QX10812). Retention time = 41.667 minutes.
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Figure S100. Analytical HPLC data for p2α25 (QX10812p). Retention time = 36.300 minutes.

Figure S101. Analytical HPLC data for 2α28 (QX10811). Retention time = 42.492 minutes.

Figure S102. Analytical HPLC data for p2α28 (QX10811p). Retention time = 36.917 minutes.
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Figure S103. Analytical HPLC data for 3α1 (QX10714). Retention time = 39.442 minutes.

Figure S104. Analytical HPLC data for 3α1-ER (QX21352). Retention time = 46.250 minutes.
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Figure S105. Analytical HPLC data for 3α1-EA (QX10713). Retention time = 40.150 minutes.

Figure S106. Analytical HPLC data for 3α1-AK (QX10712). Retention time = 39.217 minutes.

Figure S107. Analytical HPLC data for 3α1-AR (QX21531). Retention time = 45.933 minutes.

Figure S108. Analytical HPLC data for 3α1-AA (QX10711). Retention time = 39.858 minutes.
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Figure S109. Analytical HPLC data for p3α1 (QX10718). Retention time = 40.483 minutes.

Figure S110. Analytical HPLC data for p3α1-ER (QX21354). Retention time = 48.367 minutes.
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Figure S111. Analytical HPLC data for p3α1-EA (QX10717). Retention time = 40.492 minutes.

Figure S112. Analytical HPLC data for p3α1-AK (QX10716). Retention time = 40.575 minutes.

Figure S113. Analytical HPLC data for p3α1-AR (QX21353). Retention time = 47.808 minutes.

Figure S114. Analytical HPLC data for p3α1-AA (QX10715). Retention time = 41.375 minutes.
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Figure S115. Analytical HPLC data for 3α6 (QX10511). Retention time = 39.725 minutes.

Figure S116. Analytical HPLC data for 3α6-KA (QX10512). Retention time = 40.317 minutes.

Figure S117. Analytical HPLC data for 3α6-AE (QX10513). Retention time = 45.183 minutes.
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Figure S118. Analytical HPLC data for 3α6-AA (QX10514). Retention time = 45.808 minutes.

Figure S119. Analytical HPLC data for p3α6 (QX10515). Retention time = 40.425 minutes.

Figure S120. Analytical HPLC data for p3α6-KA (QX10516). Retention time = 40.267 minutes.\
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Figure S121. Analytical HPLC data for p3α6-AE (QX10517). Retention time = 45.517 minutes.

Figure S122. Analytical HPLC data for p3α6-AA (QX10518). Retention time = 46.850 minutes.
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Figure S123. Analytical HPLC data for β18 (EL1101). Retention time = 25.52 minutes.

Figure S124. Analytical HPLC data for β18-DA. Retention time = 28.93 minutes.

Figure S125. Analytical HPLC data for β18-SR (ML1006). Retention time = 25.5 minutes.
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Figure S126. Analytical HPLC data for β18-SA. Retention time = 28.91 minutes.

Figure S127. Analytical HPLC data for pβ18 (QX10492). Retention time = 26.767 minutes.

Figure S128. Analytical HPLC data for pβ18-DA (QX10494). Retention time = 30.533 minutes.
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Figure S129. Analytical HPLC data for pβ18-SA (QX10491). Retention time = 26.525 minutes.

Figure S130. Analytical HPLC data for pβ18-SA (QX10493). Retention time = 30.458 minutes.

Figure S131. HPLC data for β23-EA (SD2006#2).
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Figure S132. HPLC MS data for β23-AR (SD2018).

Figure S133. HPLC MS data for β23-AA (SD2006#1).
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Figure S134. HPLC MS data for pβ23-EA (SD2006#2C).

Figure S135. HPLC MS data for pβ23-AR (SD2018C).

Figure S136. HPLC MS data for pβ23-AA (SD2006#1C).
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2.5.2 Biophysical characterization of peptide variants
Self-association Properties of Peptides: Size Exclusion Chromatography: Previously characterized
peptide 1CW adopts a homotrimeric self-association state in solution, whereas GCN4 adopts a
homodimeric self-association state in solution. The peptides explored here (shown in Supplementary
Table 1) precluded the use of time- and resource-intensive sedimentation equilibrium experiments to
characterize their self-association properties. Consequently, we used the higher throughput size exclusion
chromatography to characterize the self-association properties of peptides by comparing their retention
times on a size-exclusion column to the retention times of homotrimeric 1CW, homodimeric GCN4 and
monomeric α-helical PSBD36.5-7
Size exclusion chromatography (SEC) was done on a Shimadzu HPLC instrument using a
Phenomenex yarra 3u sec-3000 column (batches 1 and 2) or a Zenix-C SEC 100 column (batches 3 and
4). The columns were calibrated with internal 1CW, GCN4, and PSBD36 standards. Previous
characterization

of

1CW,

GCN4,

and

PSBD36

by

sedimentation

equilibrium

analytical

ultracentrifugation under analogous buffer conditions demonstrates that 1CW adopts a trimeric
association state; that GCN4 adopts a dimeric state; and that PSBD36 is an α-helical monomer.
The retention times derived from SEC experiments on α3 series of peptides are very close to that
of trimeric 1CW, suggesting that these variants likewise adopt a trimeric association state. Similarly, the
retention times derived from SEC experiments on α2 series of peptides are close to that of dimeric GCN4,
suggesting that these variants likewise adopt a dimeric association state. Variants α210, pα21 and p3α1-
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AR have retention time between dimer and monomer or dimer and trimer simply because they are in an
equilibrium of those two states.
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Table S4. Retention times of helical peptides on a Zenix-C SEC 100 column.
Peptide
PSBD36(monomer standard)
GCN4/2α21(dimer standard)
1CW(trimer standard)
2α28
2α25
2α18
2α14
2α10
2α7
2α6
2α4
2α3
2α1
p2α28
p2α25
p2α21
p2α18
p2α14
p2α10
p2α7
p2α6
p2α4
p2α3
p2α1
2α4-AA
2α4-KA
2α4-AE
p2α4-AA
p2α4-KA
p2α4-AE
2α18-AR
2α18-EA
2α18-AA
p2α18-AR
p2α18-EA
p2α18-AA
3α6
3α6-KA
3α6-AE
3α6-AA
p3α6
p3α6-KA

Batch 1
Retention Time
12.08
10.28
9.41
10.38
10.35
10.18
10.32
11.55
10.65
10.66
10.30
10.26
10.00
10.26
10.31
10.14
10.08
10.08
10.18
10.53
10.66
11.18
10.36
9.98
10.83
10.65
10.31
10.66
10.60
10.19
11.29
10.47
10.88
11.04
10.48
10.91
9.65
9.74
9.54
9.70
9.71
9.81
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Inferred association state

dimer
dimer
dimer
dimer
dimer/monomer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer/trimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
trimer
trimer
trimer
trimer
trimer
trimer

p3α6-AE
p3α6-AA
3α1-EA
3α1
p3α1-EA
p3α1

Peptide
GCN4/2α21(dimer standard)
p2α4
3α1-AR
3α1-ER
p3α1-AR
p3α1-ER
3α1-AA
3α1-AK
p3α1-AA
p3α1-AK

9.48
9.68
9.66
9.72
9.74
9.87

Batch 2
Retention Time
12.05
11.84
10.74
10.08
11.21
10.37
10.26
10.29
10.48
10.55

trimer
trimer
trimer
trimer
trimer
trimer

Inferred association state
dimer
trimer
trimer
trimer/dimer
trimer
trimer
trimer
trimer
trimer

Circular Dichroism Spectropolarimetry: Measurements were made with an Aviv 420 Circular
Dichroism Spectropolarimeter, using quartz cuvettes with a path length of 0.1 cm. Protein solutions were
prepared in 20 mM sodium phosphate buffer, pH 7, and protein concentrations were determined
spectroscopically based on tyrosine and tryptophan absorbance at 280 nm in 6 M guanidine hydrochloride
+ 20 mM sodium phosphate (εTrp = 5690 M-1cm-1, εTyr = 1280 M-1cm-1).8 CD spectra of 30 μM solutions
were obtained from 260 to 200 nm at 25°C. Variable temperature CD data were obtained at least in
triplicate (one sample was made and then aliquoted into three different cuvettes) by monitoring the molar
ellipticity [θ] at 222 nm of 30 μM solutions of each α-helical variant and at 227 nm of 50 μM solutions of
each β-sheet variant in 20 mM sodium phosphate (pH 7) from 1 to 95 °C at 2 °C intervals, with 120 s
equilibration time between data points and 30 s averaging time.
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Triplicate variable temperature CD data for each peptide were fit globally to a two-state model for
thermally-induced unfolding. This approach treats the observed [θ] of a peptide solution at a given
temperature as the average of the [θ] values for the folded state and the unfolded ensemble, weighted
according to their relative concentrations at that temperature, as shown in the following equation:
[θ] = (uo + uo T)(1 − Ffolded ) + (fo + f1 T)(Ffolded )

(S1)

In equation S1, T is the temperature in Kelvin; uo and u1 are the intercept and slope of the pre-transition
baseline (which represents the linear dependence of the unfolded ensemble CD signal [θ] on temperature);
fo and f1 are the intercept and slope of the pre-transition baseline (which represents the linear dependence
of the folded state CD signal [θ] on temperature); and Ffolded is the fraction of the total protein concentration
that is folded as at temperature T.
Ffit is a function of the folding equilibrium constant; its precise form depends on whether or not
the associate state of the protein changes upon folding. Folding of the GCN4-p1 variants listed in Table
S1 involves association of two unfolded monomers M into a folded dimer D with temperature-dependent
equilibrium constant K as defined below:
[𝐃𝐃]

2𝐌𝐌 ⇌ 𝐃𝐃; 𝐊𝐊 = [𝐌𝐌]2

(S2)

P = [𝐌𝐌] + 2[𝐃𝐃] = [𝐌𝐌] + 2𝐊𝐊[𝐌𝐌]2

(S3)

The constant total concentration of peptide in solution P is defined by the equation S3:

The positive root of this quadratic equation provides an expression for [M] as a function of P and K:
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[𝐌𝐌] = √1+8𝐊𝐊𝐊𝐊−1

(S4)

4𝑲𝑲

Substitution of [M] into the definition of Ffolded gives the following expression for the monomer-dimer
equilibrium:
Ffolded =

2𝐊𝐊[𝐌𝐌]2
𝐏𝐏

=1+

1

4𝐊𝐊𝐊𝐊

−�

1

16𝐊𝐊2 𝐏𝐏2

−

1

(S5)

2𝐊𝐊𝐊𝐊

Folding of the 1CW variants listed in Table S2 involves association of three unfolded monomers
M into a folded trimer Tri with temperature-dependent equilibrium constant K as defined below:
[𝐓𝐓𝐓𝐓𝐓𝐓]

3𝐌𝐌 ⇌ 𝐓𝐓𝐓𝐓𝐓𝐓; 𝐊𝐊 = [𝐌𝐌]3

(S6)

P = [𝐌𝐌] + 3[𝐃𝐃] = [𝐌𝐌] + 3𝐊𝐊[𝐌𝐌]3

(S7)

The constant total concentration of peptide in solution P is defined by equation S7:

Rearranging equation S7 results in the following polynomial equation that is cubic in [M]:
0 = [𝐌𝐌]3 +

[𝐌𝐌]
3𝐊𝐊

−

𝐏𝐏

(S8)

3𝐊𝐊

Using Mathematica, we found the three roots of this polynomial, two of which are complex, whereas the
third is real. The real root of equation S8 provides an expression for [M] as a function of P and K:

[𝐌𝐌] = �

𝐏𝐏

6𝐊𝐊

+�

1

729𝐊𝐊3

𝐏𝐏2

1
2

1
3

+ 36𝐊𝐊2 � � −

1

9𝐊𝐊�

1
1 3
2

𝐏𝐏
1
𝐏𝐏2
+�
+
�
6𝐊𝐊
729𝐊𝐊3 36𝐊𝐊2

(S9)

�

Substitution of [M] into the definition of Ffolded gives the following expression for the monomer-trimer
equilibrium:
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Ffolded =

3𝐊𝐊[𝐌𝐌]3

(S10)

𝐏𝐏

Folding of the WW variants listed in Table S3 involves an equilibrium between an unfolded
monomer (U) and a folded monomer (F) temperature-dependent equilibrium constant K as defined below:
[𝐅𝐅]

𝐔𝐔 ⇌ 𝐅𝐅; 𝐊𝐊 = [U]

(S11)

P = [𝐔𝐔] + [𝐅𝐅] = [𝐔𝐔] + 𝐊𝐊[𝐔𝐔]

(S12)

The constant total concentration of peptide in solution P is defined by equation S11:

Ffolded of the monomer folding equilibrium is defined as follows:
Ffolded =

𝐊𝐊

(S13)

1+𝐊𝐊

In each of these cases, K is related to the change in free energy upon folding (ΔGf):
ΔGf

𝐊𝐊 = e− RT

(S14)

In turn, the temperature-dependence of ΔGf for the dimer or trimer can be expressed as a second order
polynomial:
∆

f

= ∆

o

+ ∆

1 (T

− To ) + ∆

2 (T −

To )2

(S15)

where ΔG0, ΔG1 and ΔG2 are parameters to be determined via least-squares regression (though ΔG2 is
excluded when its standard error is too high), and T0 is an arbitrary reference temperature that should be
close to the melting temperature. We used this expression for the GCN4-p1 and 1CW variants, though
many of the 1CW variants did not require the use of ΔG2. For the WW variants, we used the following
expression for the temperature-dependence of ΔGf, which is a function of folding enthalpy at the melting
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temperature ΔH(Tm), folding heat capacity ΔCp, and the melting temperature Tm (i.e., the temperature at
which Ffolded = 0.5 and ΔGf = 0 kcal/mol):
∆

f

=

∆H(Tm )∙(Tm −T)
Tm

+ ΔCp ∙ (T − Tm − T ∙ ln �

T

Tm

�)

(S16)

We used least-squares regression to fit the variable temperature CD for each variant to these equations.
Far-UV CD spectra and variable temperature CD data for these compounds are shown below in Figures
S137-S200, along with the parameters of the fits (and their standard errors and p-values) and fit statistics
(including R2 and sum of the squared residuals). For the monomer-dimer and monomer-trimer equilibria,
the melting temperature Tm (defined as the temperature at which Ffolded = 0.5) is not a parameter of the fit.
In these cases, we used Mathematica to solve for Tm numerically.
Each of the ΔGf values listed in Tables 1 and 2 was calculated based on parameters obtained from
least-squares regression of triplicate variable temperature CD data to equations derived from two-state
folding-unfolding equilibrium models (monomer for WW variants, monomer-dimer for GCN4-p1
variants, and monomer-trimer for 1CW variants). The least-squares regression generates a standard error
(s) and p-value (p) for each parameter. The p-value represents the probability that the parameter is
indistinguishable from zero (i.e., the null hypothesis). In general, parameters where p > 0.001 were omitted
from the fit, due to insufficient evidence for rejecting the null hypothesis. Figures S137–S200 show s and
p for each fit parameter of each protein described in the main text. In every case, parameters used to
calculate ΔGf in Tables 1 and 2 of the main text have p < 0.001, meaning that these parameters are
significant at the 99.9% level.
Standard errors in the ΔGf values in the main text were calculated and propagated based on the
variance method, using the parameter standard errors described above. In general, if f is a function of
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independent variable x and parameters a, b, and c (which have known standard errors sa, sb, and sc,
respectively), then the standard error in f(x) (i.e., sf) is given by the following equation:
𝑠𝑠𝑓𝑓 = ��

𝛿𝛿𝛿𝛿(𝑥𝑥)
𝛿𝛿𝛿𝛿

2

∙ 𝑠𝑠𝑎𝑎 � + �

𝛿𝛿𝛿𝛿(𝑥𝑥)
𝛿𝛿𝛿𝛿

2

∙ 𝑠𝑠𝑏𝑏 � + �

𝛿𝛿𝛿𝛿(𝑥𝑥)

∙ 𝑠𝑠𝑐𝑐 �

𝛿𝛿𝛿𝛿

2

(S17)

where δf(x)/δa is the partial derivative of f(x) with respect to a, δf(x)/δb is the partial derivative of f(x)
with respect to b, and δf(x)/δc is the partial derivative of f(x) with respect to c.
For the monomer folding-unfolding equilibria of the WW variants:
∆

f

=

∆H0 ∙(Tm −T)

+ ΔCp ∙ (T − Tm − T ∙ ln �

Tm

𝑑𝑑ΔGf

𝑑𝑑ΔGf

𝑑𝑑ΔGf
𝑑𝑑Tm

𝑑𝑑ΔCp

𝑑𝑑ΔH0

=

Tm −T
T

= T − Tm − T 𝑙𝑙𝑙𝑙 �

= ΔCp �

T

− 1� −

2

𝑑𝑑ΔG

T

Tm

Tm

�

ΔH0 Tm −T
�
Tm
Tm

𝑑𝑑ΔG

T

Tm

2

p

(S19)
(S20)
(S21)

− 1�
𝑑𝑑ΔG

𝜎𝜎ΔGf = ��𝑑𝑑ΔHf ∙ 𝑠𝑠ΔH0 � + �𝑑𝑑ΔC f ∙ 𝑠𝑠ΔCp � + � 𝑑𝑑T f ∙ 𝑠𝑠Tm �
0

(S18)

�)

m

2

(S22)

where T is temperature (i.e. the independent variable in our variable temperature CD experiments); Tm is
the melting temperature (i.e., the temperature at which ΔGf = 0 kcal/mol); ΔH0 is the folding enthalpy
parameter at T = Tm; ΔCp is the folding heat capacity parameter; and sΔH0, sTm, and sΔCp are standard errors
of the ΔH0, Tm, and ΔCp parameters, respectively.
For the monomer-dimer equilibria of the GCN4-p1 variants and the monomer-trimer equilibria of
the 1CW variants, the dependence of ΔGf on temperature be expressed as a second order polynomial:
∆

f

= ∆

o

+ ∆

1 (T

− To ) + ∆

𝑑𝑑ΔGf

𝑑𝑑ΔG0
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2 (T −

To )2

(S23)
(S24)

𝑑𝑑ΔGf

𝑑𝑑ΔG1

𝑑𝑑ΔGf

𝑑𝑑ΔG2
2

𝑑𝑑ΔG

(S25)

= T − T0

(S26)

= (T − T0 )2
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𝑑𝑑ΔG

𝑠𝑠ΔGf = ��𝑑𝑑ΔG f ∙ 𝑠𝑠ΔG0 � + �𝑑𝑑ΔG f ∙ 𝑠𝑠ΔG1 � + �𝑑𝑑ΔG f ∙ 𝑠𝑠ΔG2 �
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2
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(S27)

where ΔG0, ΔG1, and ΔG2 are parameters to be determined via least-squares regression; T0 is an arbitrary
reference temperature that should generally be near the thermal unfolding transition; and sΔG0, sΔG1, and
sΔG2 are standard errors of the ΔG0, ΔG1, and ΔG2 parameters, respectively.
The difference between the ΔGf values of two protein variants that differ in amino acid
composition at one position (ΔΔG) describes the impact of a single mutation on folding free energy. In a
double mutant cycle, the difference between two ΔΔG values (ΔΔΔG) can describe the strength of an
interaction between two residues. In a triple mutant cycle, the difference between two ΔΔΔGf values
(ΔΔΔΔG) can describe the impact of a third residue on the strength of an interaction between two other
residues. Propagation of error is similar for ΔΔG, ΔΔΔG, and ΔΔΔΔG:
Δ𝑛𝑛 = Δ𝑛𝑛−1
𝑑𝑑Δ𝑛𝑛 G

𝑑𝑑Δ𝑛𝑛−1 G1
𝑑𝑑Δ𝑛𝑛 G

𝑑𝑑Δ𝑛𝑛 G

𝑑𝑑Δ𝑛𝑛−1 G1

− Δ𝑛𝑛−1

= −1

𝑑𝑑Δ𝑛𝑛−1 G2

𝜎𝜎Δ𝑛𝑛 G = ��

2

=1
2

∙ 𝑠𝑠Δ𝑛𝑛−1G1 � + �

(S28)

1

(S29)
(S30)

𝑑𝑑Δ𝑛𝑛 G

𝑑𝑑Δ𝑛𝑛−1G2

∙ 𝑠𝑠Δ𝑛𝑛−1 G2 �

2

(S31)

where sΔn–1G1 and sΔn–1G2 are the standard errors in Δn–1G1 and Δn–1G2, respectively; and n = 2 (for ΔΔG),
3 (for ΔΔΔG), or 4 (for ΔΔΔΔG).
In the main text we have been careful to avoid drawing conclusions from ΔGf, ΔΔG, ΔΔΔG,
ΔΔΔΔG values that are small relative to their associated standard errors. To make this point clearer, we
have used the two-tailed t-test to test the null hypothesis that a given ΔΔG, ΔΔΔG, or ΔΔΔΔG value is
equal to zero. We reject this null hypothesis when p ≤ 0.10 (i.e., there is less than 10% probability that the
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ΔΔG, ΔΔΔG, or ΔΔΔΔG value is equal to zero); in such cases, we have highlighted the corresponding
ΔΔG, ΔΔΔG, or ΔΔΔΔG value with an asterisk. For the t-test, we have used the smallest number of
degrees of freedom possible for this comparison of two ΔG, ΔΔG, or ΔΔΔG values: n = 2 and df = n–1 =
1. Alternatively, one could argue that it would be more appropriate for n = sum of the number of data
points involved in the fits used to obtain the pertinent ΔG values; this approach would tend to decrease
the magnitude of the resulting p-values substantially relative to the p-values obtained from the df = 1
analysis. Our approach consequently provides a very conservative estimate of the statistical significance
of the ΔΔG, ΔΔΔG, or ΔΔΔΔG values give in Tables 1 and 2 of the main text.
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Figure S137. CD data spectra for 2α1 (QX108111).

Figure S138. CD data for p2α1 (QX108111p).
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Figure S139. CD data for 2α3 (QX108110).

Figure S140. CD data for p2α3 (QX108110p).
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Figure S141. CD data for 2α4 (QX10819).

Figure S142. CD data for p2α4 (QX10819p).
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Figure S143. CD data for 2α6 (QX10818).

Figure S144. CD data for p2α6 (QX10818p).
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Figure S145. CD data for 2α7 (QX10817).

Figure S146. CD data for p2α7 (QX10817p).
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Figure S147. CD data for 2α10 (QX10816).

Figure S148. CD data for p2α10 (QX10816p).
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Figure S149. CD data for 2α14 (QX10815).

Figure S150. CD data for p2α14 (QX10815p).
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Figure S151. CD data for 2α18 (QX10814).

Figure S152. CD data for p2α18 (QX10814p).
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Figure S153. CD data for 2α21 (QX10813).

Figure S154. CD data for p2α21 (QX10813p).
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Figure S155. Cd data for 2α25 (QX10812).

Figure S156. CD data for p2α25 (QX10812p).
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Figure S157. CD data for 2α28 (QX10811).

Figure S158. CD data for p2α28 (QX10811p).
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Figure S159. CD data for 2α4-AE (QX11193).

Figure S160. CD data for p2α4-AE (QX11196).
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Figure S161. CD data for 2α4-KA (QX11192).

Figure S162. CD data for p2α4-KA (QX11195).
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Figure S163. CD data for 2α4-AA (QX11191).

Figure S164. CD data p2α4-AA (QX11194).
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Figure S165. CD data for 2α18-AR (NAB10211).

Figure S166. CD data for p2α18-AR (NAB10214).
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Figure S167. CD data 2α18-EA (NAB10212).

Figure S168. CD data for p2α18-EA (NAB10215).
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Figure S169. CD data for 2α18-AA (NAB10213).

Figure S170. CD data for p2α18-AA (NAB10216).
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Figure S171. CD data for 3α6 (QX10511).

Figure S172. CD data for 3α6-KA (QX10512).
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Figure S173. CD data for 3α6-AE (QX10513).

Figure S174. CD data for 3α6-AA (QX10514).
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Figure S175. CD data for p3α6 (QX10515).

Figure S176. CD data for p3α6-KA (QX10516).
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Figure S177. CD data for p3α6-AE (QX10517).

Figure S178. CD data for p3α6-AA (QX10518).
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Figure S179. CD spectra 3α1-AA (QX10711).

Figure S180. CD spectra for 3α1-AK (QX10712).
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Figure S181. CD data for 3α1-EA (QX10713).

Figure S182. CD data for 3α1 (QX10714).
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Figure S183. CD data for p3α1-AA (QX10715).

Figure S184. CD data for p3α1-AK (QX10716).
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Figure S185. CD data for p3α1-EA (QX10717).

Figure S186. CD data for p3α1 (QX10718).
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Figure S187. CD data for pβ18-SA (QX10491).

Figure S188. CD data for pβ18-DA (QX10492).
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Figure S189. CD data for β18-SA (QX10493).

Figure S190. CD data for β18-DA (QX10494).
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Figure S191. CD data for 3α1-AR (QX21531).

Figure S192. CD data for 3α1-ER (QX21532).
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Figure S193. CD data for p3α1-AR (QX21533).

Figure S194. CD data for p3α1-ER (QX21534).
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Figure S195. CD data for β23-EA (SD2006#2).

Figure S196. CD data for β23-AR (SD2018).
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Figure S197. CD data for β23-AA (SD2006#1).
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Figure S198. CD data for pβ23-EA (SD2006#2C).

Figure S199. CD data for pβ23-AR (SD2018C).
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Figure S200. CD spectra for pβ23-AA (SD2006#1C).
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Percent Reversibility Data: Reversibility data were obtained by comparing molar ellipticity at 222 nm
for α-helical peptides or at 227 for β-sheet peptides at 25 °C before and after equilibration at 95 °C. The
values given in the table below represent the percent of the starting CD signal recovered after
equilibration at 95 °C and cooling back to 25 °C.
GCN4 Variants
Name

Percent Reversibility

2α1
p2α1
2α3
p2α3
2α4
2α4-KA
2α4-AE
2α4-AA
p2α4
2α4-KA
2α4-AE
2α4-AA
2α6
p2α6
2α7
p2α7
2α10
p2α10
2α14
p2α14
2α18
2α18-EA
2α18-AR
2α18-AA
p2α18
p2α18-EA
p2α18-AR
p2α18-AA
2α21
p2α21

83%
81%
70%
70%
80%
65%
72%
69%
86%
70%
68%
76%
61%
68%
84%
81%
82%
80%
80%
87%
84%
84%
67%
67
86%
84%
60%
74%
97%
88%
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2α25
p2α25
2α28
p2α28

94%
81%
99%
83%

1CW Variants
Name

Percent Reversibility

3α1
3α1-ER
3α1-EA
3α1-AK
3α1-AR
3α1-AA
p3α1
p3α1-ER
p3α1-EA
p3α1-AK
p3α1-AR
p3α1-AA
3α6
3α6-KA
3α6-AE
3α6-AA
p3α6
p3α6-KA
p3α6-AE
p3α6-AA

96%
99%
101%
96%
97%
97%
98%
100%
98%
98%
99%
98%
98%
96%
100%
98%
102%
93%
99%
99%

WW Variants
Name

Percent Reversibility

β18

No Data

β18-DA

No Data

β18-SR

No Data

β18-SA

No Data
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pβ18

72%

pβ18-DA

74%

pβ18-SR

67%

pβ18-SA

80%

β23

59%

β23-EA

54%

β23-AR

40%

β23-AA

52%

pβ23

56%

pβ23-EA

No Data

pβ23-AR

62%

pβ23-AA

No Data

Table S5. Triple mutant box analysis of the impact of PEGylation on salt-bridge strength within peptide
p3α1-ER.a
Peptide

Sequence

Tm (°C)

ΔGf
(kcal/mol)

ΔΔGf / nb
(kcal/mol
per
monomer)

ΔΔΔGf / nc ΔΔΔΔGf / nd
(kcal/mol
(kcal/mol
per
per
monomer) monomer)
-0.60 ± 0.02*

QVEALERKVEALESKVQKLEKKVEALEHGWDGR
3α1-ER
77.9 -15.38 ± 0.02
QVEALEA••••••••••••••••••••••••••
3α1-EA
76.0 -14.90 ± 0.02
QVAALER••••••••••••••••••••••••••
3α1-AR
73.0 -14.18 ± 0.02
QVAALEA••••••••••••••••••••••••••
3α1-AA
76.1 -14.92 ± 0.03
QVEALER••••••••••••••••••••••••••
p3α1-ER
74.7 -14.61 ± 0.02 0.38 ± 0.01* -0.56 ± 0.02* 0.05 ± 0.03
QVEALEA••••••••••••••••••••••••••
p3α1-EA
73.9 -14.40 ± 0.02 0.17 ± 0.01*
QVAALER••••••••••••••••••••••••••
p3α1-AR
70.7 -13.68 ± 0.01 0.25 ± 0.01*
QVAALEA••••••••••••••••••••••••••
p3α1-AA
74.7 -14.59 ± 0.02 0.11 ± 0.01*
a
Q = GlnPEG. Variable temperature CD experiments were performed in 20 mM phosphate buffer (pH 7) at 30 μM protein
concentration. ΔGf values are given ± standard error at the average melting temperature for these variants (347.8 K). n = 2 for
homodimeric GCN4-p1 variants (2α4, 2α18 and their derivatives); n = 3 for homotrimeric 1CW variants (3α1, and its
derivatives. bImpact of PEGylation on peptide/protein conformational stability in kcal/mol per monomer. For example, ΔΔGf
= ΔGf (p3α1-ER) – ΔGf (3α1-ER). cStrength of salt-bridge interaction per monomer. For example, ΔΔΔGf = ΔGf (3α1-ER) –
ΔGf (3α1-EA) – ΔGf (3α1-AR) + ΔGf (3α1-AA). dImpact of PEGylation on salt-bridge strength per monomer. For example,
ΔΔΔΔGf = ΔGf (p3α1-ER) – ΔGf (p3α1-EA) – ΔGf (p3α1-AR) + ΔGf (p3α1-AA) – ΔGf (3α1-ER) + ΔGf (3α1-EA) + ΔGf
(3α1-AR) – ΔGf (3α1-AA). Αsterisks indicate ΔΔGf / n, ΔΔΔGf / n, and ΔΔΔΔGf / n values for which p < 0.10 in a two-tailed
t-test.
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2.5.3 Crystallographic characterization of 2α18 and p2α18
2α18: 2α18 was crystalized by vapor diffusion in sitting drops where the well solution contained
0.1 M PCTP (sodium propionate, sodium cacodylate trihydrate, and bis-Tris Propane) and 25% w/v
PEG 1500 at pH 4. Each drop contained 0.3 μL well solution and 0.3 μL peptide (10 mg/ml in water).
Crystals were looped and cryocooled by plunging them into liquid nitrogen prior to data collection. Data
were collected at 100 K with a copper rotating anode X-ray source (Bruker FR-591 Dual Source Low
Temperature X-ray Diffractometer with CCD Detector).
p2α18: 2α18 was crystalized by vapor diffusion in sitting drops where the well solution
contained 0.1 M sodium malonate dibasic monohydrate and 25% w/v PEG 1500 at pH 4. Each drop
contained 0.3 μL well solution and 0.3 μL peptide (10 mg/ml in water). Crystals were looped and
cryocooled by plunging them into liquid nitrogen prior to data collection. Data were collected at 100 K
with a copper rotating anode X-ray source (Bruker FR-591 Dual Source Low Temperature X-ray
Diffractometer with CCD Detector).
The data were integrated and scaled using Protium. The molecular replacement and refinement
were done in Phenix. Model building was carried out in winCOOT.
Table S6. Crystallographic statistics
Data collection 2α18 unPEGylated

PDB ID: 6O2E

Data collection p2α18 PEGylated

PDB ID: 6O2F

Space Group

I 21 21 21

Space Group

I 21 21 21

Unit cell dimensions (Å)

19.3, 30.0,
107.1; 90, 90,
90

Unit cell dimensions (Å)

19.2, 30.0,
106.8; 90, 90,
90

Resolution (Å)

28.9-1.90

Resolution (Å)

28.9-1.80

Total Observations

15,787

Total Observations

33,482
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Unique observations

2,679

Unique observations

3,133

Redundancy

5.9 (1.9)

Redundancy

9.8 (1.75)

Completeness (%)

99.04 (93.02)

Completeness (%)

99.74 (99.66)

I/σ

9.5 (0.76)

<I/σI>

11.9 (0.76)

Rpim

0.067

Rpim

0.047

Refinement

Refinement

Resolution (Å)

28.9-1.90

Resolution (Å)

28.9-1.80

Rcrystb

0.214 (0.298)

Rcrystb

0.180 (0.248)

Rfreec

0.248 (0.311)

Rfreec

0.235 (0.310)

Average B-factor

26.21

Average B-factor

22.48

RMSD: bonds (Å) / angles (°)

0.008 / 1.04

RMSD: bonds (Å) / angles (°)

0.012 / 1.26
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3. Stapling of Two Asparagine-linked O-allyl PEG Oligomers Increases the Conformational Stability of
the WW Domain
Reproduced from Org. Biomol. Chem., 2018, 16, 8933 with permission from the Royal Society of Chemistry.
Kimberlee Stern contributed to the synthesis of WW variant 16/19-34.

3.1 Introduction
Conjugating polyethyleneglycol to proteins (i.e. PEGylation) is a well-known strategy for
improving the stability and pharmacokinetic properties of peptide and protein drugs.1-3 The benefits of
PEGylation are thought to derive mostly from the large hydrodynamic radius of PEG,4, 5 which increases
the serum half-life of the PEG-protein conjugate relative to its non-PEGylated counterpart by slowing
renal clearance. PEG also shields proteins from aggregation, proteolysis, and antibody-epitope
recognition. Early PEGylation efforts used low-specificity reactions that generated heterogeneous
mixtures of PEG-protein conjugates differing in the location and number of PEGylation sites. Many of
the resulting PEG-protein conjugates bound less strongly to their targets or had diminished in vitro
enzymatic activity, presumably because PEG shielded the proteins from substrates or binding partners.
More recently, advances in chemoselective biorthogonal reactions6-13 and chemical protein
synthesis14 have enabled conjugation of a single PEG to any arbitrary position within a protein. These sitespecific PEG-protein conjugates tend to retain more in vitro activity than their non-specifically PEGylated
counterparts.15 However, aside from avoiding active sites or binding interfaces, there are few guidelines
for selecting the best PEGylation site(s) for a given protein. Instead, efforts to this end generally rely on
screening many prospective sites to identify those that provide optimal pharmacokinetic benefits.16, 17
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We have previously proposed that optimal PEGylation sites will be characterized by substantial
PEG-based increases to protein conformational stability. Evidence for this hypothesis includes the
observation that PEGylated variants of the β-sheet protein WW are more resistant to proteolysis if PEG is
placed at locations where it increases protein conformational stability.18 PEG-based stabilization of
proteins depends strongly on the location of the PEGylation site and derives from an entropic effect that
likely involves the release of water molecules from the protein surface to bulk solvent.18 Simultaneous
PEGylation at two such stabilizing sites leads to even higher levels of conformational stability and
proteolytic resistance. For example, a WW variant modified with two four-unit monomethoxy PEGs at
positions 16 and 19 is more stable than either of its mono- or non-PEGylated counterparts.18 We wondered
whether connecting these two PEGs covalently might confer additional stability on the resulting
macrocyclic PEG-protein conjugate relative to its acyclic doubly PEGylated counterpart.
Macrocyclization is a well-known strategy for enhancing peptide and protein conformational
stability. Please refer to chapter 1 for detailed review of macrocyclization.
3.2 Results and Discussion
We sought to combine the advantages of hydrocarbon stapling and PEGylation by preparing WW
variant 16/19-44, in which Asn residues at positions 16 and 19 have each been modified with a four-unit
O-allyl PEG (Figure 1, m = n = 4). Variable temperature circular dichroism (CD) experiments reveal that
16/19-44 is -0.68 ± 0.02 kcal/mol more stable that its non-PEGylated counterpart 16/19-00, due to a
favorable entropy term (Table 1, Figure 2). On-resin ring-closing metathesis of 16/19-44, followed by
cleavage and HPLC purification resulted in stapled peptide s16/19-44 (Figure 1). Mass spectrometry
confirmed the identity of the desired product, which has a molecular weight that is smaller than that of
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non-stapled 16/19-44 by an amount corresponding to the molecular weight of ethylene (which is lost
during the ring-closing metathesis reaction; see supporting information). Stapled s16/19-44 is only
marginally more stable than non-stapled 16/19-44 (Table 1; Figure 2).

Figure 1. Preparation of WW variants with Asn-linked olefin-terminated PEGs at positions 16 and 19 in their stapled (s16/19mn) and non-stapled (16/19-mn) forms.

Table 1. Folding free energies of WW variants that are PEGylated vs. PEG-stapled or alkylated vs.
hydrocarbon-stapled at positions 16 and 19.a
WW
variant

m n

Tm (°C)

ΔCp
ΔΔGf
(kcal/mol/K
)
(kcal/mol)
---

Relative to 16/19-00
ΔΔHf
-TΔΔSf
ΔΔCp
(kcal/mol
(kcal/mol) (kcal/mol/K)
)
-------

16/19-00

0

0

58.9 ± 0.2 -0.34 ± 0.08

16/19-11

1

1

64.9 ± 0.3 -0.52 ± 0.03 -0.43 ± 0.03 8.5 ± 0.7 -8.9 ± 0.8

s16/19-11

1

1

16/19-12

1

s16/19-12

Impact of Stapling
ΔΔGf
ΔΔHf
-TΔΔSf
(kcal/mol) (kcal/mol) (kcal/mol)
---

---

---

-0.18 ± 0.08

---

---

---

62.4 ± 0.2 -0.49 ± 0.02 -0.25 ± 0.02 7.7 ± 0.5 -8.0 ± 0.5

-0.16 ± 0.08

0.17 ± 0.03

-0.8 ± 0.8

0.9 ± 0.8

2

66.5 ± 0.1 -0.34 ± 0.07 -0.68 ± 0.02 2.0 ± 0.6 -2.7 ± 0.7

-0.01 ± 0.10

---

---

---

1

2

65.8 ± 0.2 -0.52 ± 0.02 -0.51 ± 0.02 7.9 ± 0.7 -8.4 ± 0.6

-0.19 ± 0.08

0.17 ± 0.02

5.8 ± 0.8

-5.7 ± 0.8

16/19-22

2

2

68.0 ± 0.1 -0.62 ± 0.02 -0.80 ± 0.02 3.9 ± 0.3 -4.7 ± 0.5

-0.29 ± 0.08

---

---

---

s16/19-22

2

2

69.9 ± 0.1 -0.62 ± 0.02 -0.92 ± 0.02 5.7 ± 0.6 -6.6 ± 0.6

-0.28 ± 0.08

-0.12 ± 0.02

1.7 ± 0.6

-1.8 ± 0.5

16/19-23

2

3

67.7 ± 0.1 -0.64 ± 0.02 -0.75 ± 0.02 4.8 ± 0.4 -5.6 ± 0.6

-0.30 ± 0.08

---

---

---

s16/19-23

2

3

71.7 ± 0.1 -0.61 ± 0.02 -1.04 ± 0.02 6.8 ± 0.6 -7.8 ± 0.6

-0.28 ± 0.08

-0.29 ± 0.02

2.0 ± 0.6

-2.3 ± 0.6

16/19-33

3

3

67.5 ± 0.2 -0.39 ± 0.12 -0.77 ± 0.03 2.0 ± 1.1 -2.8 ± 1.2

-0.05 ± 0.14

---

---

---

s16/19-33

3

3

70.1 ± 0.2 -0.65 ± 0.02 -0.92 ± 0.02 6.5 ± 0.8 -7.5 ± 0.8

-0.32 ± 0.08

-0.15 ± 0.04

4.5 ± 1.3

-4.6 ± 1.3

16/19-34

3

4

67.2 ± 0.1 -0.62 ± 0.02 -0.72 ± 0.01 4.1 ± 0.4 -4.8 ± 0.6

-0.29 ± 0.08

---

---

---

s16/19-34

3

4

71.4 ± 0.1 -0.62 ± 0.01 -0.96 ± 0.02 8.2 ± 0.6 -9.2 ± 0.6

-0.28 ± 0.08

-0.25 ± 0.02

4.1 ± 0.6

-4.4 ± 0.6

16/19-44

4

4

66.5 ± 0.1 -0.63 ± 0.02 -0.68 ± 0.02 3.2 ± 0.4 -3.9 ± 0.6

-0.30 ± 0.08

---

---

---

s16/19-44

4

4

69.8 ± 0.1 -0.58 ± 0.02 -0.84 ± 0.02 7.8 ± 0.6 -8.6 ± 0.6

-0.24 ± 0.08

-0.16 ± 0.02

4.6 ± 0.6

-4.7 ± 0.6
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h16/19-22

2

2

67.5 ± 0.2 -0.74 ± 0.02 -0.78 ± 0.03 3.6 ± 0.9 -4.4 ± 0.9

hs16/1922

2

2

78.9 ± 0.1 -0.64 ± 0.02 -1.61 ± 0.04 9.0 ± 0.8 -10.6 ± 0.8 -0.30 ± 0.08

h16/19-23

2

3

57.4 ± 0.3 -0.76 ± 0.03 0.14 ± 0.03 -0.6 ± 1.0 0.7 ± 1.0

hs16/1923

2

3

73.1 ± 0.2 -0.60 ± 0.02 -1.06 ± 0.04 9.5 ± 0.9 -10.5 ± 0.9 -0.26 ± 0.08

-0.41 ± 0.08

-0.43 ± 0.08

---

---

---

-0.84 ± 0.04

5.4 ± 1.0

-6.2 ± 1.0

---

---

---

-1.20 ± 0.04 10.1 ± 1.2 -11.3 ± 1.2

Folding free energies are given ± standard error in kcal/mol at the melting temperature of control compound 16/19-00 (332 K)
in 20 mM sodium phosphate buffer (pH 7).
a

Figure 2. Changes in folding gree energy (ΔΔGf, open bars) due to PEGylation (orange) vs. stapling (light orange) of WW
variants at positions 16 and 19, along with the enthalpic (ΔΔHf, overlaid gray stripes) and entropic (-TΔΔSf, overlaid yellow
stripes) components of ΔΔGf in kcal/mol ± standard error in 20 mM sodium phosphate buffer (pH 7) at the melting temperature
of control compound 16/19-00 (332 K).

Positions 16 and 19 are only three residues apart within the same reverse turn; we wondered
whether stapling might be more stabilizing at shorter PEG lengths. To test this hypothesis, we
systematically decreased the length of the PEGs at positions 16 and/or 19 to generate WW variants s16/1934, s16/19-33, s16/19-23, s16/19-22, s16/19-12, s16/19-11 along with their non-stapled counterparts.
PEG-stapled s16/19-23 is the most stable of these variants (compare Tm values in Table 1) and is also
more stabilized by stapling than any of the other stapled variants (Figure 2). In s16/19-23, the staple-based
stabilization of -0.29 ± 0.02 kcal/mol comes from a favorable entropic component (-TΔΔSf = -2.3 ± 0.6
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kcal/mol), offset by a weaker unfavorable enthalpic component (Table 1; Figure 2). Presumably, the fiveunit PEG staple in s16/19-23 provides a level of preorganization that is compatible with the relative
locations of positions 16 and 19 in the folded conformation of WW. Shorter and more rigid PEG staples
might limit the ability of these side chains to adopt their native conformations, resulting in staple-based
destabilization (compare data for s16/19-11 vs. 16/19-11 and s16/19-22 vs 16/19-22 in Table 1 and Figure
2). In contrast, longer and more flexible PEG staples might provide insufficient preorganization and
therefore only marginally impact WW stability (compare data for s16/19-44 vs. 16/19-44 in Table 1 and
Figure 2).

Figure 3. (A) WW variants with Asn-linked olefin-terminated hydrocarbon chains at positions 16 and 19 in their stapled
(hs16/19-mn) and non-stapled (h16/19-mn) forms. (B) WW variants with four-unit Asn-linked PEGs at positions 16 and 32
in their stapled (s16/32-44) and non-stapled (16/32-44) forms.
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Figure 4. Changes in ΔGf, ΔHf (overlaid gray stripes), and -TΔSf (overlaid yellow stripes), due to alkylation (purple) vs.
hydrocarbon stapling (light purple) of WW variants at positions 16 and 19 with oligomer length as indicated. Experimental
conditions are as described in Figure 2. Analogous values for PEGylation (orange) vs. PEG stapling (light orange) are shown
for comparison.

We next wondered whether PEG-based stapling would be more or less stabilizing than
conventional hydrocarbon stapling. To address this question, we prepared WW variants h16/19-22 and
h16/19-23, in which Asn residues at positions 16 and 19 have each been modified with olefin-terminated
hydrocarbons of the same length as the PEG-chains in 16/19-22 and 16/19-23, respectively (Figure 3A).
We also prepared their stapled counterparts hs16/19-22 and hs16/19-23 as described above. Alkylated
variant h16/19-22 is -0.78 ± 0.03 kcal/mol more stable than unmodified 16/19-00; stapling stabilizes
hs16/19-22 by an additional -0.84 ± 0.04 kcal/mol relative to h16/19-22 (Table 1; Figure 4). In contrast,
h16/19-23 is moderately less stable than 16/19-00 (ΔΔGf = 0.14 ± 0.03), but stapling stabilizes hs16/1923 by -1.20 ± 0.04 kcal/mol relative to h16/19-23 (Table 1; Figure 4). In both cases, staple-based
stabilization comes from a favorable entropic term, offset by an unfavorable enthalpic term, which is
similar to what we observed for PEG-stapling.
Though unrelated to stapling, the high stability of h16/19-22 (Tm = 67.5 ± 0.2 °C) relative to
h16/19-23 (Tm = 57.4 ± 0.3 °C) is striking given the subtle structural difference between the two variants
(i.e. four methylene groups). Alkyation increases ΔHf and decreases the -TΔSf of h16/19-22 by 3.6 ± 0.9
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kcal/mol and -4.4 ± 0.9 kcal/mol, respectively, relative to 16/19-00, making the folded conformation of
h16/19-22 more stable than the unfolded ensemble by -0.78 ± 0.03 kcal/mol at 332 K. Adding four
methylene groups to hydrocarbon chain at position 19 reverses these trends (compare h16/19-23 vs
h16/19-22: ΔΔHf = -4.2 ± 1.1 kcal/mol, -TΔΔSf = 5.1 ± 1.2 kcal/mol, ΔΔGf = 0.91 ± 0.04 kcal/mol), such
that h16/19-23 is slightly less stable than 16/19-00. It is possible that the additional four carbons allow the
position 19 hydrocarbon chain in h16/19-23 to interact with a non-polar group on the WW surface that is
inaccessible to the shorter chain in h16/19-22. Such an interaction would be consistent with the observed
favorable difference in enthalpy between h16/19-23 and h16/19-22; the larger offsetting change in the
entropic term could reflect a concomitant loss of conformational entropy. The similar ΔCp values for
h16/19-23 and h16/19-22 suggest that the addition of four methylene groups does not substantially change
how much non-polar surface area is buried in the folded conformation of each variant.
The magnitude of staple-based stabilization is much greater for alkylated hs16/19-22 (-0.84 ± 0.04
kcal/mol) and hs16/19-23 (-1.20 ± 0.04 kcal/mol) than for PEGylated s16/19-22 (-0.12 ± 0.02 kcal/mol)
and s16/19-23 (-0.29 ± 0.02 kcal/mol), respectively, relative to their unstapled counterparts (Table 1,
Figure 4). However, the overall impact of PEGylation + stapling relative to 16/19-00 (-0.92 ± 0.02
kcal/mol for s16/19-22; -1.04 ± 0.02 kcal/mol for s16/19-23) more closely approximates that of alkylation
+ stapling (-1.61 ± 0.04 for hs16/19-22; -1.06 ± 0.04 for hs16/19-23), suggesting the possibility of using
PEG stapling and hydrocarbon stapling in similar contexts.
We wondered whether the modest staple-based stabilization of s16/19-23 relative to 16/19-23
could reflect the proximity of positions 16 and 19 not only in tertiary structure but also in primary
sequence: the entropic cost of bringing these positions into close proximity in the folded state might
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already be small, thus limiting the impact of staple-based preorganization. In contrast, we would expect
stapling to be more impactful between two positions that are close in tertiary structure but far apart in
primary sequence. Positions 16 and 32 are sixteen residues apart in sequence, but their side-chain βcarbons are only 9 Å apart in the folded structure of the parent WW protein from which the WW variants
herein were derived.19
We explored this possibility by preparing WW variant 16/32-44, in which Asn residues at positions
16 and 32 have each been modified with an olefin-terminated four-unit PEG (Figure 3B). We also
prepared its stapled counterpart s16/32-44, along with non-PEGylated control compound 16/32-00.
PEGylated 16/32-44 is -0.74 ± 0.06 kcal/mol more stable than its non-PEGylated counterpart 16/32-00.
Stapling via olefin metathesis stabilizes s16/32-44 by an additional -0.72 ± 0.06 kcal/mol relative to nonstapled 16/32-44 (Table 1, Figure 5). This staple-based stabilization is more than double what we observed
previously for s16/19-23 relative to 16/19-23, consistent with the hypothesis that stapling is most
beneficial for locations that are distant in primary sequence, but close in tertiary structure.

Figure 5. Changes in ΔGf, ΔHf (overlaid gray stripes), and -TΔSf (overlaid yellow stripes), due to PEGylation (blue) vs. stapling
(light blue) at positions 16 and 32 within WW, with oligomer length as indicated. Experimental conditions are as described in
Figure 2. Analogous values for PEGylation (orange) vs. stapling (light orange) at positions 16 and 19 are shown for comparison.

The enthalpies of transfer of nonpolar molecules to water tend to have strong positive temperature
dependencies (i.e., heat capacities: ΔCp = ∂ΔΗ/∂Τ), which increase linearly with nonpolar surface area.20
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These observations reflect the limited translational and orientation freedom experienced by first shell
water molecules around a nonpolar solute vs. in pure bulk water: applied energy must “melt” this ice-like
shell prior to increasing overall temperature of solution; the heat capacity of the system is therefore higher
after transfer of the non-polar molecule to water (i.e. the transfer process has a large positive ΔCp). By
analogy, large positive ΔCp values are generally associated with aqueous processes that involve increased
exposure of nonpolar surface area to water. Similarly, large negative ΔCp values are associated with
processes driven by the hydrophobic effect, which involve sequestering nonpolar surface area from water
(e.g., protein folding).
We wondered whether the ΔCp values for the PEGylated/stapled WW variants in Table 1 might
provide some insight into the origin of the overall stabilization associated with PEGylation and stapling.
The impact of PEGylation + stapling on the folding free energy (ΔGf) and heat capacity (ΔCp) values for
WW variants s16/19-mn and s16/32-44 (relative to their non-PEGylated non-stapled counterparts 16/1900 and 16/32-00, respectively) appear in Figure 6. ΔΔGf varies somewhat linearly with ΔΔCp; the most
negative ΔΔCp values are associated with the most negative ΔΔGf values. This observation suggests that
PEGylation + stapling decreases the amount of solvent-exposed surface area in the folded conformation
of WW, thereby stabilizing it relative to the unfolded conformation. ΔΔGf and ΔΔCp values for alkylated
+ stapled hs16/19-mn variants relative to their unmodified counterpart 16/19-00 follow this trend less
closely, which could reflect the fact that alkylation + stapling has a smaller impact on the non-polar surface
area of WW than does PEGylation + stapling owing to the nonpolar character of the hydrocarbon staple.
In contrast, ΔΔCp and ΔΔGf data for s16/32-44 relative to 16/32-00 do not agree with this trend, suggesting
the possibility that PEGylation + stapling at these positions increases WW stability via an effect that does
not rely strongly on burial of non-polar surface area.
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Figure 6. ΔΔGf vs. ΔΔCp of WW variants s16/19-mn (orange), s16/32-mn (blue), hs16/19-mn (purple), vs. their unmodified
counterparts. Solid orange-to-blue gradient line represents the fit of the ΔΔGf vs. ΔΔCp data for s16/19-mn and s16/32-44 via
linear regression. Dotted gray line represents the fit of the ΔΔGf vs. ΔΔCp data for s16/19-mn, s16/32-44, and hs16/19-mn.
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3.3 Conclusions
Here we compared the impact of PEG stapling vs. hydrocarbon stapling on the conformational
stability of the β-sheet protein WW. For two sites that are close in both primary sequence and tertiary
structure, we found that PEGylation and stapling both increase WW conformational stability via an
entropic effect and that varying the length of the stapled PEGs can optimize the impact of subsequent
stapling. The overall impact of PEGylation + stapling on WW conformational stability is similar to that
of hydrocarbon modification + stapling; though hydrocarbon stapling tends to account for a greater
proportion of this overall stabilization than does PEG stapling. Finally, we found that PEG stapling
contributes more to WW conformational stability when the two PEG sites are far apart in primary sequence
but close in tertiary structure. Our results highlight the possibility of combining the stabilizing impact of
hydrocarbon stapling with the conformational and pharmacokinetic benefits of PEGylation in the future
development of peptide and protein drugs.
3.4 Experimental Sections
All WW variants were synthesized as C-terminal acids on Fmoc-Gly-Wang LL resin (EMD
Biosciences) by microwave-assisted solid phase peptide synthesis using a standard Fmoc Nα protection
strategy as described previously21. All Fmoc-protected amino acids were purchased from Advanced Chem
Tech, except for the modified non-natural asparagine derivatives with PEG or hydrocarbon chain on the
residue, which were synthesized as described in the supporting information section below. Unstapled WW
variants were cleaved from resin and purified by preparative reverse-phase high-performance liquid
chromatography (HPLC) on a C18 column using a linear gradient of water in acetonitrile with 0.1% v/v
trifluoroacetic acid. Peptide identity was confirmed by electrospray ionization time-of-flight mass
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spectrometry. For stapled WW variants, ring-closing olefin metathesis was performed on resin using the
first-generation Grubbs ruthenium complex prior to cleavage and purification as described in the
supporting information section below. Conformational stability of stapled and unstapled WW variants was
assessed by variable-temperature circular dichroism spectropolarimetry; melting temperatures and folding
free energy, enthalpy, and entropy values were derived from global fits of the CD data to a two-state
folding model.
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3.6 Supporting Information
3.6.1 Structure of WW variants

Figure S6. Sequence and structures of WW variants

3.6.2 Global Fitting of Variable Temperature CD Data
For WW variants 16/19-00, 16/19-11, s16/19-11, 16/19-12, s16/19-12, 16/19-22, s16/19-22,
16/19-23, s16/19-23, 16/19-33, s16/19-33, 16/19-34, s16/19-34, 16/19-44, s16/19-44, h16/19-22,
hs16/19-22, h16/19-23, hs16/19-23, 16/32-00, 16/32-44, s16/32-44 data from the three replicate variable
temperature CD experiments on each protein were fit globally to a model for a two-state thermally
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induced unfolding transition, as shown in equation S1:
[θ] = [(cn + dn• T) + Kf(an + bn • T )]/(1+Kf),

(S1)

where T is temperature in Kelvin, cn is the y-intercept and dn is the slope of the post-transition baseline
for replicate n (c1 and d1 for replicate 1; c2 and d2 for replicate 2; c3 and d3 for replicate 3); an is the yintercept and bn is the slope of the pre-transition baseline for melt n (a1 and b1 for replicate 1; a2 and b2
for replicate 2; a3 and b3 for replicate 3); and Kf is the temperature-dependent folding equilibrium
constant. Kf is related to the temperature-dependent free energy of folding ΔGf according to the
following equation:
Kf = exp[-ΔGf / RT],

(S2)

where R is the universal gas constant (0.0019872 kcal/mol/K). ΔGf is a function of temperature, as
shown in the following equation:
ΔGf = ΔH0 • (Tm – T)/Tm + ΔCp• [T – Tm – T • ln(T/Tm) ],

(S3)

where Tm is the midpoint of the unfolding transition and the temperature at which ΔGf = 0; ΔH0 is the
change in enthalpy upon folding at T = Tm; and ΔCp is the change in heat capacity upon folding. The
parameters for equations S1–S3 were used to calculate the values of ΔGf for each WW variant in the
main text and in the tables below. Variable temperature CD data for each WW variant are shown in
Figures S2–S23, along with the parameters (± standard error) obtained from the fit process described
above. The standard error for each fitted parameter is also shown. These standard parameter errors were
used to estimate the uncertainty in the average thermodynamic values given in the main text by
propagation of error.
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Figure S7. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variant 16/19-00
in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf,
ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S8. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/1911 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S9. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants s16/1911 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S10. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/1912 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S11. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants s16/1912 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S12. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/1922 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S13. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants s16/1922 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S14. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/1923 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S15. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants s16/1923 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S16. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/1933 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S17. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants s16/1933 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S18. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/1934 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S19. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants s16/1934 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S20. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/1944 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S21. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants s16/1944 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S22. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants
h16/19-22 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated
values for ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S23. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants
sh16/19-22 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated
values for ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S24. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants
h16/19-23 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated
values for ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S25. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants
h16/19-23 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated
values for ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S26. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants
sh16/19-23 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated
values for ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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Figure S27. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/3200 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

Figure S28. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants 16/3244 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.

191

Figure S29. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM solutions of WW variants s16/3244 in 20 mM sodium phosphate, pH 7. Fit parameters from equations S1–S3 appear in the table, as do calculated values for
ΔGf, ΔHf, and -TΔSf at 333.15 K, with the indicated standard errors.
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3.6.3 ESI-TOF spectra data of WW variants
Table S2. Summary of the mass spectrum data for the WW variants
z

Expected
[M+z∙H]/z

Observed
[M+z∙H]/z

16/19-00

C179H270N56O50
S

4

1010.009

1010.012

16/19-11

C189H286N56O52
S

4

1052.038

1052.034

s16/19-11

C187H282N56O52
S

4

1045.030

1045.037

16/19-12

C191H290N56O53
S

4

1063.044

1063.044

s16/19-12

C189H286N56O53
S

4

1056.036

1056.035

16/19-22

C193H294N56O54
S

4

1074.051

1074.050

s16/19-22

C191H290N56O54
S

4

1067.043

1067.039

16/19-23

C195H298N56O55
S

4

1085.057

1085.055

s16/19-23

C193H294N56O55
S

4

1078.049

1078.046

16/19-33

C197H302N56O56
S

4

1096.064

1096.058

s16/19-33

C195H298N56O56
S

4

1089.056

1089.049

16/19-34

C199H306N56O57
S

4

1107.070

1107.072

s16/19-34

C197H302N56O57
S

4

1100.062

1100.062

Name

Molecular
Formula
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16/19-44

C201H310N56O58
S

4

1118.077

1118.070

s16/19-44

C199H306N56O58
S

4

1111.069

1111.061

h16/19-22

C197H302N56O50
S

4

1072.071

1072.072

hs16/19-22

C195H298N56O50
S

4

1065.064
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ESI-TOF spectra for WW variant 16/19-00, 16/19-11, s16/19-11, 16/19-12, s16/19-12, 16/19-22,
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S25–S46.
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Figure S30. ESI-TOF spectrum for WW variant 16/19-00. Expected [M+4H+]/4 = 1010.009 Da. Obs’d [M+4H+]/4 =
1010.012 Da.
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Figure S31. ESI-TOF spectrum for WW variant 16/19-11. Expected [M+4H+]/4 = 1052.038 Da. Obs’d [M+4H+]/4 =
1052.034 Da.
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Figure S32. ESI-TOF spectrum for WW variant s16/19-11. Expected [M+4H+]/4 = 1045.030 Da. Obs’d [M+4H+]/4 =
1045.037 Da.
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Figure S33. ESI-TOF spectrum for WW variant 16/19-12. Expected [M+4H+]/4 = 1063.044 Da. Obs’d [M+4H+]/4 =
1063.044 Da.
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Figure S34. ESI-TOF spectrum for WW variant s16/19-12. Expected [M+4H+]/4 = 1056.036 Da. Obs’d [M+4H+]/4 =
1056.035 Da
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Figure S35. ESI-TOF spectrum for WW variant 16/19-22. Expected [M+4H+]/4 = 1074.051 Da. Obs’d [M+4H+]/4 =
1074.050 Da.
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Figure S36. ESI-TOF spectrum for WW variant s16/19-22. Expected [M+4H+]/4 = 1067.043 Da. Obs’d [M+4H+]/4 =
1067.039 Da.
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Figure S37. ESI-TOF spectrum for WW variant 16/19-23. Expected [M+4H+]/4 = 1085.057 Da. Obs’d [M+4H+]/4 =
1085.055 Da.
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Figure S38. ESI-TOF spectrum for WW variant s16/19-23. Expected [M+4H+]/4 = 1078.049 Da. Obs’d [M+4H+]/4 =
1078.046 Da.
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Figure S39. ESI-TOF spectrum for WW variant 16/19-33. Expected [M+4H+]/4 = 1096.064 Da. Obs’d [M+4H+]/4 =
1096.058 Da.
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Figure S40. ESI-TOF spectrum for WW variant s16/19-33. Expected [M+4H+]/4 = 1089.056 Da. Obs’d [M+4H+]/4 =
1089.049 Da.
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Figure S41. ESI-TOF spectrum for WW variant 16/19-34. Expected [M+4H+]/4 = 1107.070 Da. Obs’d [M+4H+]/4 =
1107.072 Da.
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Figure S42. ESI-TOF spectrum for WW variant s16/19-34. Expected [M+4H+]/4 = 1100.062 Da. Obs’d [M+4H+]/4 =
1100.062 Da.
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Figure S43. ESI-TOF spectrum for WW variant 16/19-44. Expected [M+4H+]/4 = 1118.077 Da. Observed [M+4H+]/4 =
1118.070 Da.
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Figure S44. ESI-TOF spectrum for WW variant s16/19-44. Expected [M+4H+]/4 = 1111.069 Da. Obs’d [M+4H+]/4 =
1111.061 Da.
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Figure S45. ESI-TOF spectrum for WW variant h16/19-22. Expected [M+4H+]/4 = 1072.071 Da. Obs’d [M+4H+]/4 =
1072.0718 Da.

199

x10

3

+ESI Scan (rt: 0.086-0.436 min, 22 scans) Frag=250.0V 280917-6272-qx2007.d

2.5

1065.5572

2.25

1065.8072

2
1065.3061

1.75

1066.0558

1.5
1.25
1

1065.0563

1066.3068

0.75

1066.5528

0.5
0.25
0

1064.8

1065

1065.2

1065.4

1066.8

1066.6

1066.4

1066.2

1066

1065.8

1065.6

1067

1067.2

Counts vs. Mass-to-Charge (m/z)

Figure S46. ESI-TOF spectrum for WW variant sh16/19-22. Expected [M+4H+]/4 = 1065.064 Da. Obs’d [M+4H+]/4 =
1065.056 Da.
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Figure S47. ESI-TOF spectrum for WW variant h16/19-23. Expected [M+4H+]/4 = 1082.583 Da. Obs’d [M+4H+]/4 =
1082.579 Da.
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Figure S48. ESI-TOF spectrum for WW variant hs16/19-23. Expected [M+4H+]/4 = 1075.575 Da. Obs’d [M+4H+]/4 =
1075.572 Da.
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Figure S49. ESI-TOF spectrum for WW variant 16/32-00. Expected [M+4H+]/4 = 1010.009 Da. Obs’d [M+4H]+/4 =
1010.008 Da.
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Figure S50. ESI-TOF spectrum for WW variant 16/32-44. Expected [M+4H+]/4 = 1118.077 Da. Obs’d [M+4H+]/4 =
1118.072 Da.
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Figure S51. ESI-TOF spectrum for WW variant s16/32-44. Expected [M+4H+]/4 = 1111.069 Da. Observed [M+4H+]/4 =
1111.068 Da.

3.6.4 Analytical HPLC data
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Analytical HPLC traces for WW variant 16/19-00, 16/19-11, s16/19-11, 16/19-12, s16/19-12, 16/19-22, s16/19-22, 16/19-23,
s16/19-23, 16/19-33, s16/19-33, 16/19-34, s16/19-34, 16/19-44, s16/19-44, h16/19-22, hs16/19-22, h16/19-23, hs16/19-23,
16/32-00, 16/32-44, s16/32-44 are shown in Figures S47–S68.

Figure S52. Analytical HPLC Data for WW variant 16/19-00. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S53. Analytical HPLC Data for WW variant 16/19-11. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S54. Analytical HPLC Data for WW variant s16/19-11. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S55. Analytical HPLC Data for WW variant 16/19-12. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S56. Analytical HPLC Data for WW variant s16/19-12. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S57. Analytical HPLC Data for WW variant 16/19-22. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S58. Analytical HPLC Data for WW variant s16/19-22. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S59. Analytical HPLC Data for WW variant 16/19-23. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S60. Analytical HPLC Data for WW variant s16/19-23. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S61. Analytical HPLC Data for WW variant 16/19-33. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S62. Analytical HPLC Data for WW variant s16/19-33. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S63. Analytical HPLC Data for WW variant 16/19-34. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S64. Analytical HPLC Data for WW variant s16/19-34. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S65. Analytical HPLC Data for WW variant 16/19-44. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S66. Analytical HPLC Data for WW variant s16/19-44. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S67. Analytical HPLC Data for WW variant h16/19-22. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S68. Analytical HPLC Data for WW variant hs16/19-22. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S69. Analytical HPLC Data for WW variant h16/19-23. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S70. Analytical HPLC Data for WW variant sh16/19-23. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S71. Analytical HPLC Data for WW variant 16/32-00. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S72. Analytical HPLC Data for WW variant 16/32-44. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S73. Analytical HPLC Data for WW variant s16/32-44. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a
10-minute rinse (95% B), and a 10-minute column re-equilibration.

3.6.5 Asparagine derivatives synthesis and characterization
2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol (QX1011)

To a solution of NaN3 (3.85 g, 59.30 mmol) in water (200 mL) was added 2-(2-(2chloroethoxy)ethoxy)ethan-1-ol (5.00 g, 29.65 mmol) at room temperature. The reaction mixture was then
refluxed overnight. The crude mixture was extracted with DCM for 3 times after the reaction was
completed. The combined organic phases were washed with saturated brine and dried over anhydrous
sodium sulfate, evaporated to dryness to obtain QX1011 as colorless oil without further purification. Yield
quantitative. MS(ESI-TOF) m/z calc. for C6H13N3O3Na+ 198.08, found 198.08 [M+Na+]. 1H NMR (500
MHz, Chloroform-d) δ 3.74 (t, J = 4.5 Hz, 2H, N3-CH2-CH2-O-CH2-CH2-O-CH2-CH2-OH), 3.71 – 3.67
(m, 6H, N3-CH2-CH2-O-CH2-CH2-O-CH2-CH2-OH), 3.62 (t, J = 4.7 Hz, 2H, N3-CH2-CH2-O-CH2 -CH2O-CH2-CH2-OH), 3.41 (t, J = 5.0 Hz, 2H, N3-CH2-CH2-O-CH2-CH2-O-CH2 -CH2-OH). 13C NMR (126
MHz, Chloroform-d) δ 72.47 (N3-CH2-CH2-O-CH2-CH2-O-CH2 -CH2-OH), 70.66, 70.39, 70.07 (N3-CH2CH2-O-CH2-CH2-O-CH2-CH2-OH), 61.77 (N3-CH2-CH2-O-CH2 -CH2-O-CH2-CH2-OH), 50.64 (N3-CH2CH2-O-CH2-CH2-O-CH2-CH2-OH).
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Figure S74. ESI-TOF MS data for compound QX1011.

Figure S75. 1H NMR for compound QX1011.
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Figure S76. 13C NMR for compound QX1011.

Figure S77. HSQC data for compounds QX1011.

3-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)prop-1-ene (QX1013)

211

To NaH (60 % in mineral oil, 1.3 g, 32.30 mmol, washed with dry hexane) in THF (50 mL) was
added QX1011 (2.83 g, 16.15 mmol) at 0°C under argon. The reaction mixture was stirred at 0°C for 1
hour, allyl bromide (3.9 g, 32.30 mmol) in THF (10 mL) was added slowly at 0°C and stirring was
continued for another 2 hours at room temperature. The reaction mixture was poured into cold saturated
ammonium chloride solution (40 mL) and extracted with ethyl acetate. The combined organic phases were
washed with saturated brine and dried over anhydrous sodium sulfate, evaporated to dryness. The products
were separated by flash column chromatography to obtain the desired product QX1013 as colorless oil.
Yield 67.5%; MS(ESI-TOF) m/z calc. for C9H17N3O3NH4+ 223.16, found 233.16 [M+NH4+]; 1H NMR
(500 MHz, Chloroform-d) δ 5.86 (ddt, J = 16.4, 10.8, 5.7 Hz, 1H, -CH2-O-CH2-CH-CHaHb), 5.2 (dd, J =
17.2, 1.0 Hz, 1H, -CH2-O-CH2-CH-CHaHb), 5.12 (dd, J = 10.4, 1.7 Hz, 1H, -CH2-O-CH2-CH-CHaHb),
3.97 (d, J = 5.5 Hz, 2H, -CH2-O-CH2-CH-CHaHb), 3.63 – 3.61 (m, 8H, N3-CH2-CH2-O-CH2 -CH2-O-CH2CH2-O-), 3.55 (t, J = 5.1 Hz, 2H, N3-CH2-CH2-O-CH2-CH2 -O-CH2-CH2 -O-), 3.33 (t, J = 5.1 Hz, 2H, N3CH2-CH2-O-CH2-CH2-O-CH2-CH2-O-). 13C NMR (126 MHz, Chloroform-d) δ 134.72 (-CH2-O-CH2CH-CHaHb), 116.97 (-CH2-O-CH2-CH-CHaHb), 72.13 (-CH2-O-CH2-CH-CHaHb), 70.65, 70.64, 70.62,
69.98 (N3-CH2-CH2-O-CH2-CH2-O-CH2-CH2 -O-), 69.36 (N3-CH2-CH2-O-CH2-CH2-O-CH2 -CH2-O-),
50.61 (N3-CH2-CH2-O-CH2-CH2-O-CH2-CH2-O-).
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Figure S78. ESI-TOF MS data for compounds QX1013.

Figure S79. 1H NMR data for compound QX1013.
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Figure S80. 13C NMR data for compound QX1013.

Figure S81. HSQC NMR data for compound QX1013.

2-(2-(2-(allyloxy)ethoxy)ethoxy)ethan-1-amine (QX1015)

214

Compound QX1013 (2.35g, 10.90 mmol) and PPh3 (5.73 g, 21.80 mmol) in a mixture of THF (40
mL) and water (1 mL) were stirred at room temperature overnight. 1M HCl (60 mL) was added and
extracted 3 times with diethyl ether. The aqueous phase was lyophilized to obtain compound 9 as colorless
oil without further purification. Isolated yield 72%; MS(ESI-TOF) m/z calc. for C9H19NO3H+ 190.14,
found 190.15 [M+H+]. 1H NMR (500 MHz, Chloroform-d) δ 8.25 (s, 2H, NH2-CH2-CH2-O-), 5.94 (ddt,
J = 16.4, 11.2, 5.8 Hz, 1H, -O-CH2-CH-CHa,Hb), 5.30 (dd, J = 17.2, 1.2 Hz, 1H, -O-CH2-CH-CHaHb),
5.23 (d, J = 10.4 Hz, 1H, -O-CH2-CH-CHaHb), 4.07 (d, J = 5.8 Hz, 2H, -O-CH2-CH-CHaHb), 3.86 (t, J =
4.8 Hz, 2H, NH2-CH2-CH2-O-), 3.74 – 3.66 (m, 8H, -O-CH2-CH2 -O-CH2-CH2-O-), 3.25(dd, J = 5.6, 2.9
Hz, 2H, NH2-CH2-CH2-O-). 13C NMR (126 MHz, Chloroform-d) δ 134.42 (-O-CH2-CH-CHaHb), 117.93
(-O-CH2-CH-CHaHb), 72.17 (-O-CH2-CH-CHaHb ), 70.24, 70.22, 70.03, 68.96 (-O-CH2-CH2 -O-CH2CH2-O-), 66.66 (NH2-CH2-CH2-O-), 39.80 (NH2-CH2-CH2-O-).
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Figure S82. ESI-TOF MS data for compound QX1015.
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Figure S83. 1H NMR data for compound QX1015.

Figure S84. 13C NMR data for compound QX1015.
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Figure S85. HSQC data for compound QX1015.
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tert-butyl (S)-16-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-14-oxo-4,7,10-trioxa-13azaheptadec-1-en-17-oate (QX1017)

To Fmoc-Asp-tBu (1.65 g, 4.0 mmol) dissolved in dry DMF (25 ml) was added HATU (2.5 g, 6.0
mmol), HOBT (920 mg, 6.0 mmol), DIPEA (2 ml, 12.0 mmol). Then the mixture was stirred for 15
minutes at room temperature. Then compound QX1015 (dissolved in 5 ml DMF) was added to the mixture
and the system was stirred for another 2 hours at room temperature. Upon completion of the reaction
monitored by TLC, 30 ml water was added to the flask and extracted 3 times with ethylacetate. The organic
phases were combined, washed with saturated brine and evaporated to dryness. The crude was then applied
to flash column chromatography to obtain the product QX1017 as white solid. Yield 78%; MS(ESI-TOF)
m/z calc. for C32H42N2O8H+ 583.30, C32H42N2O8NH4+ 600.33, C32H42N2O8Na+ 605.28, found 583.30
[M+H+], 600.33 [M+NH4+], 605.28 [M+Na+]. 1H NMR (500 MHz, Chloroform-d) δ 7.77 (d, J = 7.6 Hz,
2H, Fmoc aryl C-H), 7.62 (dd, J = 7.6, 3.5 Hz, 2H, Fmoc aryl C-H), 7.40 (t, J = 7.4 Hz, 2H, Fmoc aryl CH), 7.32 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 6.31 (s, 1H, -CO-NH-CH2-CH2-O-), 6.07 (d, J = 8.5 Hz,
1H, -CO-CαH-NH-Fmoc), 5.91 (ddt, J = 16.5, 11.0, 5.8 Hz, 1H, -O-CH2-CH-CHaHb), 5.28 (dd, J = 17.2,
1.6 Hz, 1H, -O-CH2-CH-CHaHb), 5.20 (d, J = 10.3 Hz, 1H, -O-CH2-CH-CHaHb), 4.49 (dt, J = 8.9, 4.6 Hz,
1H, -CαH-COO-), 4.43 (dd, J = 10.6, 7.1 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.36 (dd, J = 10.7, 7.2 Hz,
1H, Fmoc Ar2CH-CHaHb-O-), 4.23 (t, J = 7.1 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.02 (d, J = 5.8 Hz, 2H,
-O-CH2-CH-CHa,Hb), 3.66 – 3.52 (m, 12H, -O-CH2-CH2-O-CH2-CH2 -O-CH2-CH2-NH-), 2.86 (dd, J =
15.5, 4.4 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.69 (dd, J = 15.5, 4.4 Hz, 1H, -CαHNHFmoc-CβHaHbCO-), 1.48 (s, 9H, -O-C-(CH3)3).
x10

1

+ESI Scan (0.119-0.423 min, 19 scans) Frag=150.0V 191216-34451-QX10171.d Subtract
600.3261
7
6

605.2812

5
4

583.3002

3
2
1
0

570

575

580

585

590

595

600

605

Counts (%) vs. Mass-to-Charge (m/z)

Figure S86. ESI-TOF MS data for compound QX1017.
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Figure S87. 1H NMR data for compound QX1017.

(S)-16-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-14-oxo-4,7,10-trioxa-13-azaheptadec-1-en-17oic acid (QX1019)

Compound QX1017 (953 mg, 1.80 mmol) was dissolved in a mixture of TFA (3 ml) and water (150
uL). Then the reaction mixture was stirred at room temperature for 2 hours. After completion of the
reaction, TFA and water were removed by rotavapor. Yield quantitative; MS(ESI-TOF) m/z calc. for
C28H34N2O8H+ 527.23, found 527.24 [M+H+]; 1H NMR (500 MHz, Chloroform-d) δ 10.59 (s, 1H, COOH), 7.76 (d, J = 7.5 Hz, 2H, Fmoc aryl C-H), 7.60 (d, J = 7.3 Hz, 2H, Fmoc aryl C-H), 7.40 (t, J =
7.4 Hz, 2H, Fmoc aryl C-H), 7.32 (d, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.08 (s, 1H, , -CO-NH-CH2CH2-O-), 6.28 (d, J = 7.4 Hz, 1H, -CO-CαH-NH-Fmoc), 5.84 (ddt, J = 16.6, 11.0, 5.9 Hz, 1H, , -OCH2-CH-CHaHb), 5.24 (d, J = 17.2 Hz, 1H, -O-CH2-CH-CHaHb), 5.18 (d, J = 10.3 Hz, 1H, -O-CH2-CHCHaHb), 4.51 – 4.45 (m, 1H, -CαH-COO-), 4.43 (d, J = 7.2 Hz, 2H, Fmoc Ar2CH-CHaHb-O-), 4.22 (t, J
= 7.1 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 3.99 (d, J = 5.9 Hz, 2H, -O-CH2-CH-CHa,Hb), 3.75 (m, 2H, OCH2-CH2-NH-), 3.69 – 3.56 (m, 12H, -O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-NH-), 2.92 (dd, J = 15.5,
3.9 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.77 (dd, J = 15.3, 6.4 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-).
13
C NMR (75 MHz, Chloroform-d) δ 176.18 (-CβHaHb-CO-), 174.73 (-COOH), 156.25 (Fmoc Ar2CH219

CHaHb-O-CO-NH-), 143.55, 143.50, 141.30 (Fmoc aryl ipso C’s), 133.98 (-O-CH2-CH-CHaHb),
127.79, 127.07, 125.00, 119.99 (Fmoc Ar C-H), 117.98 (-O-CH2-CH-CHaHb), 72.23 (-O-CH2-CHCHa,Hb), 70.17, 70.15, 69.67, 69.02, 66.93 -O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-NH-), 67.21 (Fmoc
Ar2CH-CHaHb-O-), 49.90 (-CαH-COO-), 46.91 (Fmoc Ar2CH-CHaHb-O-), 38.05 (-O-CH2-CH2-NH),
35.45 (-CαHNHFmoc-CβHaHb-CO-).
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Figure S88. ESI-TOF MS data for compound QX1019.

Figure S89. 1H NMR data for compound QX1019.

221

734.3819

668.3864
525

600

625

650

675

700

725

750

784.3380
800
775

Figure S90. 13C NMR data for compound QX1019.

Figure S91. HSQC data for compound QX1019.

2-(2-azidoethoxy)ethan-1-ol (QX1083)

222

Procedure was performed as described above for compound QX1011 but using 2-(2chloroethoxy)ethan-1-ol as starting material. Yield: 44.3% MS(ESI-TOF) m/z calc. for C4H9N3O2H+
132.08, found 132.08 [M+H+]; 1H NMR (300 MHz, Chloroform-d) δ 3.77 (dd, J = 5.3, 3.7 Hz, 2H, -OCH2-CH2-OH), 3.72 (dd, J = 5.3, 3.7 Hz, 2H, -O-CH2-CH2-OH), 3.63 (dd, J = 5.2, 3.7 Hz, 2H, N3-CH2CH2-O-), 3.43 (t, J = 5.0 Hz, 2H, N3-CH2-CH2-O-), 2.24 (b.r.s, 1H, -O-CH2-CH2-OH). 13C NMR (75 MHz,
Chloroform-d) δ 72.44 (N3-CH2-CH2-O-), 70.07 (-O-CH2 -CH2-OH), 61.79 (-O-CH2-CH2 -OH), 50.74
(N3-CH2-CH2-O-).
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Figure S92. ESI-TOF MS data for compound QX1083.
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Figure S93. 1H NMR data for compound QX1083.

Figure S94. 13C NMR data for compound QX1083.
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Figure S95. HSQC data for compound QX1083.

3-(2-(2-azidoethoxy)ethoxy)prop-1-ene (QX1085)

Procedure was performed as described above for compound QX1013 but using QX1083 as starting
material. Yield: 82.7%; Not detectable on Mass Spectrum; 1H NMR (500 MHz, Chloroform-d) δ 5.92 (ddt,
J = 17.3, 10.3, 5.7 Hz, 1H, -O-CH2-CH-CHaHb), 5.28 (dd, J = 17.3, 1.7 Hz, 1H, -O-CH2-CH-CHaHb),
5.19 (dd, J = 10.4, 1.6 Hz, 1H, -O-CH2-CH-CHaHb), 4.04 (dt, J = 5.7, 1.5 Hz, 2H, -O-CH2-CH-CHa,Hb),
3.72 – 3.64 (m, 4H, -O-CH2-CH2 -O-), 3.65 – 3.59 (m, 2H, N3-CH2-CH2-O-), 3.40 (t, J = 5.1 Hz, 2H, N3CH2-CH2-O-). 13C NMR (126 MHz, Chloroform-d) δ 134.66 (-O-CH2-CH-CHaHb), 117.15 (-O-CH2-CHCHaHb), 72.29 (-O-CH2-CH-CHa,Hb), 70.73, 70.06 (-O-CH2-CH2 -O-), 69.45 (N3-CH2-CH2-O-), 50.68
(N3-CH2-CH2-O-).
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Figure S96. 1H NMR data for compound QX1085.

Figure S97. 13C NMR data for compound QX1085.
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Figure S98. HSQC data for compound QX1085.

2-(2-(allyloxy)ethoxy)ethan-1-amine (QX1095)

Procedure was performed as described above for compound QX1015 but using QX1085 as
starting material. Yield: quantitative; MS(ESI-TOF) m/z calc. for C7H15NO2H+ 146.12, found 146.12
[M+H+]; 1H NMR (500 MHz, Chloroform-d) δ 8.14 (b.r.s, 2H, NH2-CH2-CH2-O-), 5.91 (ddt, J = 17.3,
10.4, 5.8 Hz, 1H, -O-CH2-CH-CHaHb), 5.29 (dd, J = 17.2, 1.5 Hz, 1H, -O-CH2-CH-CHaHb), 5.20 (dd, J
= 10.3, 1.2 Hz, 2H, -O-CH2-CH-CHaHb), 4.04 (d, J = 5.8 Hz, 1H, -O-CH2-CH-CHa,Hb), 3.83 (t, J = 5.1
Hz, 2H, NH2-CH2-CH2-O-), 3.73 – 3.68 (m, 2H, -O-CH2-CH2-O- or -O-CH2 -CH2-O-), 3.66 – 3.61 (m,
2H, -O-CH2-CH2-O- or -O-CH2-CH2-O-), 3.3 – 3.2 (m, 2H, NH2-CH2-CH2-O-). 13C NMR (126 MHz,
Chloroform-d) δ 134.25 (-O-CH2-CH-CHaHb), 117.94 -O-CH2-CH-CHaHb), 72.13 (-O-CH2-CHCHa,Hb), 70.21 (-O-CH2-CH2-O- or -O-CH2 -CH2-O-), 69.13 (-O-CH2-CH2 -O- or -O-CH2-CH2 -O-),
66.69 (NH2-CH2-CH2-O-), 39.73 (NH2-CH2-CH2-O-).
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Figure S99. ESI-TOF MS data for compound QX1095.

Figure S100. 1H NMR data for compound QX1095.
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Figure S101. 13C NMR data for compound QX1095.

Figure S102. HSQC data for compound QX1095.

tert-butyl N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(2-(2-(allyloxy)ethoxy)ethyl)-Lasparaginate (QX1099)

229

Procedure was performed as described above for compound QX1017 but using QX1095 as starting
material. Yield: 85.8%; MS(ESI-TOF) m/z calc. for C30H38N2O7H+ 539.28, found 539.28 [M+H+]; 1H
NMR (300 MHz, Chloroform-d) δ 7.78 (d, J = 7.5 Hz, 2H, Fmoc aryl C-H), 7.63 (d, J = 7.2 Hz, 2H, Fmoc
aryl C-H), 7.41 (t, J = 7.3 Hz, 2H, Fmoc aryl C-H), 7.33 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 6.26 (t, J =
6.0 Hz, 1H, -CO-NH-CH2-CH2-O-), 6.11 (d, J = 8.4 Hz, 1H, -CO-CαH-NH-Fmoc), 5.92 (ddt, J = 16.4,
10.9, 5.7 Hz, 1H, -O-CH2-CH-CHaHb), 5.29 (dd, J = 17.2, 1.7 Hz, 1H, -O-CH2-CH-CHaHb), 5.21 (dd, J
= 10.4, 1.5 Hz, 1H, -O-CH2-CH-CHaHb), 4.52 – 4.48 (m, 1H, -CαH-COO-), 4.43 (t, J = 8.8 Hz, 1H, Fmoc
Ar2CH-CHaHb-O-), 4.33 (t, J = 8.8 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.25 (dd, J = 10.3, 7.1 Hz, 1H,
Fmoc Ar2CH-CHaHb-O-), 4.03 (d, J = 5.7 Hz, 2H, -O-CH2-CH-CHa,Hb), 3.60 – 3.55 (m, 6H, -O-CH2CH2-O-CH2-CH2-NH-), 3.47 (m, 2H, -O-CH2-CH2 -NH-), 2.91 (dd, J = 15.6, 4.5 Hz, 1H, -CαHNHFmocCβHaHb-CO-), 2.72 (dd, J = 15.6, 4.5 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 1.49 (s, 9H. -O-C-(CH3)3).
13
C NMR (75 MHz, Chloroform-d) δ 170.02 (-CβHaHb-CO-), 169.83 (-COO-), 156.19 (Fmoc Ar2CHCHaHb-O-CO-NH-), 144.00, 143.85, 141.26 (Fmoc aryl ipso C’s), 134.51 (-O-CH2-CH-CHaHb), 127.67,
127.06, 125.20, 119.93 (Fmoc Ar C-H), 117.45 (-O-CH2-CH-CHaHb), 82.23(-O-C-(CH3)3), 72.23 (-OCH2-CH-CHa,Hb), 70.30, 69.68, 69.33 (-O-CH2-CH2-O-CH2-CH2-NH-), 67.11 (Fmoc Ar2CH-CHaHb-O-),
51.43 (-CαH-COO-), 47.15 (Fmoc Ar2CH-CHaHb-O-), 39.23 (-O-CH2-CH2 -NH-), 37.92 (-CαHNHFmocCβHaHb-CO-), 27.93 (-O-C-(CH3)3).
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Figure S103. 1H NMR data for compound QX1099.
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Figure S104. 13C NMR data for compound QX1099.

Figure S105. HSQC data for compound QX1099.

N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(2-(2-(allyloxy)ethoxy)ethyl)-L-asparagine (QX1101)

Procedure was performed as described above for compound QX1019 but using QX1099 as starting
material. Yield: quantitative; MS(ESI-TOF) m/z calc. for C26H30N2O7H+ 482.22, found 482.23. [M+H+];
232

1

H NMR (300 MHz, Chloroform-d) δ 10.94 (b.r.s, 1H, -COOH), 7.79 (d, J = 7.5 Hz, 2H, Fmoc aryl CH), 7.61 (dd, J = 12.4, 7.4 Hz, 2H, Fmoc aryl C-H), 7.43 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.34 (t, J =
7.4 Hz, 2H, Fmoc aryl C-H), 6.98 (s, 1H, -CO-NH-CH2-CH2-O-), 6.30 (d, J = 7.5 Hz, 1H, -CO-CαHNH-Fmoc), 5.89 (ddt, J = 16.4, 11.7, 6.1 Hz, 1H, -O-CH2 -CH-CHaHb), 5.39 – 5.16 (m, 2H, -O-CH2-CHCHaHb), 4.50 – 4.48 (m, 1H, -CαH-COO-), 4.48 – 4.38 (m, 2H, Fmoc Ar2CH-CHaHb-O-), 4.20 (q, J =
6.3 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.07 (dd, J = 16.4, 5.9 Hz, 2H, -O-CH2-CH-CHa,Hb), 3.84 – 3.54
(m, 8H, -O-CH2-CH2-O-CH2-CH2-NH-), 2.90 (dd, J = 18.3, 5.4 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-),
2.77 (dd, J = 18.3, 5.4 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-). 13C NMR (75 MHz, Chloroform-d) δ 176.01
(-CβHaHb-CO-), 174.45 (-COO-), 164.08 (Fmoc Ar2CH-CHaHb-O-CO-NH-), 143.54, 143.49, 141.33
(Fmoc aryl ipso C’s), 134.31 (-O-CH2-CH-CHaHb), 127.84, 127.17,125.05, 120.03 (Fmoc Ar C-H),
117.80 (-O-CH2-CH-CHaHb), 72.09 (-O-CH2-CH-CHa,Hb), 69.75, 69.08, 66.85 (-O-CH2-CH2-O-CH2CH2-NH-), 67.29 (Fmoc Ar2CH-CHaHb-O-), 50.01(-CαH-COO-), 47.00 (Fmoc Ar2CH-CHaHb-O-), 38.27
(-O-CH2-CH2-NH-), 35.73 (-CαHNHFmoc-CβHaHb-CO-).
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Figure S106. ESI-TOF MS data for compound QX1101.
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Figure S107. 1H NMR data for compound QX1101.

Figure S108. 13C NMR data for compound QX1101.
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Figure S109. HSQC data for compound QX1101.

2-(allyloxy)ethan-1-amine (QX1107)

Procedure was performed as described above for compound QX1015 but using 2-azidoethan-1-ol
as starting material. Yield: 90.7%; MS(ESI-TOF) m/z calc. for C5H11NOH+ 102.09, found 102.09 [M+H+];
1
H NMR (300 MHz, Chloroform-d) δ 8.24 (s, 2H, NH2-CH2-CH2-O-), 5.95 (ddt, J = 16.4, 10.9, 5.6 Hz,
1H, -O-CH2-CH-CHaHb), 5.34 (dd, J = 17.3, 1.7 Hz, 1H, -O-CH2 -CH-CHaHb), 5.23 (d, J = 10.4 Hz, 1H,
-O-CH2-CH-CHaHb), 4.09 (d, J = 5.6 Hz, 2H, -O-CH2-CH-CHa,Hb), 3.78 (t, J = 5.1 Hz, 2H, NH2-CH2CH2-O-), 3.28 (q, J = 5.4 Hz, 2H, NH2-CH2-CH2-O-). 13C NMR (75 MHz, Chloroform-d) δ 134.07 (-OCH2-CH-CHa,Hb), 117.93 (-O-CH2-CH-CHa,Hb), 72.12 (-O-CH2-CH-CHa,Hb), 65.41 (NH2-CH2-CH2-O-),
39.68 (NH2-CH2-CH2-O-).
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Figure S110. ESI-TOF MS data for compound QX1107.

Figure S111. 1H NMR data for compound QX1107.
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Figure S112. 13C NMR data for compound QX1107.

Figure S113. HSQC data for compound QX1107.

N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(2-(allyloxy)ethyl)-L-asparagine (QX1111)

Procedure was performed as described above for compound QX1019 but using QX1107 as starting
material. Yield: quantitative; MS(ESI-TOF) m/z calc. for C24H26N2O6H+ 439.19, found 439.18 [M+H+];
238

1

H NMR (300 MHz, Chloroform-d) δ 9.38 (s, 1H, -COOH), 7.79 (d, J = 7.5 Hz, 2H, Fmoc aryl C-H),
7.62 (d, J = 7.7 Hz, 2H, Fmoc aryl C-H), 7.43 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.34 (t, J = 7.4 Hz, 2H,
Fmoc aryl C-H), 6.88 (s, 1H, -CO-NH-CH2-CH2-O-), 6.38 (d, J = 7.1 Hz, 1H, -CO-CαH-NH-Fmoc), 5.88
(ddt, J = 16.5, 11.1, 5.8 Hz, 1H, -O-CH2-CH-CHaHb), 5.29 (d, J = 16.3 Hz, 1H, -O-CH2-CH-CHaHb), 5.25
(d, J = 9.9 Hz, 1H, -O-CH2-CH-CHaHb), 4.69 – 4.60 (m, 1H, -CαH-COO-), 4.48 – 4.36 (m, 2H, Fmoc
Ar2CH-CHaHb-O-), 4.31 – 4.14 (m, 1H, Fmoc Ar2CH-CHaHb -O-), 4.02 (d, J = 6.0 Hz, 2H, -O-CH2-CHCHa,Hb), 3.60 – 3.55 (m, 2H, -NH-CH2-CH2-O-), 3.55 – 3.45 (m, 2H, -NH-CH2-CH2-O-),3.05 (d, J = 17.9,
5.7 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.90 (dd, J = 15.9, 6.6 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-).
13
C NMR (75 MHz, Chloroform-d) δ 174.13 (-CβHaHb-CO-), 171.82 (-COO-), 156.79 (Fmoc Ar2CHCHaHb-O-CO-NH-), 143.45, 143.34, 141.32 (Fmoc aryl ipso C’s), 133.32 (-O-CH2-CH-CHaHb), 127.89,
127.17, 125.08, 120.07 (Fmoc Ar C-H), 118.68 (-O-CH2-CH-CHaHb), 72.11 (-O-CH2-CH-CHa,Hb), 67.92
(Fmoc Ar2CH-CHaHb-O-), 67.83 (-NH-CH2-CH2-O-), 50.62 (-CαH-COO-), 46.92 (Fmoc Ar2CH-CHaHbO-), 39.84 (-NH-CH2-CH2 -O-), 37.63(-CαHNHFmoc-CβHaHb-CO-).
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Figure S114. ESI-TOF MS data for compound QX1111.

Figure S115. 1H NMR data for compound QX1111.
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Figure S116. 13C NMR data for compound QX1111.

Figure S117. HSQC data for compound QX1111.

3,6,9,12-tetraoxapentadec-14-en-1-ol (QX1127)

Procedure was performed as described above for compound QX1013 but using 2,2'((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethan-1-ol) as starting material. Yield: 33.10% MS(ESI-TOF) m/z
calc. for C11H22O5H+ 235.15, found 235.15 [M+H+]; 1H NMR (500 MHz, Chloroform-d) δ 5.92 (ddt, J =
241

17.3, 10.3, 5.7 Hz, 1H, -O-CH2-CH-CHaHb), 5.28 (dd, J = 17.3, 1.7 Hz, 1H, -O-CH2-CH-CHaHb), 5.19
(dd, J = 10.4, 1.5 Hz, 1H, -O-CH2 -CH-CHaHb), 4.68 (b.r.s 1H, -O-CH2-CH2-OH), 4.03 (dt, J = 5.7, 1.4
Hz, 2H, -O-CH2-CH-CHaHb), 3.70 – 3.65 (m, 12H, -O-CH2-CH2 -O-CH2-CH2 -O-CH2-CH2-O-CH2 -CH2OH), 3.63 – 3.60 (m, 4H, -O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-OH). 13C NMR (75 MHz,
Chloroform-d) δ 134.73 (-O-CH2-CH-CHa,Hb), 117.18 (-O-CH2-CH-CHa,Hb), 72.23 (-O-CH2-CHCHa,Hb), 70.57, 70.55, 70.48, 70.46, 69.37, 69.30 (-O-CH2 -CH2-O-CH2-CH2-O-CH2-CH2 -O-CH2-CH2OH).
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Figure S118. ESI-TOF MS data for compound QX1127.
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Figure S119. 1H NMR data for compound QX1127.

Figure S120. 13C NMR data for compound QX1127.
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Figure S121. HSQC data for compound QX1127.

3,6,9,12-tetraoxapentadec-14-en-1-amine (QX1139)

Procedure was performed as described above for compound QX1015 but using 1-azido-3,6,9,12tetraoxapentadec-14-ene as starting material. Yield: quantitative. MS(ESI-TOF) m/z calc. for
C11H23NO4H+ 234.17, found 234.17 [M+H+]; 1H NMR (500 MHz, DMSO-d6) δ 8.02 (s, 2H, -O-CH2-CH2NH2), 5.87 (ddt, J = 17.3, 10.6, 5.4 Hz, 1H, -O-CH2-CH-CHaHb), 5.24 (dd, J = 17.3, 1.8 Hz, 1H, -O-CH2CH-CHaHb), 5.13 (dd, J = 10.5, 1.8 Hz, 1H, -O-CH2-CH-CHaHb), 3.94 (dt, J = 5.4, 1.6 Hz, 2H, -O-CH2CH-CHaHb), 3.60 (t, J = 5.3 Hz, 2H, -O-CH2-CH2-NH2), 3.57 – 3.46 (m, 12H, -O-CH2-CH2 -O-CH2-CH2O-CH2-CH2-O-), 2.94 (q, J = 5.6 Hz, 2H, -O-CH2-CH2-NH2). 13C NMR (75 MHz, Chloroform-d) δ 135.82
(-O-CH2-CH-CHa,Hb), 117.15 (-O-CH2-CH-CHa,Hb), 71.50 (-O-CH2-CH-CHa,Hb), 70.25, 70.21, 70.19,
70.12, 70.08, 69.45, 67.08 (-O-CH2-CH2-O-CH2-CH2-O-CH2 -CH2-O-CH2 -CH2-NH2), 38.91 (-O-CH2CH2-NH2).
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Figure S122. ESI-TOF MS data for compound QX1139.

Figure S123. 1H NMR data for compound QX1139.
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Figure S124. 13C NMR data for compound QX1139.

Figure S125. HSQC data for compound QX1139.
tert-butyl (S)-19-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-17-oxo-4,7,10,13-tetraoxa-16-aza-icos-1-en-20-oate
(QX1141)

Procedure was performed as described above for compound QX1017 but using QX1139 as starting
material. Yield: 67.2%; MS(ESI-TOF) m/z calc. for C34H46N2O9H+ 627.32, found 627.32 [M+H+]; 1H
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NMR (500 MHz, Chloroform-d) δ 7.75 (d, J = 7.5 Hz, 2H, Fmoc aryl C-H), 7.60 (t, J = 8.0 Hz, 2H, Fmoc
aryl C-H), 7.38 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.30 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 6.48 (s, 1H,
-CO-NH-CH2-CH2-O-), 6.15 (d, J = 8.5 Hz, 1H, -CO-CαH-NH-Fmoc), 5.89 (ddt, J = 16.4, 10.9, 5.7 Hz,
1H, -O-CH2-CH-CHaHb), 5.25 (dd, J = 17.3, 1.8 Hz, 1H, -O-CH2 -CH-CHaHb), 5.16 (d, J = 10.3 Hz, 1H,
-O-CH2-CH-CHaHb), 4.48 (dt, J = 8.8, 4.6 Hz, 1H, -CαH-COO-), 4.41 (dd, J = 10.5, 7.2 Hz, 1H, Fmoc
Ar2CH-CHaHb-O-), 4.30 (dd, J = 10.6, 7.4 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.22 (t, J = 7.2 Hz, 1H,
Fmoc Ar2CH-CHaHb-O-), 3.99 (d, J = 5.7 Hz, 2H, -O-CH2-CH-CHa,Hb), 3.63 – 3.53 (m, 14H, -O-CH2CH2-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-NH-), 3.43 – 3.41 (m, 2H, -O-CH2 -CH2-NH-), 2.88 (dd, J =
15.7, 4.9 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.70 (dd, J = 15.6, 4.4 Hz, 1H, -CαHNHFmoc-CβHaHbCO-), 1.47 (s, 9H, -O-C-(CH3)3). 13C NMR (126 MHz, Chloroform-d) δ 172.63 (-CβHaHb-CO-), 171.34
(-COOH), 156.04 (Fmoc Ar2CH-CHaHb-O-CO-NH-), 143.89, 143.74, 141.24, 141.23 (Fmoc aryl ipso
C’s), 134.65 (-O-CH2-CH-CHaHb), 127.69, 127.10, 125.22, 119.92 (Fmoc Ar C-H), 117.21 (-O-CH2-CHCHaHb), 82.08 (-O-C-(CH3)3), 72.17 (-O-CH2-CH-CHa,Hb), 70.53, 70.51, 70.44, 70.24, 69.66, 69.35 (-OCH2-CH2-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-NH-), 67.00 (Fmoc Ar2CH-CHaHb-O-), 51.44 (-CαHCOO-), 47.05 (Fmoc Ar2CH-CHaHb-O-), 39.32 (-O-CH2-CH2-NH), 37.36 (-CαHNHFmoc-CβHaHb-CO-),
27.88 (-O-C-(CH3)3).
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Figure S126. ESI-TOF data for compound QX1141.

Figure S127. 1H NMR data for compound QX1141.
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Figure S128. 13C NMR data for compound QX1141.

Figure S129. HSQC data for compound QX1141.
(S)-19-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-17-oxo-4,7,10,13-tetraoxa-16-azaicos-1-en-20-oic acid (QX1143)
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Procedure was performed as described above for compound QX1019 but using QX1141 as starting
material. Yield: quantitative; MS(ESI-TOF) m/z calc. for C30H38N2O9H+ 571.26, found 571.26 [M+H+];
1
H NMR (500 MHz, Chloroform-d) δ 7.75 (d, J = 7.5 Hz, 2H, Fmoc aryl C-H), 7.60 (t, J = 8.0 Hz, 2H,
Fmoc aryl C-H), 7.38 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.30 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.22
(s, 1H, -CO-NH-CH2 -CH2-O-), 6.29 (d, J = 7.2 Hz, 1H, -CO-CαH-NH-Fmoc), 5.87 (ddt, J = 16.4, 10.9,
5.7 Hz, 1H, -O-CH2-CH-CHaHb), 5.24 (dd, J = 17.3, 1.8 Hz, 1H, -O-CH2-CH-CHaHb), 5.16 (d, J = 10.3
Hz, 1H, -O-CH2-CH-CHaHb), 4.49 – 4.46 (m, 1H, -CαH-COO-), 4.38 (dd, J = 10.5, 7.3 Hz, 1H, Fmoc
Ar2CH-CHaHb-O-), 4.31 (dd, J = 10.5, 7.3 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.21 (t, J = 7.3 Hz, 1H,
Fmoc Ar2CH-CHaHb-O-), 3.99 (d, J = 5.7 Hz, 2H, -O-CH2-CH-CHa,Hb), 3.67 – 3.50 (m, 14H, -O-CH2CH2-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-NH-), 3.43 – 3.41 (m, 2H, -O-CH2-CH2-NH-), 2.78 (d, J =
6.3 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.75 (d, J = 6.1 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-). 13C
NMR (126 MHz, Chloroform-d) δ 172.63 (-CβHaHb-CO-), 171.38 (-COOH), 156.05 (Fmoc Ar2CHCHaHb-O-CO-NH-), 143.89, 143.74, 141.24, 141.23 (Fmoc aryl ipso C’s), 134.65 (-O-CH2-CH-CHaHb),
127.71, 127.11, 125.20, 119.94 (Fmoc Ar C-H), 117.51 (-O-CH2-CH-CHaHb), 72.17 (-O-CH2-CHCHa,Hb), 70.51, 70.39, 70.32, 70.30, 69.98, 69.35, 69.20 (-O-CH2-CH2 -O-CH2-CH2-O-CH2 -CH2-O-CH2CH2-NH-), 67.21 (Fmoc Ar2CH-CHaHb-O-), 50.83 (-CαH-COO-), 47.05 (Fmoc Ar2CH-CHaHb-O-), 39.62
(-O-CH2-CH2-NH), 37.83 (-CαHNHFmoc-CβHaHb-CO-).
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Figure S130. ESI-TOF MS data for compound QX1143.

Figure S131. 1H NMR data for compound QX1143.
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Figure S132. 13C NMR data for compound QX1143.

Figure S133. HSQC data for compound QX1143.

9-azidonon-1-ene (QX1151)
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To a solution of NaN3 (650 mg, 10 mmol) in DMSO (20 mL) was added 9-Bromo-1-nonene (1 ml,
5 mmol) at room temperature. The reaction mixture was heated up to 100 OC for 8 hours. The crude
mixture was extracted with ethyl ether for 3 times after the reaction was completed. The combined organic
phases were washed with saturated brine and dried over anhydrous sodium sulfate, evaporated to dryness
to obtain QX1151 as colorless oil. Yield quantitative. Not detectable on Mass Spectrum; 1H NMR (300
MHz, Chloroform-d) δ 5.83 (ddt, J = 16.9, 10.1, 6.6 Hz, 1H, -CH2-CH-CHaHb), 5.02 (dd, J = 17.1, 1.9
Hz, 1H, -CH2-CH-CHaHb), 4.96 (dd, J = 10.2, 2.0 Hz, 1H, -CH2-CH-CHaHb), 2.10 – 2.02 (m, 2H, -CH2CH-CHaHb), 1.61 (q, J = 7.1 Hz, 2H, N3-CH2-CH2-), 1.43 – 1.33 (m, 10H, N3-CH2-CH2-CH2-CH2 -CH2CH2-CH2-CH-CHaHb).

Figure S134. 1H NMR data for compound QX1151.

non-8-en-1-amine (QX1153)

Procedure was performed as described above for compound QX1015 but using QX1151 as starting
material. Yield: 54.5% MS(ESI-TOF) m/z calc. for C9H19NH+ 142.16, found 142.16 [M+H+]; 1H NMR
(300 MHz, Chloroform-d) δ 8.16 (b.r.s, 2H, NH2-CH2-CH2 -), 5.82 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, -CH2CH-CHaHb), 5.02 (dd, J = 17.1, 1.9 Hz, 1H, -CH2-CH-CHaHb), 4.96 (dd, J = 10.1, 1.9 Hz, 1H, -CH2-CHCHaHb), 3.08 – 2.93 (m, 2H, NH2-CH2-CH2-), 2.06 (q, J = 6.8 Hz, 2H, -CH2-CH-CHaHb), 1.80 – 1.75 (m,
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2H, NH2-CH2-CH2-), 1.48 – 1.29 (m, 8H, NH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH-CHaHb). 13C
NMR (75 MHz, Chloroform-d) δ 138.93 (-CH2-CH-CHaHb), 114.32 (-CH2-CH-CHaHb), 40.09 (NH2CH2-CH2-), 33.65 (-CH2-CH-CHaHb), 28.86, 28.78, 26.56 (NH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2 -CHCHaHb), 27.50 (NH2-CH2-CH2-).
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Figure S135. ESI-TOF MS data for compound QX1153.
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Figure S136. 1H NMR data for compound QX1153.

Figure S137. 13C NMR data for compound QX1153.
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Figure S138. HSQC data for compound QX1153.

tert-butyl N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(non-8-en-1-yl)-L-asparaginate (QX2001)

Procedure was performed as described above for compound QX1017 but using QX1153 as starting
material. Yield: 42.4% MS(ESI-TOF) m/z calc. for C32H42N2O5H+ 535.31, found 535.31 [M+H+]; 1H
NMR (300 MHz, Chloroform-d) δ 7.79 (d, J = 7.5 Hz, 2H, Fmoc aryl C-H), 7.64 (dd, J = 7.5, 2.2 Hz, 2H,
Fmoc aryl C-H), 7.43 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.33 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 6.16
(d, J = 8.2 Hz, 1H, -CO-CαH-NH-Fmoc), 5.82 (ddt, J = 17.1, 10.3, 6.8 Hz, 1H, -CH2-CH-CHaHb), 5.78
(s, 1H, -CO-NH-CH2-CH2-), 5.01 (d, J = 17.8 Hz, 1H, -CH2-CH-CHaHb), 4.96 (d, J = 11.1 Hz, 2H, -CH2CH-CHaHb), 4.50 (dt, J = 8.7, 4.6 Hz, 1H, -CαH-COO-), 4.46 – 4.40 (m, 1H, Fmoc Ar2CH-CHaHb-O-),
4.34 (t, J = 8.8 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.25 (t, J = 7.1 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 3.25
(q, J = 7.2 Hz, 2H, -NH-CH2-CH2-), 2.89 (dd, J = 15.6, 4.8 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.73
(dd, J = 15.6, 4.5 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.04 (q, J = 7.1, 6.3 Hz, 2H, -CH2-CH-CHaHb),
1.51 (s, 9H, -O-C(CH3)3), 1.41 – 1.25 (m, 10H, -NH-CH2-CH2-CH2-CH2-CH2-CH2-CH2 -CH-CHaHb).
13
C NMR (75 MHz, Chloroform-d) δ 170.08 (-CβHaHb-CO-), 169.73 (-COOH), 156.28 (Fmoc Ar2CHCHaHb-O-CO-NH-), 143.92, 143.80, 141.27 (Fmoc aryl ipso C’s), 139.06 (-CH2-CH-CHaHb), 127.73,
127.11, 125.26, 119.99 (Fmoc Ar C-H), 114.27 (-CH2-CH-CHaHb), 82.37 (-O-C(CH3)3), 67.20 (Fmoc
Ar2CH-CHaHb-O-), 51.49 (-CαH-COO-), 47.13 (Fmoc Ar2CH-CHaHb-O-), 39.65 (-NH-CH2-CH2-), 38.07
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(-CαHNHFmoc-CβHaHb-CO-), 33.75 (-CH2-CH-CHaHb), 29.60, 29.13, 29.01, 28.83, 26.87 (-NH-CH2CH2-CH2-CH2 -CH2-CH2-CH2-CH-CHaHb), 27.95 (-O-C(CH3)3).
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Figure S139. ESI-TOF MS data for compound QX2001.
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Figure S140. 1H NMR data for compound QX2001.

Figure S141. 13C NMR data for compound QX2001.
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Figure S142. HSQC data for compound QX2001.

N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(non-8-en-1-yl)-L-asparagine (QX2003)

Procedure was performed as described above for compound QX1019 but using QX2001 as starting
material. Yield: quantitative; MS(ESI-TOF) m/z calc. for C28H34N2O5H+ 479.25, found 479.25 [M+H+];
1
H NMR (500 MHz, Chloroform-d) δ 10.86 (b.r.s, 1H, -COOH), 7.77 (d, J = 7.5 Hz, 2H, Fmoc aryl CH), 7.59 (dd, J = 7.7, 3.5 Hz, 2H, Fmoc aryl C-H), 7.41 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.36 – 7.29
(m, 2H, Fmoc aryl C-H), 6.59 (s, 1H, -CO-NH-CH2-CH2-), 6.44 (s, 1H, -CO-CαH-NH-Fmoc), 5.79 (ddt,
J = 17.0, 12.3, 6.3 Hz, 1H, -CH2-CH-CHaHb), 4.99 (d, J = 17.3 Hz, 1H, -CH2-CH-CHaHb), 4.94 (d, J =
10.1 Hz, 1H, -CH2-CH-CHaHb), 4.58 (s, 1H, -CαH-COO-), 4.43 – 4.30 (m, 2H, Fmoc Ar2CH-CHaHb-O-),
4.21 (t, J = 7.2 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 3.27 – 3.20 (m, 2H, -NH-CH2-CH2-), 2.98 (dd, J = 15.6,
4.7 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.88 (dd, J = 15.6, 4.7 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-),
2.02 (q, J = 7.1 Hz, 2H, -CH2-CH-CHaHb), 1.55 – 1.25 (m, 10H, -NH-CH2-CH2-CH2-CH2-CH2-CH2CH2-CH-CHaHb). 13C NMR (126 MHz, Chloroform-d) δ 173.93 (-CβHaHb-CO-), 171.67 (-COOH),
156.81 (Fmoc Ar2CH-CHaHb-O-CO-NH-), 143.40, 143.26, 141.33, 141.29 (Fmoc aryl ipso C’s), 138.99
(-CH2-CH-CHaHb), 127.92, 127.17, 125.07, 120.08 (Fmoc Ar C-H), 114.26 (-CH2-CH-CHaHb), 67.97
(Fmoc Ar2CH-CHaHb-O-), 50.72 (-CαH-COO-), 46.85 (Fmoc Ar2CH-CHaHb-O-), 40.48 (-NH-CH2259

CH2-), 37.60 (-CαHNHFmoc-CβHaHb-CO-), 33.68 (-CH2-CH-CHaHb), 28.99, 28.97, 28.89, 28.75, 26.68
(-NH-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH-CHaHb).
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Figure S143. ESI-TOF MS data for compound QX2003.
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Figure S144. ESI-TOF MS data for compound QX2003.

Figure S145. 13C NMR data for compound QX2003.
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Figure S146. HSQC data for compound QX2003.

12-bromododec-1-ene (QX2009)

Yield: 54.4% To a stirred solution of 1,12-dibromododecane (1.64 g, 5 mmol) in 10 mL THF
was added dropwise a solution of t-BuOK (561 mg, 5 mmol) in THF (5 mL) at 75 ºC over 30 min. The
reaction mixture was kept stirring for 30 min at this temperature and then cooled back to room
temperature. After standard workup with Et2O, the crude product was purified by flash column
chromatography with hexanes as mobile phase to afford the title compound as colorless clear oil (672
mg, 54%). MS(ESI-TOF) m/z calc. for C12H23BrH+ 247.10, found 247.10 [M+H+]; 1H NMR (500 MHz,
Chloroform-d) δ 5.82 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H, -CH2-CH-CHaHb), 5.00 (d, J = 17.2 Hz, 1H, CH2-CH-CHaHb), 4.94 (d, J = 10.2 Hz, 1H, -CH2-CH-CHaHb), 3.42 (t, J = 6.9 Hz, 2H, Br-CH2-CH2-),
2.05 (q, J = 6.7 Hz, 2H, -CH2-CH-CHaHb), 1.86 (dt, J = 14.5, 7.0 Hz, 2H, Br-CH2-CH2-), 1.45 – 1.29
(m, 14H, Br-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-). 13C NMR (126 MHz, Chloroform-d) δ
139.19 (-CH2-CH-CHaHb), 114.11 (-CH2-CH-CHaHb), 34.02 (Br-CH2-CH2-), 33.81 (-CH2-CH-CHaHb),
32.84 (Br-CH2-CH2-), 29.48, 29.44, 29.42, 29.12, 28.93, 28.77, 28.18 (Br-CH2-CH2-CH2-CH2 -CH2CH2-CH2-CH2 -CH2-).
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Figure S147. ESI-TOF MS data for compound QX2009.

Figure S148. 1H NMR data for compound QX2009.
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Figure S149. 13C NMR data for compound QX2009.

Figure S150. HSQC data for compound QX2009.

dodec-11-en-1-amine (QX2013)

Procedure was performed as described above for compound QX1015 but using QX2009 as starting
material. Yield: 73.6% MS(ESI-TOF) m/z calc. for C12H25NH+ 184.20, found 184.20 [M+H+]; 1H NMR
(300 MHz, Chloroform-d) δ 8.15 (b.r.s, 2H, NH2-CH2-CH2 -), 5.82 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H, -CH2264

CH-CHaHb), 5.00 (dd, J = 17.4, 1.8 Hz, 1H, -CH2-CH-CHaHb), 4.94 (d, J = 10.3 Hz, 1H, -CH2-CHCHaHb), 3.01 (s, 2H, NH2-CH2-CH2-), 2.05 (q, J = 7.0 Hz, 2H, -CH2-CH-CHaHb), 1.79 (t, J = 7.6 Hz, 2H,
NH2-CH2-CH2-), 1.47 – 1.18 (m, 14H, NH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2 -). 13C NMR
(75 MHz, Chloroform-d) δ 139.17 (-CH2-CH-CHaHb), 114.14 (-CH2-CH-CHaHb), 40.20 (NH2-CH2CH2-), 33.81 (-CH2-CH-CHaHb), 29.52, 29.46, 29.45, 29.14, 29.06, 28.94, 26.62 (NH2-CH2-CH2-CH2CH2-CH2-CH2 -CH2-CH2-CH2-), 27.72 (NH2-CH2-CH2-).
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Figure S151. ESI-TOF MS data for compound QX2013
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Figure S152. 1H NMR data for compound QX2013.

Figure S153. 13C NMR data for compound QX2013.
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Figure S154. HSQC data for compound QX2013.

tert-butyl N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(dodec-11-en-1-yl)-L-asparaginate
(QX2015)

Procedure was performed as described above for compound QX1017 but using QX2013 as starting
material. Yield: 57.4% MS(ESI-TOF) m/z calc. for C35H48N2O5H+ 577.36, found 577.3648 [M+H+]; 1H
NMR (300 MHz, Chloroform-d) δ 7.79 (d, J = 7.5 Hz, 2H, Fmoc aryl C-H), 7.64 (dd, J = 7.5, 2.2 Hz, 2H,
Fmoc aryl C-H), 7.43 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.34 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 6.12
(d, J = 8.2 Hz, 1H, -CO-CαH-NH-Fmoc), 5.84 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H, -CH2-CH-CHaHb), 5.66
(s, 1H, -CO-NH-CH2-CH2-), 5.02 (dd, J = 17.1, 1.9 Hz, 1H, -CH2-CH-CHaHb), 4.96 (dd, J = 10.4, 2.1 Hz,
1H, -CH2-CH-CHaHb), 4.50 (dt, J = 8.3, 4.5 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.41 (d, J = 7.4 Hz, 1H,
Fmoc Ar2CH-CHaHb-O-), 4.34 (t, J = 8.8 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 4.25 (t, J = 7.1 Hz, 1H, Fmoc
Ar2CH-CHaHb-O-), 3.26 (q, J = 7.0 Hz, 2H, -NH-CH2-CH2-), 2.90 (dd, J = 15.6, 4.7 Hz, 1H, CαHNHFmoc-CβHaHb-CO-), 2.73 (dd, J = 15.7, 4.5 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.06 (q, J =
7.9 Hz, 2H, -CH2-CH-CHaHb), 1.51 (s, 9H, -O-C(CH3)3), 1.45 – 1.22 (m, 16H, -NH-CH2-CH2-CH2 -CH2CH2-CH2- CH2-CH2-CH2-). 13C NMR (75 MHz, Chloroform-d) δ 170.01 (-CβHaHb-CO-), 169.67 (COOH), 156.25 (Fmoc Ar2CH-CHaHb-O-CO-NH-), 143.93, 143.79, 141.28, 141.27 (Fmoc aryl ipso C’s),
139.23 (-CH2-CH-CHaHb), 127.70, 127.07, 125.20, 119.97 (Fmoc Ar C-H), 114.13 (-CH2-CH-CHaHb),
82.39 (-O-C(CH3)3), 67.19 (Fmoc Ar2CH-CHaHb-O-), 51.46 (-CαH-COO-), 47.14 (Fmoc Ar2CH-CHaHb267

O-), 39.67 (-NH-CH2-CH2 -), 38.10 (-CαHNHFmoc-CβHaHb-CO-), 33.83 (-CH2-CH-CHaHb), 29.62, 29.54,
29.54, 29.48, 29.29, 29.15, 28.95, 26.92 (-NH-CH2-CH2-CH2-CH2-CH2-CH2-CH2 -CH2-CH2 -, 27.94 (O-C(CH3)3).
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Figure S155. ESI-TOF MS data for compound QX2015.

Figure S156. 1H NMR data for compound QX2015.

Figure S157. 13C NMR data for compound QX2015.
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Figure S158. HSQC data for compound QX2015.

N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(dodec-11-en-1-yl)-L-asparagine (QX2017)

Procedure was performed as described above for compound QX1019 but using QX2015 as starting
material. Yield: quantitative; MS(ESI-TOF) m/z calc. for C31H40N2O5H+ 521.30, found 521.30 [M+H+];
1
H NMR (300 MHz, Chloroform-d) δ 10.99 (b.r.s., 1H, -COOH), 7.80 (d, J = 7.5 Hz, 2H, Fmoc aryl CH), 7.61 (d, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.44 (t, J = 7.4 Hz, 2H, Fmoc aryl C-H), 7.34 (t, J = 7.4 Hz,
2H, Fmoc aryl C-H), 6.46 (s, 1H, -CO-NH-CH2-CH2-), 6.39 (d, J = 6.5 Hz, 1H, -CO-CαH-NH-Fmoc),
5.84 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, -CH2-CH-CHaHb), 5.02 (d, J = 17.5 Hz, 1H, -CH2-CH-CHaHb), 4.96
(d, J = 11.0 Hz, 2H, -CH2-CH-CHaHb), 4.57 (s, 1H, -CαH-COO-), 4.47 – 4.34 (m, 2H, Fmoc Ar2CHCHaHb-O-), 4.24 (t, J = 7.0 Hz, 1H, Fmoc Ar2CH-CHaHb-O-), 3.29 (q, J = 6.9 Hz, 2H, -NH-CH2-CH2-),
3.02 (dd, J = 15.8, 3.9 Hz, 1H, -CαHNHFmoc-CβHaHb-CO-), 2.87 (dd, J = 15.9, 7.5 Hz, 1H, CαHNHFmoc-CβHaHb-CO-), 2.06 (q, J = 7.0 Hz, 2H, -CH2-CH-CHaHb), 1.45 – 1.20 (m, 16H, -NH-CH2CH2-CH2-CH2 -CH2-CH2-CH2-CH2-CH2-). 13C NMR (75 MHz, Chloroform-d) δ 173.51 (-CβHaHb-CO-),
171.76 (-COOH), 156.68 (Fmoc Ar2CH-CHaHb-O-CO-NH-), 143.42, 143.26, 141.33, 141.32 (Fmoc aryl
ipso C’s), 139.23 (-CH2-CH-CHaHb), 127.92, 127.18, 125.06, 120.10 (Fmoc Ar C-H), 114.13 (-CH2-CH270

CHaHb), 67.94 (Fmoc Ar2CH-CHaHb-O-), 50.62 (-CαH-COO-), 46.89 (Fmoc Ar2CH-CHaHb-O-), 40.54
(-NH-CH2 -CH2-), 37.62 (-CαHNHFmoc-CβHaHb-CO-), 33.82 (-CH2-CH-CHaHb), 29.51, 29.46, 29.17,
29.13, 28.93, 26.77 (-NH-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-).
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Figure S159. ESI-TOF MS data for compound QX2017.

271

530

532

534

536

538

540

542

Figure S160. 1H NMR data for compound QX2017.

Figure S161. 13C NMR data for compound QX2017.
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Figure S162. HSQC data for compound QX2017.
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4. Long-range PEG Stapling: Macrocyclization for Increased Protein Conformational Stability and
Resistance to Proteolysis
Reproduced from RSC Chem. Biol., 2020, 1, 273 with permission from the Royal Society of Chemistry.
Dallin S. Ashton contributed to the synthesis and purification of WW variant 14/30-00. Katherine P. Thompson
contributed to the synthesis of SH3 variant 20/37-44.

4.1 Introduction
Please refer to chapter 1 for introduction of macrocyclization of peptides and proteins.
We are interested in understanding the origin and determinants of protein stabilization via
macrocyclization/stapling in diverse structural contexts. The WW domain is a triple-stranded antiparallel
β-sheet protein;1 positions 16 and 19 within WW are close in sequence and in tertiary structure: both are
located within a reverse turn that connects first and second β-strands. Each is also a location where AsnPEGylation is substantially stabilizing.2 In WW variant 16/19-o23, residues 16 and 19 are occupied by
Asn residues that have been modified with two- and three-unit O-allyl PEGs, respectively (Figure S1).3
Bis-PEGylated 16/19-o23 is -0.75 ± 0.02 kcal/mol more stable than its non-PEGylated counterpart 16/1900; Crosslinking of the O-allyl PEGs via olefin metathesis results in stapled variant s16/19-o23, which is
-0.29 ± 0.02 kcal/mol more stable than 16/19-o23. This stabilizing change in folding free energy (ΔΔG)
comes from a favorable change in entropy (i.e., –TΔΔS), partially offset by an unfavorable change in
enthalpy (ΔΔH), an observation that is consistent with the anticipated impact of macrocyclization on
protein folding as described above. However, the ΔΔG associated with stapling (-0.29 ± 0.02 kcal/mol;
compare s16/19-o23 vs. 16/19-o23) is much smaller than the ΔΔG associated with bis-PEGylation (-0.75
± 0.02 kcal/mol; compare s16/19-o23 vs. 16/19-00). Incorporating PEGs of longer and shorter lengths
within this staple failed to improve the observed staple-based stabilization.3
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We wondered whether the limited energetic benefits of stapling positions 16 and 19 reflected their
proximity in primary sequence (3 residues apart) as well as in tertiary structure (4.0 Å between Cβ’s of
these positions in the crystal structure of the parent WW domain4): positions 16 and 19 may be similarly
close in both folded and unfolded conformations of non-stapled WW, such that covalently linking them
together has only marginal benefits. We hypothesized that stapling between positions that are farther apart
in primary sequence but still relatively close in the folded tertiary structure would have a more favorable
impact. Position 32 at the C-terminal end of the third β-strand in WW is a stabilizing Asn-PEGylation site
2

; it is on the same face of WW as is position 16 (9.4 Å between Cβ’s of these positions), but is much

farther from position 16 in primary sequence (i.e. 16 residues) than is position 19. Bis-PEGylated WW
variant 16/32-o44 (with Asn-linked four-unit O-allyl PEGs at positions 16 and 32) is -0.40 ± 0.05 kcal/mol
more stable than non-PEGylated 16/32-00. Olefin-stapled s16/32-o44 is -1.11 ± 0.04 kcal/mol more stable
than non-stapled 16/32-o44 due to a favorable entropic effect offset by a smaller unfavorable change in
enthalpy.3 The ΔΔG and –TΔΔS values associated with stapling of positions 16 and 32 are much more
favorable than we observed for positions 16 and 19, presumably because the staple increases the proximity
of positions 16 and 32 in the unfolded ensemble, thereby reducing the entropic cost of their proximity in
the folded conformation.3
These published observations suggest that substantial separation in primary sequence but
proximity in tertiary structure are important criteria for identifying stabilizing PEG-stapling sites within
proteins. Here we validate these criteria by identifying new PEG-stapling sites within WW and the Src
SH3 domain. We also explore the stabilizing impact of stapling via olefin metathesis vs. CuAAC at
selected locations within WW and demonstrate that staple-based stabilization is associated with enhanced
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resistance to proteolytic degradation. Finally, we show that intermolecular PEG stapling increases the
quaternary structural stability of an α-helical GCN4 coiled-coil heterodimer.
4.2 Results and Discussion
Positions 14 and 30 in WW are 16 residues apart in primary sequence and occupy the same face
of WW (11.7 Å between Cβ’s of these positions4), similar to the relationship between positions 16 and
32. We wondered whether PEG stapling of positions 14 and 30 would be similarly stabilizing. A potential
complicating issue is our previous observation that Asn-PEGylation at position 14 or position 30 has a
minimal impact on WW conformational stability, whereas Asn-PEGylation at position 16 or position 32
is stabilizing.2 We wondered if this difference would affect the impact of PEG-stapling of positions 14
and 30. Bis-PEGylated WW variant 14/30-o55 (with Asn-linked five-unit O-allyl PEGs at positions 14
and 30) is -0.34 ± 0.02 kcal/mol more stable than its non-PEGylated counterpart 14/30-00. Olefin-stapled
s14/30-o55 is -0.49 ± 0.05 kcal/mol more stable than 14/30-o55, a more favorable value than we observed
previously for stapling of positions 16 and 19 (ΔΔG = -0.29 ± 0.02 kcal/mol), but less favorable than for
stapling of positions 16 and 32 (ΔΔG = -1.11 ± 0.04 kcal/mol). The small magnitude and high uncertainty
in the values of ΔΔH and –TΔΔS for s14/30-o55 vs. 14/30-o55 make it difficult to assess the entropic vs.
enthalpic origin of the staple-based stabilization at positions 14 and 30, as indicated in Table 1. These
results show that close proximity in tertiary structure and substantial separation in primary sequence are
important criteria for identifying locations where PEG stapling will be stabilizing; however, they also
suggest that optimal staple-based stabilization may depend moderately on the intrinsic impact of
PEGylation at the prospective staple sites. It is also noteworthy that the relatively flexible linkers
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(containing 5-10 ethylene oxide units) within s16/19-o23, s16/32-o44, and s14/30-o55 can provide such a
substantial level (-0.3 to -1.2 kcal/mol) of staple-based stabilization.
We next sought to apply these criteria to a larger and more structurally complex protein. We
previously found that Asn-PEGylation at position 20 within the Src SH3 domain (hereafter called SH3)
substantially increases the conformational stability of the PEGylated SH3 variant relative to its nonPEGylated counterpart.2 Positions 20 and 37 occur within two different unstructured loops in SH3 and are
far apart in primary sequence (i.e. 17 residues); however, they occupy the same face of folded SH3 tertiary
structure (17.0 Å between Cβ’s of these positions in the crystal structure of the parent SH35). We
hypothesized that metathesis-based PEG stapling of these two positions would increase the
conformational stability of SH3. Accordingly, we prepared bis-PEGylated SH3 variant 20/37-o44, in
which positions 20 and 37 are each occupied by four-unit Asn-linked O-allyl PEGs. The thermal unfolding
behavior of variant 20/37-o44 was not consistent with two-state folding, which precluded detailed analysis
of its conformational stability. In contrast, olefin-stapled variant s20/37-o44 (Tm = 76.0 ± 0.8 °C) is -0.93
± 0.07 kcal/mol more stable than non-PEGylated 20/37-00 (Tm = 61.1 ± 0.3 °C). The unusual thermal
unfolding behavior of 20/37-o44 prevents us from determining how much of the favorable ΔΔG value for
s20/37-o44 vs. 20/37-00 comes from bis-PEGylation vs. olefin stapling. However, these observations hint
at the intriguing potential for olefin-based PEG stapling to rescue two-state folding and restore
conformational stability to proteins with unusual thermal unfolding behavior.
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Figure 163. Sequences and structures of olefin-stapled WW variants s16/32-o44 and s14/30-o55; triazole-stapled WW
variants s16/32-c44 and s14/30-c44; and olefin-stapled SH3 variant s20/37-o44. N represents a PEG-modified Asn
residue; the PEG oligomer(s) within each variant have the number of ethylene oxide units and the olefin, azide, alkyne,
or triazole functional groups as indicated in the structural drawings.

We next wondered whether stapling of Asn-linked PEGs via CuAAC (i.e., click stapling) would
provide levels of stabilization similar to what we observed previously for olefin stapling. To explore this
possibility, we prepared WW variant 16/32-c44, in which an O-propargyl four-unit Asn-PEG occupies
position 16, with an azide-terminated four-unit Asn-PEG at position 32 (Figure 1). Click stapling results
in variant s16/32-c44, which is -1.24 ± 0.03 kcal/mol more stable than its non-stapled counterpart.
Similarly, click-stapled WW variant s14/30-c44 is -0.61 ± 0.02 kcal/mol more stable than non-stapled
14/30-c44, as shown in Table 1. These results demonstrate that the impact of stapling is tolerant of
variations in the nature of the staple, with click stapling slightly more stabilizing than olefin stapling at
the positions we investigated.
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Table 1. Folding free energies of PEGylated and PEG-stapled WW, SH3, and GCN4 variants. a

Tm (°C)

ΔG
(kcal/mol)

16/32-00

49.2 ± 0.6

0.00 ± 0.04

16/32-o44

54.0 ± 0.2

-0.40 ± 0.02

s16/32-o44

71.7 ± 0.3

-1.51 ± 0.04

16/32-c44

54.2 ± 0.2

-0.44 ± 0.02

s16/32-c44

71.4 ± 0.1

-1.68 ± 0.03

14/30-00

28.6 ± 0.2

0.00 ± 0.01

14/30-o55

33.2 ± 0.1

-0.34 ± 0.01

s14/30-o55

39.5 ± 0.6

-0.83 ± 0.05

14/30-c44

30.5 ± 0.2

-0.13 ± 0.01

s14/30-c44

41.3 ± 0.1

-0.73 ± 0.01

20/37-00

61.1 ± 0.3

0.00 ± 0.02

s20/37-o44

76.0 ± 0.8

-0.94 ± 0.06

d27/29’-c40

41.1 ± 0.2

0.00 ± 0.02

sd27/29’-c40

48.2 ± 0.1

-0.65 ± 0.01

27/29’-c40

34.8

---

s27/29’-c40

82.0 ± 0.2

---

Protein

Impact of Stapling
ΔΔG
(kcal/mol)

ΔΔH
(kcal/mol)

-TΔΔS
(kcal/mol)

-1.11 ± 0.04

2.1 ± 0.9

-3.2 ± 0.9

-1.24 ± 0.03

8.3 ± 0.8

-9.6 ± 0.8

-0.49 ± 0.05

-1.2 ± 0.9

0.7 ± 0.9

-0.61 ± 0.02

1.9 ± 0.4

-2.5 ± 0.4

-0.93 ± 0.07

9.9 ± 1.3

-10.8 ± 1.3

-0.65 ± 0.02

1.3 ± 0.6

-1.9 ± 0.6

---

---

---

Folding free energies for each variant are given ± std. error in kcal/mol at the melting temperature of its non-stapled nonPEGylated counterpart. WW variants 16/32-00, 14/30-00 and SH3 variant 20/37-00 and their derivatives were analyzed at 50
μM protein concentration in 20 mM sodium phosphate buffer (pH 7). GCN4 disulfide-bound heterodimer d27/29’-c40 and
its triazole-stapled counterpart sd27/29’-c40 were analyzed at 15 μM protein concentration in 20 mM sodium phosphate
buffer (pH 7) + 4.0 M GdnHCl. GCN4 noncovalent heterodimer 27/29’-c40 and its triazole-stapled counterpart s27/29’-c40
were analyzed at 15 μM protein concentration in 20 mM sodium phosphate buffer (pH 7) + 0.5 M GdnHCl.
a

We previously showed that PEG-based increases in WW conformational stability are associated
with increased levels of protection from proteolysis. We wondered whether this would be true for PEGstapled WW variants. We explored this possibility by exposing 50 μM solutions of WW variants 16/1900, 16/19-o23, s16/19-o23, 16/32-00, 16/32-o44, and s16/32-o44 to proteinase K (17 μg/mL) and
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monitoring the amount of full-length protein remaining in solution at regular intervals by analytical HPLC.
We fit the resulting data to a monoexponential decay function to obtain apparent proteolysis rate constants.
The results of this analysis are shown in Figure 2A,B. PEGylated olefin-stapled variant s16/19-o23 is
more resistant to proteolysis than its PEGylated but non-stapled counterpart 16/19-o23, which is, in turn,
more resistant to proteolysis than non-PEGylated non-stapled 16/19-00. Similarly, PEGylated olefinstapled variant s16/32-o44 is more resistant to proteolysis than PEGylated but non-stapled 16/32-o44,
which is more resistant to proteolysis than non-stapled non-PEGylated 16/32-00. For each variant, we
calculated a proteolytic resistance factor r, which is the ratio between the apparent rate constant for a
PEGylated olefin-stapled variant or its PEGylated but non-stapled counterpart relative to the parent nonPEGylated non-stapled variant. Variants with smaller values of r are more resistant to proteolysis than the
corresponding parent variant. We then plotted the natural logarithm of r against the corresponding
difference in free energy for the compound relative to its non-PEGylated non-stapled parent variant
(Figure 2C). ln r varies linearly with ΔΔG as indicated by least-squares regression (R2 = 0.996), indicating
that more stabilized WW variants experience greater levels of proteolytic resistance, independent of
whether the increased stability comes primarily from PEGylation, olefin-stapling, or a combination of the
two.
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Figure 2. Proteolysis of (A) 16/19-00 (blue circles), 16/19-o23 (brown circles), and s16/19-o23 (magenta circles) and of (B)
16/32-00 (blue circles), 16/32-o44 (brown circles), and s16/32-o44 by proteinase K (17 µg/mL) at 50 μM protein concentration
in 20 mM sodium phosphate buffer (pH 7) as monitored by HPLC. Data points represent the average of three replicate
experiments. Solid lines represent fits of the data to a mono-exponential decay function, which was used to determine apparent
proteolysis rate constants. (C) Plot of the impact of PEGylation or PEG-stapling on proteolytic resistance (as assessed by the
natural logarithm of r, the ratio of apparent proteolysis rate constant for PEGylated or PEG-stapled WW variants relative to
their non-stapled non-PEGylated counterparts) vs. the impact of PEGylation or PEG-stapling on WW conformational stability
(ΔΔG). Dotted line represents fit of the ln r vs. ΔΔG data to a linear equation. Slope = 1.55 ± 0.07; intercept = -0.28 ± 0.07; R2
= 0.996.

In the examples described above, we installed olefin or click staples between two positions in the
same monomeric protein (WW or SH3). We wondered whether the extent of stabilization observed in
these monomeric systems might extend to intermolecular staples between subunits of quaternary structure.
We explored this possibility within an α-helical coiled coil, one of the best understood tertiary/quaternary
structural motifs in proteins.6-8 Coiled-coil primary sequence is comprised of a seven-residue repeating
unit called a heptad; the first and fourth residues within this unit (i.e. positions a and d of an abcdefg
heptad) are typically occupied by nonpolar residues, with charged residues at e and g positions and polar
or charged residues at b, c, and f positions.9, 10 Burial of non-polar residues at a and d positions provides
the major driving force for folding; the shape of these a and d residues can specify coiled-coil
oligomerization state (dimer, trimer, tetramer, etc.).11-16 Complementary electrostatic interactions between

281

an e residue on one helix and an g residue on the other provide specificity for homo- vs.
heteroligomerization17-20 and for parallel vs. antiparallel orientation.21-23
Others have already begun to apply intermolecular stapling to α-helical coiled coils, but with
limited focus on the thermodynamic consequences of stapling.
We explored the quantitative impact of interhelical stapling on α-helical coiled-coil
conformational stability in the context of a previously characterized coiled-coil tertiary structure based on
the GCN4 homodimer, in which acidic peptide A and basic peptide B are covalently connected via a
disulfide bond to form parallel monomeric coiled coil A/B.24 In disulfide-bound A/B, e-position Glu
residues in peptide A engage in interhelical salt bridges with g-position Lys residues in peptide B
(similarly, e-position Lys residues in B interact with g-position Glu residues in A). Each e/g pair is oriented
such that a g residue on one helix is close to the e residue from the previous heptad on the other helix. For
example, Oε2 of e-position Glu27 in A is only 4.3 Å from Nζ of g-position Lys22’ in B but is 9.7 Å of
from Nζ of g-position Lys29’. Whereas Arora25, 26 and Liu27 used stapling to replace e/g salt bridges within
parallel coiled coils, we wondered how a longer-range staple might influence coiled-coil conformational
stability.
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Figure 3. (A) Sequences of acidic peptide A and basic peptide B, along with disulfide-bonded parallel coiled-coil
monomer A/B. Ribbon diagram of the published crystal structure of A/B (PDB ID: 1KD9), with side chains shown as
sticks. e-position Glu residues on peptide A are colored blue; g-position Lys residues on peptide B are colored orange;
non-polar a- and d-position residues on peptides A and B are colored dark grey. Black dotted lines indicate distances
between the Oε2 of Glu and Nζ of Lys within each of four e/g’ interhelical salt bridges (i.e., Glu6/Lys1’, Glu13/Lys8’,
Glu20/Lys15’, and Glu27/Lys22’). The blue dotted line indicates the distance between Oε2 of Glu27 and Nζ of Lys29’,
which are not involved in an interhelical salt bridge with each other (B) Sequences of acidic variant 27-c4, basic variant
29’-c0, disulfide-bound coiled-coil monomer d27/29’-c40, and its triazole-stapled counterpart sd27/29’-c40. X
represents propargyl glycine and N represents an azide-terminated Asn-PEG, with the structures as shown.

We addressed this question by preparing peptide 27-c4 (a variant of acidic peptide A in which eposition Glu27 has been replaced with an azide-terminated Asn-PEG comprised of four ethylene oxide
units) and peptide 29’-c0 (a variant of basic peptide B in which g-position Lys29 has been replaced with
propargylglycine), as shown in Figure 3. We chose these positions because Glu27 in A and Lys29 in B
are not involved in a salt bridge with each other in the parent disulfide-bound coiled-coil monomer A/B.
We mixed 27-c4 and 29’-c0 in an equimolar ratio in the presence of air to form monomeric disulfidebound d27/29’-c40; we then prepared its click-stapled counterpart sd27/29’-c40 via CuAAC. CD data for
d27/29’-c40 and sd27/29’-c40 are consistent with the formation of an α-helical coiled-coil tertiary
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structure. The disulfide bond makes both variants monomeric even though one is stapled and the other is
not; this facilitates direct comparison of their folding free energies. In the presence of 4 M GdnHCl,
triazole-stapled sd27/29’-c40 (Tm = 48.2 ± 0.1 °C) is -0.65 ± 0.01 kcal/mol more stable than non-stapled
d27/29’-c40 (Tm = 41.1 ± 0.2 °C), as can be seen from Table 1; we used 4 M GdnHCl because these
variants were too stable to characterize via variable temperature CD in the absence of denaturant (i.e.,
their thermal unfolding transitions were not complete even at 94 °C). These results indicate that a longrange interhelical staple between non-interacting e and g positions can increase the conformational
stability of a coiled coil to a similar extent as we observed above for click and olefin staples within the βsheet-rich WW and SH3 domains.
We wondered how much this interhelical staple would stabilize a heterodimeric coiled-coil
quaternary structure in which the individual helices were not disulfide-bound. Accordingly, we prepared
peptides 27A-c4 and 29A’-c0, variants of 27-c4 and 29’-c0, respectively, in which Ala occupies position
33 instead of Cys. Peptides 27A-c4 and 29A’-c0 combine in a 1:1 ratio to form noncovalent heterodimeric
coiled coil 27/29’-c40; the CD spectrum of 27/29’-c40 is consistent with coiled-coil quaternary structure;
variable temperature CD data in the presence of 0.5 M GdnHCl indicate that 27/29’-c40 undergoes a
cooperative thermal unfolding transition with. Tm = 34.8 °C. Click stapling converts noncovalent
heterodimer 27/29’-c40 into stapled monomeric s27/29’-c40, which has a similar CD spectrum, and
undergoes a cooperative thermal unfolding transition with Tm = 82.0 ± 0.2 °C. The folding free energies
of 27/29’-c40 and s27/29’-c40 are not directly comparable because of their distinct association states: the
ΔG of noncovalent heterodimer 27/29’-c40 is concentration dependent, whereas the ΔG of stapled
monomeric s27/29’-c40 is not. However, stapling increases the melting temperature of s27/29’-c40 by
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49.2 °C relative to noncovalent heterodimer 27/29’-c40 in 0.5 M GdnHCl, suggesting that the stabilizing
impact of intermolecular interhelical stapling is substantial.
4.3 Conclusion
Here we have shown that PEG stapling enhances WW conformational stability best when the
staple sites are distant in primary sequence, close in tertiary structure, and are each individually stabilized
by Asn-PEGylation. We applied these criteria to the SH3 domain, where PEG stapling increased the
stability of the stapled variant by -0.9 kcal/mol relative to its non-PEGylated non-stapled counterpart. We
found that staple-based stabilization is associated with increased proteolytic resistance and is tolerant of
variation in linker chemistry, with triazole and olefin linkers providing similar energetic benefits. We also
found that an intermolecular PEG staple between non-interacting e- and g-positions in a GCN4-derived
α-helical coiled-coil heterodimer dramatically increases the stability of the stapled coiled-coil relative to
its non-stapled counterpart.
We previously found that staples comprised of PEGs shorter than a certain threshold can actually
decrease protein conformational stability, presumably because the PEGs are too short to accommodate
the distance between the staple sites in the folded tertiary structure.3 We originally expected longer PEG
staples to have a less stabilizing impact; we reasoned that a longer PEG would not be as effective at
promoting folding by restricting the freedom of the staple sites. Our results were not consistent with this
hypothesis: we found that incremental increases to PEG length beyond the minimum threshold do not
dramatically change the stabilizing impact of stapling or its entropic origin.3 In agreement with these
previous results, we herein observed substantial levels of entropy-derived stabilization despite the length
of the PEG staples: eight ethylene oxide units in s16/32-o44, s16/32-c44, and 20/37-o44; ten in 14/30285

o55; and four in s27/29’-c40. It is possible that the length and flexibility of the PEG staple is responsible
for its versatility in the secondary, tertiary, and quaternary structural contexts investigated here (β-sheet
tertiary structures, α-helical coiled-coil quaternary structure). This versatility should be useful in
applying PEG stapling to the stabilization of therapeutic proteins. In any case, it will be interesting to
see whether the stabilizing impact of longer staples is a unique feature of PEG stapling or whether it also
extends to stapling with other linkers (e.g., hydrocarbons).
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4.5 Electronic Supplementary Information
4.5.1 Structures and sequences of WW, SH3, and GCN4 variants
The structures and sequences of newly synthesized WW and SH3 variants are shown in Figure S1.
WW variants 16/19-00, 16/19-23, s16/19-23, 16/32-00, 16/32-44, s16/32-44 and SH3 variant SH3 20/3700 mentioned in the main text, those structures and sequences were reported before by our lab.1, 2

Figure S6. Sequences and structures of olefin-stapled WW variants s16/32-o44 and s14/30-o55; triazole-stapled WW variants
s16/32-c44 and s14/30-c44; olefin-stapled WW variants s16/19-o23; and olefin-stapled SH3 variant s20/37-o44. N represents
a PEG-modified Asn residue; the PEG oligomer(s) within each variant have the number of ethylene oxide units and the olefin,
azide, alkyne, or triazole functional groups as indicated in the structural drawings.
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Figure S7. Acidic GCN4 monomer 27A-c4, basic GCN4 monomer 29A’-c0, noncovalent GCN4 heterodimer 27/29’-c40, and
its triazole-stapled counterpart 27/29’-c40. Also shown are cysteine-containing acidic GCN4 monomer 27-c4, basic GCN4
monomer 29’-c0, disulfide-bound GCN4 heterodimer d27/29’-c40, and its triazole-stapled counterpart sd27/29’-c40. X
represents propargyl glycine; N represents a PEG-modified Asn residue; the PEG oligomer(s) within each variant have the
number of ethylene oxide units indicated in the structural drawings

4.5.2 Synthesis of WW, SH3 and GCN4 variants
Peptide Synthesis: WW variants 16/32-00, 16/32-o44, s16/32-o44, and SH3 variant 20/37-00 were
prepared previously. WW variants 16/32-c44, 14/30-00, 14/30-o55, and 14/30-c44 were synthesized as
C-terminal acids on Fmoc-Gly-Wang LL resin (EMD Biosciences) and SH3 variant 20/37-o44 and GCN4
variants 27-c4, 29’-c0, and their Cys33Ala mutants 27A-c4, 29A’-c0 were prepared as C-terminal amides
on Rink amide MBHA LL resin (EMD Biosciences), by microwave-assisted solid phase peptide synthesis
using a standard Fmoc Nα protection strategy as described previously.2 Fmoc-protected amino acids were
purchased from Advanced Chem Tech, except for the PEGylated asparagine derivatives, which were
synthesized as described in section 7 below. Unstapled WW, SH3, and GCN4 variants were cleaved from
resin and purified by preparative reverse-phase high-performance liquid chromatography (HPLC) on a
C18 column using a linear gradient of water in acetonitrile with 0.1% v/v trifluoroacetic acid. Peptide
identity was confirmed by electrospray ionization time-of-flight mass spectrometry. We used an analogous
approach to prepare the stapled WW variants and SH3 variant, except we reduced the resin loading (i.e.
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the number of Fmoc-protected amino groups on resin) by approximately 50% using a 1:1 mixture of Fmocand Boc-protected amino acids during the first coupling reaction.

Stapling via olefin metathesis: We prepared olefin-stapled variants s14/30-o55 and s20/37-o44 from
their resin-bound non-stapled precursors 14/30-o55 and 20/37-o44 via on-resin olefin metathesis, as we
have done previously, except we heated the reaction mixture to 60 °C. We monitored reaction
completeness by microcleavage and ESI-TOF MS. Following the reaction, we cleaved and purified
s14/30-o55 and s20/37-o44 as described above.
Disulfide formation in the GCN4 heterodimer: We prepared the disulfide-bonded GCN4 heterodimer
d27/29’-c40 (notebook number QX22031) by mixing its purified cysteine-containing precursors 27-c4
(notebook number QX21971) and 29’-c0 (notebook number QX21973) in a 1:1 ratio (total peptide
concentration of 8 mg/mL) in an aqueous solution of ammonium bicarbonate with exposure to air for 3 h.
Reaction completeness was monitored by analytical HPLC; GCN4 variant d27/29’-c40 was then purified
by preparative HPLC and characterized by ESI-TOF MS.
Stapling via copper-catalyzed azide/alkyne cycloaddition (CuAAC): We prepared triazole-stapled
variants s16/32-c44, s14/30-c44, sd27/29’-c40, and s27/29’-c40 (i.e., the non-disulfide-bound counterpart
of sd27/29’-c40) by stirring their purified non-stapled precursors 16/32-c44, 14/30-c44, d27/29’-c40, and
27/29’-c40 (i.e., the non-covalent GCN4 heterodimer formed by a 1:1 mixture of 27A-c4 and 29A’-c0) in
2:1 (v/v) water/tert-butanol with 10 eq. copper sulfate pentahydrate and 10 eq. sodium ascorbate at room
temperature for 2 hours. The reaction was monitored by analytical HPLC, where we observed small
changes in retention time upon stapling. The triazole-stapled variants were purified via preparative HPLC.
The successful conversion of non-covalent heterodimer 27/29’-c40 into triazole-stapled s27/29’c40 was readily confirmed by ESI-TOF MS; the non-covalent heterodimer 27/29’-c40 separates into its
component monomers 27A-c4 (notebook number QX22091) and 29A’-c0 (notebook number QX22092)
in the mass spectrometer, whereas triazole-stapled s27/29’-c40 does not. However, the CuAAC reaction
does not change the mass of the monomeric triazole-stapled variants s16/32-c44, s14/30-c44, sd27/29’c40 (notebook number QX2204) relative to their non-stapled azide/alkyne precursors 16/32-c44, 14/30291

c44, and d27/29’-c40 (notebook number QX22031). To confirm the completion of the CuAAC reaction,
we subjected each azide-containing variant (16/32-c44, 14/30-c44, and d27/29’-c40) and its triazolestapled counterpart (s16/32-c44, s14/30-c44, and sd27/29’-c40) separately to a solution of dithiothreitol
(DTT, 31 mg) and diisopropylethylamine (DIEA, 17 μL) in 100 μL water, followed by stirring for 1 h.
Presence of the azide groups in non-stapled 16/32-c44 (notebook number QX21852), 14/30-c44, and
d27/29’-c40 was confirmed by their conversion to amino groups under reducing conditions, as detected
by ESI-TOF MS (i.e., a loss of N2 and the addition of two hydrogens). Presence of the triazole group in
s16/32-c44 (notebook number QX2188), s14/30-c44, and sd27/29’-c40 were confirmed by the absence of
this mass change under reducing conditions. The results of this analysis are shown below in Figures S3–
S8.
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Figure S8. Analytical HPLC retention time for WW variant 16/32-c44 (notebook number QX21852) before (A) and after (B)
exposure to reducing conditions (aqueous DTT and DIEA) for 1 h; and for its triazole-stapled counterpart s16/32-c44 (notebook
number QX2188) before (C) and after (D) exposure to reducing conditions for 1 h. Peptide solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S9. ESI-TOF MS data for azide-containing WW variant 16/32-c44 (notebook number QX21852) before (A,C) and after
(E,G) exposure to reducing conditions (aqueous DTT and DIEA) for 1 h. Expected [M+4H+]/4 = 1113.82 Da for 16/32-c44
prior to reduction; expected [M+4H+]/4 = 1107.32 Da after reduction of the azide at position 32 to the corresponding amine.
Also shown are ESI-TOF MS data for triazole-stapled s16/32-c44 (notebook number QX21852) before (B,D) and after (F,H)
exposure to reduction conditions for 1 h. Expected [M+4H+]/4 = 1113.82 Da for triazole-stapled s16/32-c44 both before and
after reduction.
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Figure S10. Analytical HPLC retention time for WW variant 14/30-c44 (notebook number QX22154) before (A) and after (B)
exposure to reducing conditions (aqueous DTT and DIEA) for 1 h; and for its triazole-stapled counterpart s14/30-c44 (notebook
number QX22154s) before (C) and after (D) exposure to reducing conditions for 1 h. Peptide solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S11. ESI-TOF MS data for azide-containing WW variant 14/30-c44 (notebook number QX22154) before (A,C) and
after (E,G) exposure to reducing conditions (aqueous DTT and DIEA) for 1 h. Expected [M+4H+]/4 = 1089.80 Da for 14/30c44 prior to reduction; expected [M+4H+]/4 = 1083.30 Da after reduction of the azide at position 30 to the corresponding amine.
Also shown are ESI-TOF MS data for triazole-stapled s14/30-c44 (notebook number QX22154s) before (B,D) and after (F,H)
exposure to reducing conditions for 1 h. Expected [M+4H+]/4 = 1089.80 Da for triazole-stapled s14/30-c44 both before and
after reduction.
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Figure S12. Analytical HPLC retention time for disulfide-bound GCN4 heterodimer d27/29’-c40 (notebook number
QX22031) before (A) and after (B) exposure to reducing conditions (aqueous DTT and DIEA) for 1 h; and for its triazolestapled counterpart sd27/29’-c40 (notebook number QX2204) before (C) and after (D) exposure to reducing conditions for 1
h. Peptide solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1%
TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S13. ESI-TOF MS data for disulfide-bound GCN4 heterodimer d27/29’-c40 (notebook number QX22031) before (A,C)
and after (E,G,H) exposure to reducing conditions (aqueous DTT and DIEA) for 1 h. Expected [M+6H+]/6 = 1410.59 Da for
d27/29’-c40 prior to reduction. Following reduction, d27/29’-c40 splits into its component peptides: alkyne-containing 27-c4
(notebook number QX21971; expected [M+4H+]/4 = 1031.62 Da) and 29’-c0 (notebook number QX21973) in which the azide
at position 29’ has been reduced to an amine (expected [M+4H+]/4 = 1078.78 Da) Also shown are ESI-TOF MS data for
triazole-stapled GCN4 variant sd27/29’-c40 before (B,D) and after (F) exposure to reducing conditions. Expected [M+6H+]/6
= 1410.59 Da for sd27/29’-c40 prior to reduction. After reduction, the triazole staple should be intact, but the disulfide bond
should not; expected [M+6H+]/6 = 1410.92 Da.
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4.5.3 Global Fitting of Variable Temperature CD Data
Following purification and characterization (as described above), the conformational stability of stapled
and unstapled WW, SH3, and GCN4 variants was assessed by variable-temperature circular dichroism
spectropolarimetry. Data from three replicate variable temperature CD experiments were each fit globally
to a model for a two-state thermally induced unfolding transition using the program Mathematica
(Wolfram Research).
We used a model based on two-state monomer folding for WW variants 16/19-00, 16/19-o23, s16/19-o23,
16/32-c44, s16/32-c44, 14/30-00, 14/30-o55, s14/30-o55, 14/30-c44 and s14/30-c44; SH3 variant s20/37o44; and GCN4 variants d27/29’-c40, sd27/29’-c40, and s27/29’-c40. This model is described in equation
S1:
[θ] =

[K∙(an +bn ∙T)+(cn +dn ∙T)]
1+K

, (S1)

where T is temperature in Kelvin, an is the y-intercept and bn is the slope of the pre-transition baseline for
melt n (a1 and b1 for replicate 1, a2 and b2 for replicate 2, a3 and b3 for replicate 3, etc.); cn is the y-intercept
and dn is the slope of the post-transition baseline for replicate n (c1 and d1 for replicate 1, c2 and d2 for
replicate 2, c3 and d3 for replicate 3, etc.); and K is the temperature-dependent folding equilibrium
constant. K is related to the temperature-dependent free energy of folding ΔG according to the following
equation:
𝐾𝐾 = exp �–

ΔG
RT

�,

(S2)

where R is the universal gas constant (0.0019872 kcal/mol/K). ΔG is a function of temperature, as shown
in the following equation:
Δ =

ΔΗ0 ∙(Tm −Τ)
Tm

+ ΔCp ∙ (T − Tm − T ∙ ln �

T

Tm

�),

(S3)

where Tm is the midpoint of the unfolding transition and the temperature at which ΔGf = 0; ΔH0 is the
change in enthalpy upon folding at T = Tm; and ΔCp is the change in heat capacity upon folding.
In contrast, we used a model based on two-state dimer folding for noncovalent GCN4 heterodimer 27/29’c40, as described in equation S4:
[θ] = F ∙ (an + bn ∙ T) + (1 − F) ∙ (cn + dn ∙ T),

(S4)

where T, an, bn, cn, are defined as described above, and F is the temperature-dependent fraction of the total
peptide concentration that is folded. F is related to the temperature-dependent equilibrium constant K and
the total peptide concentration P as shown in equation S5:
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F=1+

1

4KP

−�

1

16K2 P2

+

1

2KP

,

(S5)

K is related to the folding free energy ΔG as described above in equation S2. Because equation S3 is only
appropriate for monomer folding equilibria, we used the following polynomial expression to describe the
temperature-dependence of ΔG for noncovalent GCN4 heterodimer 27/29’-c40:
Δ =Δ

0

+Δ

1

∙ (T − T0 ) + Δ

2

∙ (T − T0 )2 ,

(S6)

where ΔG0, ΔG1, and ΔG2 are parameters of the fit and T0 is an arbitrary reference temperature, usually
chosen as Tm, the temperature at which F = 0.5 (determined numerically for monomer-dimer equilibria).
In some cases, we found that some fit parameters had sufficiently high standard errors as to render them
indistinguishable from zero and therefore not essential to the fit (as judged by their p-values). When this
occurred, we repeated the fitting process without the non-essential parameters. We used the fit parameters
for each variant to calculate the ΔG values given in the main text; we calculated the uncertainty for each
ΔG value by propagation of error using the standard errors of the fit parameters.
CD spectra and variable temperature CD data for WW variants 16/19-00, 16/19-o23, s16/19-o23, 16/32c44, s16/32-c44, 14/30-00, 14/30-o55, s14/30-o55, 14/30-c44 and s14/30-c44; SH3 variant s20/37-o44;
and GCN4 variants d27/29’-c40, sd27/29’-c40, 27/29’-c40, and s27/29’-c40 are shown in Figures S9–
S26, along with the fit parameters ± standard error. Standard parameter errors were used to estimate the
uncertainty in the thermodynamic values given in the main text by propagation of error.
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Figure S14. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant 16/19-00 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 332.0 K (the melting temperature of 16/19-00), with the indicated standard errors.

Figure S15. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant 16/19-o23 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 332.0 K (the melting temperature of 16/19-00), with the indicated standard errors.

301

Figure S16. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant s16/19-o23 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 332.0 K (the melting temperature of 16/19-00), with the indicated standard errors.

Figure S17. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant 16/32-00 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 322.3 K (the melting temperature of 16/32-00), with the indicated standard errors.
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Figure S18. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant 16/32-o44 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 322.3 K (the melting temperature of 16/32-00), with the indicated standard errors.

Figure S19. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant s16/32-o44 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 322.3 K (the melting temperature of 16/32-00), with the indicated standard errors.
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Figure S20. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant 16/32-c44 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 322.3 K (the melting temperature of 16/32-00), with the indicated standard errors.

Figure S21. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant s16/32-c44 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 322.3 K (the melting temperature of 16/32-00), with the indicated standard errors.
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Figure S22. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant 14/30-00 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 301.7 K (the melting temperature of 14/30-00), with the indicated standard errors.

Figure S23. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant 14/30-o55 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 301.7 K (the melting temperature of 14/30-00), with the indicated standard errors.
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Figure S24. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant 14/30-c44 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 301.7 K (the melting temperature of 14/30-00), with the indicated standard errors.

Figure S25. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM WW variant s14/30-c44 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 301.7 K (the melting temperature of 14/30-00), with the indicated standard errors.
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Figure S26. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM SH3 variant 20/37-00 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 334.2 K (the melting temperature of 20/37-00), with the indicated standard errors.

Figure S27. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 50 μM SH3 variant s20/37-o44 in 20 mM
sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and
-TΔSf at 334.2 K (the melting temperature of 20/37-00), with the indicated standard errors.
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Figure S28. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound GCN4 heterodimer
d27/29’-c40 in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table,
as do calculated values for ΔGf, ΔHf, and -TΔSf at 334.2 K (the melting temperature of d27/29’-c40), with the indicated standard
errors.

Figure S29. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant sd27/29’-c40 in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3
appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 334.2 K (the melting temperature of d27/29’-c40), with
the indicated standard errors.
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Figure S30. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM non-covalent GCN4 heterodimer
27/29’-c40 in 20 mM sodium phosphate (pH 7) with 0.5 M GdnHCl. Fit parameters from equations S4–S6 appear in the table,
as does the calculated value for ΔGf at 308.0 K (the melting temperature of 27/29’-c40), with the indicated standard errors.

Figure S31. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM triazole-stapled GCN4 s27/29’c04 in 20 mM sodium phosphate (pH 7) with 0.5 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as does
the calculated value for ΔG, ΔH, and -TΔS at 355.2 K (the melting temperature of s27/29’-c04), with the indicated standard
errors.
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4.5.4 Proteolysis of WW variants
50 μM protein solutions in 20 mM sodium phosphate buffer (pH 7) were incubated at ambient
temperature with 17 μg/mL proteinase K respectively for up to 1 hour. At each of the several time points,
the proteolysis reaction was quenched by adding 100 μL of aqueous trifluoroacetic acid (1% v/v) to 50 uL
of the reaction mixture. The quenched mixture was then analyzed in triplicate by reverse phase HPLC
analytical column, monitored by a UV-Vis detector at 220 nm. The degradation of the proteins was
assessed using the integrated HPLC peak area to account for how much of the full-length protein remained
at each time point. The protein half-lives were calculated by fitting the integrated peak areas as a function
of time to a mono exponential decay equation:
Area(t) = A • exp [-kt],
where t is time in minutes, A is a constant corresponding to relative integrated peak area at t = 0,
and τ is the decay time, which is related to the protein half-life t1/2 (t1/2 = τ ln 2). Decay traces for proteins
WW variants, 16/19-00, 16/19-o23, s16/19-o23, 16/32-00, 16/32-o44, s16/32-o44, are shown in Figures
S27– S32.

Figure S32. Proteolysis of 16/19-00 (50 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17 µg/mL) as monitored by HPLC. Data points for 16/19-00 are shown as blue circles, and each represents the average of
three replicate experiments. Solid lines represent fits of the data to a mono exponential decay function, which was used to
calculate the indicated half-lives.
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Figure S33. Proteolysis of 16/19-o23 (50 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17 µg/mL) as monitored by HPLC. Data points for 16/19-o23 are shown as orange circles, and each represents the average
of three replicate experiments. Solid lines represent fits of the data to a mono exponential decay function, which was used to
calculate the indicated half-lives.

Figure S34. Proteolysis of 16/19-o23 (50 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17 µg/mL) as monitored by HPLC. Data points for 16/19-o23 are shown as pink circles, and each represents the average of
three replicate experiments. Solid lines represent fits of the data to a mono exponential decay function, which was used to
calculate the indicated half-lives.
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Figure S35. Proteolysis of 16/32-00 (50 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17 µg/mL) as monitored by HPLC. Data points for 16/32-00 are shown as blue circles, and each represents the average of
three replicate experiments. Solid lines represent fits of the data to a mono exponential decay function, which was used to
calculate the indicated half-lives.

Figure S36. Proteolysis of 16/32-o44 (50 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17 µg/mL) as monitored by HPLC. Data points for 16/32-o44 are shown as orange circles, and each represents the average
of three replicate experiments. Solid lines represent fits of the data to a mono exponential decay function, which was used to
calculate the indicated half-lives.
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Figure S37. Proteolysis of s16/32-o44 (50 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17 µg/mL) as monitored by HPLC. Data points for s16/32-o44 are shown as orange circles, and each represents the average
of three replicate experiments. Solid lines represent fits of the data to a mono exponential decay function, which was used to
calculate the indicated half-lives.
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4.5.5 ESI-TOF MS data for WW, SH3, and GCN4 variants
Table S1. Summary of the mass spectrum data for the new WW, SH3, and GCN4 variants described here.
Name

Notebook
Number

Molecular
Formula

z

14/30-00

DA10434

C175H261N52O51S

4 985.989

985.996

14/30-55

QX2183

C201H310N52O61S

4 1116.070

1116.071

s14/30-55

QX2183s

C199H306N52O61S

4 1109.062

1109.058

14/30-c44

QX22154

C194H294N55O57S

4 1089.797

1089.790

s14/30-c44

QX22154s

C194H294N55O57S

4 1089.797

1089.790

16/32-c44

QX21852

C198H303N59O57S

4 1113.817

1113.806

s16/32-c44

QX2188

C198H303N59O57S

4 1113.817

1113.810

20/37-44

KT1027

C310H471N77O98

4 1711.114

1171.092

s20/37-44

QX2217

C308H467N77O98

4 1704.106

1704.108

27-c4

QX21971

C187H324N56O46S

4 1031.620

1031.618

29’-c0

QX21973

C184H293N51O68S

4 1085.277

1085.271

QX22031

C371H611N105O114
S2

6 1410.592

1410.753

QX2204

C371H611N105O114
S2

6 1410.592

1410.736

27A-c4

QX22091

C187H324N56O46

4 1023.627

1023.620

29A’-c0

QX22092

C184H293N51O68

4 1077.284

1077.276

QX2214

C371H613N105O114
S2

6 1400.271

1400.583

d27/29’-c40
sd27/29’-c40

s27/29’-c40
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Expected
[M+z∙H]/z

Observed
[M+z∙H]/z

ESI-TOF MS data for WW variants 14/30-00, 14/30-o55, s14/30-o55, 14/30-c44, s14/30-c44,
16/32-c44 and s16/32-c44; SH3 variants 20/37-o44 and s20/37-o44; and GCN4 variants 27-c4, 29’-c0,
d27/29’-c40, sd27/29’-c40, 27A-c4, 29A’-c0, and s27/29’-40 are shown in Figures S33–S48.

Figure S38. ESI-TOF spectrum for WW variant 14/30-00. Expected [M+4H+]/4 = 985.989 Da. Observed [M+4H+]/4 =
985.996 Da.

Figure S39. ESI-TOF spectrum for WW variant 14/30-o55. Expected [M+4H+]/4 = 1116.070 Da. Observed [M+4H+]/4 =
1116.071 Da.
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Figure S40. ESI-TOF spectrum for WW variant s14/30-o55. Expected [M+4H+]/4 = 1109.062 Da. Observed [M+4H+]/4 =
1109.058 Da.

Figure S41. ESI-TOF spectrum for WW variant 14/30-c44. Expected [M+4H+]/4 = 1089.797 Da. Observed [M+4H+]/4 =
1089.790 Da.
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Figure S42. ESI-TOF spectrum for WW variant s14/30-c44. Expected [M+4H+]/4 = 1089.797 Da. Observed [M+4H+]/4 =
1089.790 Da.

Figure S43. ESI-TOF spectrum for WW variant 16/32-c44. Expected [M+4H+]/4 = 1113.817 Da. Observed [M+4H+]/4 =
1113.806 Da.
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Figure S44. ESI-TOF spectrum for WW variant s16/32-c44. Expected [M+4H+]/4 = 1113.817 Da. Observed [M+4H+]/4 =
1113.809 Da.

Figure S45. ESI-TOF spectrum for SH3 variant 20/37-o44. Expected [M+4H+]/4 = 1711.114 Da. Observed [M+4H+]/4 =
1711.092 Da.
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Figure S46. ESI-TOF spectrum for SH3 variant s20/37-o44. Expected [M+4H+]/4 = 1704.106 Da. Observed [M+4H+]/4 =
1704.108 Da.

Figure S47. ESI-TOF spectrum for GCN4 monomer 27-c4. Expected [M+4H+]/4 = 1031.620 Da. Observed [M+4H+]/4 =
1031.618 Da.
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Figure S48. ESI-TOF spectrum for GCN4 monomer 29’-c0. Expected [M+4H+]/4 = 1085.277 Da. Observed [M+4H+]/4 =
1085.271 Da.

Figure S49. ESI-TOF spectrum for disulfide-bound GCN4 heterodimer d27/29’-c40. Expected [M+6H+]/6 = 1410.592 Da.
Observed [M+6H+]/6 = 1410.753 Da.
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Figure S50. ESI-TOF spectrum for triazole-stapled disulfide-bound GCN4 heterodimer sd27/29’-c40. Expected [M+6H+]/6
= 1410.592 Da. Observed [M+6H+]/6 = 1410.736 Da.

Figure S51. ESI-TOF spectrum for GCN4 monomer 27A-c4. Expected [M+4H+]/4 = 1023.627 Da. Observed [M+4H+]/4 =
1023.620 Da.
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Figure S52. ESI-TOF spectrum for GCN4 monomer 29A’-c0. Expected [M+4H+]/4 = 1077.284 Da. Observed [M+4H+]/4 =
1077.276 Da.
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Figure S53. ESI-TOF spectrum for triazole-stapled GCN4 heterodimer s27/29’-c40. Expected [M+6H+]/6 = 1400.271 Da.
Observed [M+6H+]/6 = 1400.583 Da.

4.5.6 Analytical HPLC data
Analytical HPLC data WW variants 14/30-00, 14/30-o55, s14/30-o55, 14/30-c44, s14/30-c44,
16/32-c44 and s16/32-c44; SH3 variants 20/37-o44 and s20/37-o44; and GCN4 variants 27-c4, 29’-c0,
d27/29’-c40, sd27/29’-c40, 27A-c4, 29A’-c0, and s27/29’-40 are shown in Figures S49–S64.

Figure S54. Analytical HPLC Data for WW variant 14/30-00 (notebook number DA10434). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S55. Analytical HPLC Data for WW variant 14/30-o55 (notebook number QX2183). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S56. Analytical HPLC Data for WW variant s14/30-o55 (notebook number QX2183S). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S57. Analytical HPLC Data for WW variant 14/30-c44 (notebook number QX22154). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S58. Analytical HPLC Data for WW variant s14/30-c44 (notebook number QX22154s). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S59. Analytical HPLC Data for WW variant 16/32-c44 (notebook number QX21852). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S60. Analytical HPLC Data for WW variant s16/32-c44 (notebook number QX2188). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S61. Analytical HPLC Data for SH3 variant 20/37-o44 (notebook number KT1027). Protein solution was injected onto
a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S62. Analytical HPLC Data for SH3 variant s20/37-44 (notebook number QX2117). Protein solution was injected onto
a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S63. Analytical HPLC Data for GCN4 monomer 27-c4 (notebook number QX21971). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S64. Analytical HPLC Data for GCN4 monomer 29’-c0 (notebook number QX21972). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S65. Analytical HPLC Data for disulfide-bound GCN4 heterodimer d27/29’-c40 (notebook number QX22031). Protein
solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B=
MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S66. Analytical HPLC Data for triazole-stapled disulfide-bound GCN4 variant sd27/29’-c40 (notebook number
QX2204). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A =
H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column reequilibration.
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Figure S67. Analytical HPLC Data for GCN4 monomer 27A-c4 (notebook number QX22091). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S68. Analytical HPLC Data for GCN4 monomer 29A’-c0 (notebook number QX22092). Protein solution was injected
onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S69. Analytical HPLC Data for triazole-stapled GCN4 heterodimer s27/29’-c40 (notebook number QX2214). Protein
solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B=
MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

4.5.7 Synthesis and characterization of PEGylated Asn derivatives
((Oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) dimethanesulfonate (QX2157)

Methanesulfonyl chloride (23 g, 200 mmol) was added dropwise to a stirred solution of tetra ethylene
glycol (10 g, 50 mmol) and TEA (20 g, 200 mmol) in dichloromethane (250 mL) at 0 °C. After the
addition was complete, the resulting mixture was stirred at r.t. for 15 h. Water was added to quench the
reaction. The organic phase was separated, and the aqueous phase was extracted with dichloromethane
(2 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL), dried with anhydrous
sodium sulfate, filtered, and the solvent was removed by rotary evaporation to afford 17.5 g of colorless
oil, which was used in the next step without purification. Yield quantitative. MS(ESI-TOF) m/z calc. for
C10H23O9S2+ 351.08, found 351.08 [M+H+]; calc. for C10H26NO9S2+ 368.10, found 368.11 [M+NH4+].
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1-Azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (QX2158)

To a solution of NaN3 (13 g, 200 mmol) in DMF (200 mL) was added QX2157 (17.5 g, 50 mmol) at
room temperature. The reaction mixture was heated to 70 oC and stirred for 12 hours. The crude mixture
was extracted with DCM for 3 times after the reaction was completed. The combined organic phases
were washed with saturated brine and dried over anhydrous sodium sulfate, evaporated and purified by
flash column (Hexane/EA 1:1 to 0:1) to obtain a colorless oil. (10 g, 82% yield). MS(ESI-TOF) m/z
calc. for C8H17N6O3+ 245.14, found 245.13 [M+H+]. 1H NMR (300 MHz, Chloroform-d) δ 3.70 – 3.66
(m, 12H), 3.39 (t, J = 5.5 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 70.74, 70.73, 70.71, 70.70,
70.66, 70.04, 50.67.
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2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine (QX2160)
334

Triphenylphosphine (4 g, 15 mmol, 0.9 eq.) dissolved in ether (75 mL) was added to a solution of
QX2158 (4 g, 16.5 mmol) in 5% aqueous HCl (50 mL). Addition was performed in 30 minutes at room
temperature and the reaction was stirred for additional 2.5 hours. Phases were separated by a separation
funnel and the aqueous layer was washed with DCM (3 × 50 mL). The aqueous layer was adjusted to pH
10 using sodium hydroxide powder. Product was then extracted with DCM (3 × 75 mL). Combined
organic layer was dried over anhydrous sodium sulfate and filtered. After removal of the solvent under
reduced pressure, a yellow oil was afforded (1.5 g, yield 46%) MS(ESI-TOF) m/z calc. for C8H19N4O3+
219.15, found 219.15 [M+H+]. 1H NMR (500 MHz, Chloroform-d) δ 3.65 – 3.62 (m, 10H), 3.60 – 3.58
(m, 2H), 3.47 (t, J = 5.5 Hz, 2H), 3.35 (t, J = 5.5 Hz, 2H), 2.8 (t, J = 5.5 Hz, 2H). 13C NMR (500 MHz,
Chloroform-d) δ 73.49, 70.69, 70.63, 70.61, 70.26, 70.02, 50.64, 41.7.
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tert-Butyl (S)-15-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-azido-13-oxo-3,6,9-trioxa-12azahexadecan-16-oate (QX2161)

To Fmoc-Asp-tBu (1.15 g, 2.8 mmol) dissolved in dry DMF (20 ml) was added HATU (1.6 g, 4.2
mmol), HOBT (567.5 mg, 4.2 mmol), DIPEA (1.46 ml, 8.4 mmol). Then the mixture was stirred for 15
minutes at room temperature. Then compound QX2160 (730 mg, 3.25 mmol, dissolved in 5 ml DMF)
was added to the mixture and the system was stirred for another 2 hours at room temperature. Upon
completion of the reaction monitored by TLC, 30 ml water was added to the flask and extracted 3 times
with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over
anhydrous sodium sulfate and evaporated to dryness. The crude was used in the next step without
purification; MS(ESI-TOF) m/z calc. for C31H41N5O8H+ 612.30, found 612.30 [M+H+];
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(S)-15-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-azido-13-oxo-3,6,9-trioxa-12azahexadecan-16-oic acid (QX2162)

Compound QX2161 (800 mg, 1.31 mmol) was dissolved in a mixture of TFA (3 ml) and water (150
uL). Then the reaction mixture was stirred at room temperature for 2 hours. After completion of the
reaction, TFA and water were removed by rotary evaporation. Yield quantitative; MS(ESI-TOF) m/z
calc. for C27H34N5O8H+ 556.24, found 556.24 [M+H+]; 1H NMR (300 MHz, Chloroform-d) δ 7.78 (d, J
= 6.5 Hz, 2H), 7.63 (t, J = 6.5 Hz, 2H), 7.42 (t, J = 6.5 Hz, 2H), 7.34 (t, J = 6.5 Hz, 2H), 6.85 (br s., 1H),
6.25 (d, J = 6.9 Hz, 1H), 4.60 (m., 1H), 4.48 – 4.33 (m, 2H), 4.25 (t, J = 6.9 Hz, 1H), 3.68 – 3.63 (m,
12H), 3.57 – 3.55 (m, 2H), 3.42 – 3.37 (m, 2H), 2.97 (dd, J = 15, 7.2 Hz, 1H), 2.76 (dd, J = 15, 7.2 Hz,
1H). 13C NMR (500 MHz, Chloroform-d) δ 172.22, 171.34, 156.03, 143.88, 141.29, 127.76, 127.14,
125.25, 125.19, 120.00, 70.75, 70.44, 70.40, 70.02, 69.94, 50.85, 50.63, 47.07, 39.71, 38.69, 37.98.
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3,6,9,12-Tetraoxapentadec-14-yn-1-ol (QX2163)
340

To a solution of tetra ethylene glycol (3.88 g, 20 mmol) in 80 mL of freshly distilled THF was added tBuOK (1.12 g, 10 mmol) at 0 oC, the mixture was stirred at r.t. for 30 mins, then cooled to 0 oC, and
propargyl bromide (1.2 g, 10 mmol) dissolved in 5 mL of THF was added dropwise. After that the
reaction mixture was stirred at 0 oC for 10 mins then warmed to r.t. and stirred at r.t. overnight. Then the
reaction was filtered, washed with THF, and the filtrate was concentrated and purified by flash
chromatography (Hexane/EA : 1/2 to 0/1), the desired intermediate was obtained as a yellow oil. (2.0 g
Yield 86%) MS(ESI-TOF) m/z calc. for C11H21O5+ 233.14, found 233.14 [M+H+]; calc. for
C11H20NaO5+ 255.12 found 255.12 [M+Na+]. 1H NMR (500 MHz, DMSO-d6) δ 4.58 (t, J = 5.5 Hz, 1H),
4.13 (d, J = 2.5 Hz, 2H), 3.55 – 3.52 (m, 4H), 3.52 – 3.50 (m, 8H), 3.47 (t, J = 5.5 Hz, 2H), 3.42 (t, J =
2.5 Hz, 1H), 3.40 (t, J = 5.5 Hz, 2H). 13C NMR (500 MHz, DMSO-d6) δ 80.80, 77.57, 72.80, 70.69,
70.27, 70.23, 69.50, 68.97, 60.66, 57.94.
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3,6,9,12-Tetraoxapentadec-14-yn-1-yl methanesulfonate (QX2167)

Procedure was performed as described above for compound QX2157 but using QX2163 as starting
material. Product was obtained as yellow oil (2.08 g Yield: 78%) MS(ESI-TOF) m/z calc. for
C12H23O7S+ 311.11, found 311.11 [M+H+]; calc. for C12H26NO7S+ 328.14, found 328.15 [M+NH4+]. 1H
NMR (500 MHz, DMSO-d6) δ 4.31 – 4.29 (m, 2H), 4.13 (d, J = 2.0 Hz, 2H), 3.66 (t, J = 4.0 Hz, 2H),
3.55 – 3.51 (m, 12H), 3.41 (t, J = 2.5 Hz, 1H), 3.17 (s, 3H). 13C NMR (500 MHz, DMSO-d6) δ 80.80,
77.56, 70.20, 70.19, 70.16, 70.14, 69.94, 68.97, 68.73, 57.94, 37.27.
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1-Azido-3,6,9,12-tetraoxapentadec-14-yne (QX2168)
345

Procedure was performed as described above for compound QX2158 but using QX2167 as starting
material. Product was obtained as yellow oil (1.68 g Yield: 97%) MS(ESI-TOF) m/z calc. for
C11H20N3O4+ 258.14, found 258.15 [M+H+]. 1H NMR (300 MHz, DMSO-d6) 4.16 (d, J = 2.4 Hz, 2H),
3.64 – 3.59 (m, 2H), 3.58 – 3.54 (m, 12H), 3.43 – 3.39 (m, 3H). 13C NMR (300 MHz, DMSO-d6) δ
80.80, 77.54, 70.29, 70.24, 70.21, 70.17, 69.99, 69.74. 69.00 57.97, 50.48.
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3,6,9,12-Tetraoxapentadec-14-yn-1-amine (QX2169)
347

Compound QX2168 (1.68 g, 6.5 mmol) and PPh3 (3.4 g, 13.0 mmol) in a mixture of THF (30 mL) and
water (1.6 mL) were stirred at room temperature overnight. 1M HCl (60 mL) was added and extracted 3
times with diethyl ether. The aqueous phase was lyophilized to obtain the product as colorless oil
without further purification. Yield quantitative; MS(ESI-TOF) m/z calc. for C11H22NO4H+ 232.15, found
232.15 [M+H+]. 1H NMR (500 MHz, DMSO-d6) δ 4.13 (d, J = 2.0 Hz, 2H), 3.60 (t, J = 5.5 Hz, 2H),
3.54 – 3.50 (m, 12H), 3.43 (t, J = 2.5 Hz, 1H), 2.93 – 2.90 (m, 2H). 13C NMR (500 MHz, DMSO-d6) δ
80.78, 77.64, 70.17, 70.09, 70.06, 69.91, 68.95, 67.02, 57.94, 38.87.
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tert-Butyl (S)-19-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-17-oxo-4,7,10,13-tetraoxa-16azaicos-1-yn-20-oate (QX2170)

Procedure was performed as described above for compound QX2161 but using QX2169 as starting
material. Product was obtained as colorless oil (2.4 g Yield: 59%) MS(ESI-TOF) m/z calc. for
C34H45N2O9+ 625.31, found 625.31 [M+H+]. 1H NMR (500 MHz, Chloroform-d) δ 7.78 (d, J = 7.5 Hz,
2H), 7.60 (dd, J = 7.5, 5.5 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 6.38 (br.s., 1H),
6.07 (d, J = 8.5 Hz, 1H), 4.54 (dt, J = 8.5, 5.0 Hz, 1H, αH), 4.45 (d, J = 7.5 Hz, 2H), 4.24 – 4.21 (m, 3H,
1H of Fmoc, 2H of propargyl group), 3.71 – 3.37 (m, 16H), 2.80 (dd, J = 15.5, 5.0 Hz, 1H), 2.66 (dd, J
= 15.5, 5.0 Hz, 1H), 1.49 (s, 9H). 13C NMR (500 MHz, Chloroform-d) δ 171.17, 170.30, 156.31, 143.87,
143.68, 141.31, 141.23, 127.76, 127.20, 127.11, 125.08, 125.02, 119.99, 82.53, 79.38, 74.89, 69.76,
69.67, 68.17, 66.69, 58.33, 51.49, 47.11, 39.27, 38.53, 36.50, 31.43, 27.91.
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(S)-19-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-17-oxo-4,7,10,13-tetraoxa-16-azaicos-1-yn20-oic acid (QX2170A)

Procedure was performed as described above for compound QX2162 but using QX2170 as starting
material. Product was obtained as yellow oil. Yield quantitative. MS(ESI-TOF) m/z calc. for
C30H37N2O9+ 569.25, found 569.25 [M+H+]. 1H NMR (300 MHz, Chloroform-d) δ 7.79 (d, J = 7.5 Hz,
2H), 7.61 (d, J = 7.2 Hz, 2H), 7.43 (t, J = 7.2 Hz, 2H), 7.34 (t, J = 7.5 Hz, 2H), 6.12 (d, J = 6 Hz, 1H),
5.98 (br.s., 1H), 4.58 – 4.50 (m, 1H), 4.48 (d, J = 6.6 Hz, 2H), 4.24 (t, J = 6.6 Hz, 1H, from Fmoc), 4.16
(d, J = 1.8 Hz, 2H), 3.79 – 3.61 (m, 16H), 3.11 (dd, J = 17.7, 9 Hz, 1H), 2.82 (dd, J = 17.4, 5.1 Hz, 1H).
13
C NMR (300 MHz, Chloroform-d) δ 143.61, 143.35, 141.33, 127.81, 127.15, 125.04, 120.03, 79.43,
74.82, 70.37, 70.26, 70.21, 70.14, 69.88, 69.85, 67.03, 58.30, 50.13, 47.10, 38.35, 35.70.
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3,6,9,12,15-Pentaoxaoctadec-17-en-1-ol (QX2165)

To NaH (60 % in mineral oil, 360 mg, 9 mmol, washed with dry hexane) in THF (30 mL) was added
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pentaethylene glycol (4.76 g, 20 mmol) at 0°C under argon. The reaction mixture was stirred at 0°C for
1 hour, allyl bromide (846 uL, 10 mmol) in THF (10 mL) was added slowly at 0°C and stirring was
continued for another 2 hours at room temperature. The reaction mixture was poured into cold saturated
ammonium chloride solution (50 mL) and extracted with ethyl acetate. The combined organic phases
were washed with saturated brine and dried over anhydrous sodium sulfate, evaporated to dryness. The
products were separated by flash column chromatography to obtain the desired product QX2165 as
yellow oil. (1.2 g, Yield 43%); MS(ESI-TOF) m/z calc. for C13H27O6+ 279.18, found 279.18 [M+NH4+];
calc. for C13H26NaO6+ 301.16, found 301.16 [M+Na+]. 1H NMR (500 MHz, DMSO-d6) δ 5.91 – 5.83
(m, 1H), 5.24 (dd, J = 17.5, 2.0 Hz, 1H), 5.13 (dd, J = 10.5, 1.5 Hz, 1H), 3.94 (dt, J = 5.5, 1.5 Hz, 2H),
3.53 – 3.46 (m, 18H), 3.40 (t, J = 5.0 Hz, 2H). 13C NMR (500 MHz, DMSO-d6) δ 135.74, 116.74,
72.80, 71.50, 70.28, 70.25, 70.23, 70.22, 69.46, 60.66.
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3,6,9,12,15-Pentaoxaoctadec-17-en-1-yl methanesulfonate (QX2166)

Procedure was performed as described above for compound QX2157 but using QX2165 as starting
material. Product was obtained as yellow oil (1.45 g Yield: 95%) MS(ESI-TOF) m/z calc. for
C14H32NO8S+ 374.18, found 374.19 [M+NH4+]. 1H NMR (500 MHz, Chloroform-d) δ 5.90 (ddt, J =
17.5, 10.5, 5.5 Hz, 1H), 5.27 (dd, J = 17.5, 1.5 Hz, 1H), 5.18 (d, J = 10.5 Hz, 1H), 4.39 – 4.37 (m, 2H),
4.02 (d, J = 6.0 Hz, 2H), 3.77 – 3.75 (m, 2H), 3.65 – 3.64 (m, 14H), 3.61 – 3.59 (m, 2H), 3.08 (s, 3H).
13
C NMR (500 MHz, Chloroform-d) δ 134.75, 117.10, 72.23, 70.63, 70.58, 70.53, 70.52, 69.89, 69.87,
69.41, 69.34, 69.01, 37.74.
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1-Azido-3,6,9,12,15-pentaoxaoctadec-17-ene(QX2178)

Procedure was performed as described above for compound QX2158 but using QX2166 as starting
material. Product was obtained as colorless oil. Yield quantitative. (The mass spectrum information was
not detected since it is hard to be charged.) 1H NMR (300 MHz, Chloroform-d) δ 5.92 (ddt, J = 17.5,
10.5, 5.5 Hz, 1H), 5.27 (dd, J = 17.4, 1.8 Hz, 1H), 5.18 (dd, J = 10.5, 1.5 Hz, 1H), 4.03 (d, J = 5.4 Hz,
2H), 3.70 – 3.65 (m, 16H), 3.62 – 3.60 (m, 2H), 3.40 (t, , J = 5.1 Hz, 2H). 13C NMR (300 MHz,
Chloroform-d) δ 134.78, 117.10, 72.24, 70.70, 70.68, 70.63, 70.64, 70.61, 70.04, 69.43, 50.69.
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3,6,9,12,15-Pentaoxaoctadec-17-en-1-amine (QX2179)

Procedure was performed as described above for compound QX2168 but using QX2178 as starting
material. Product was obtained as yellow oil (1.0 g Yield: 88%) MS(ESI-TOF) m/z calc. for C13H28NO5+
278.20, found 278.20 [M+H+]. 1H NMR (500 MHz, Chloroform-d) δ 5.91 (ddt, J = 17.5, 10.5, 5.5 Hz,
1H), 5.29 (dd, J = 17.5, 1.5 Hz, 1H), 5.21 (d, J = 10.0, 1H), 4.05 (d, J = 6.0 Hz, 2H), 3.91 – 3.89 (m,
2H), 3.76 – 3.74 (m, 2H), 3.70 – 3.62 (m, 14H), 3.16 – 3.11 (m, 2H). 13C NMR (500 MHz, Chloroformd) δ 134.16, 118.24, 72.26, 70.45, 70.18, 69.99, 69.91, 69.88, 69.86, 69.63, 68.90, 66.65, 40.41.
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tert-Butyl (S)-22-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-20-oxo-4,7,10,13,16-pentaoxa-19azatricos-1-en-23-oate (QX2180)

Procedure was performed as described above for compound QX2161 but using QX2179 as starting
material. Product was obtained as colorless oil. (0.94 g Yield: 41%) MS(ESI-TOF) m/z calc. for
C36H51N2O10+ 671.35, found 671.35 [M+H+]; calc. for C36H54N3O10+ 688.38, found 688.38 [M+NH4+].
1
H NMR (500 MHz, Chloroform-d) δ 7.77 (d, J = 7.5 Hz, 2H), 7.62 (dd, J = 7.5, 5.5 Hz, 2H), 7.40 (t, J
= 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 6.43 (br.s., 1H), 6.14 (d, J = 8.5 Hz, 1H), 5.89 (ddt, J = 17.5,
10.5, 5.5 Hz, 1H), 5.27 (dd, J = 17.5, 1.5 Hz, 1H), 5.18 (d, J = 10.5 Hz, 1H), 4.49 (dt, J = 8.5, 4.5 Hz,
1H), 4.44 (dd, J = 10.5, 7.5 Hz, 1H), 4.34 (dd, J = 10.5, 7.5 Hz, 1H), 4.23 (t, J = 7.5 Hz, 1H), 4.02 (d, J
= 5.5 Hz, 2H), 3.68 – 3.51 (m, 18H), 3.44 (dt, J = 4.5, 5.0 Hz, 2H), 2.90 (dd, J = 15.5, 5.0 Hz, 1H), 2.71
(dd, J = 15.5, 5.0 Hz, 1H), 1.47 (s, 9H). 13C NMR (500 MHz, Chloroform-d) δ 170.19, 156.24, 143.98,
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143.83, 141.27, 134.62, 127.68, 127.10, 127.08, 125.25, 125.18, 119.94, 117.28, 110.00, 82.16, 72.21,
70.38, 70.21, 69.86, 69.27, 66.96, 51.42, 47.13, 39.32, 38.62, 37.82, 27.93.
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(S)-22-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-20-oxo-4,7,10,13,16-pentaoxa-19-azatricos-1en-23-oic acid (QX2181)

Procedure was performed as described above for compound QX2162 but using QX2180 as starting
material. Product was obtained as yellow oil. Yield quantitative. MS(ESI-TOF) m/z calc. for
C32H43N2O10+ 615.29, found 615.29 [M+H+]. 1H NMR (300 MHz, Chloroform-d) δ 7.78 (d, J = 7.5 Hz,
2H), 7.63 (dd, J = 7.5, 5.5 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 6.30 (d, J = 7.2 Hz,
1H), 5.90 (ddt, J = 17.5, 10.5, 5.5 Hz, 1H), 5.27 (dd, J = 17.5, 1.5 Hz, 1H), 5.18 (d, J = 10.5 Hz, 1H),
4.60 (dt, J = 8.5, 4.5 Hz, 1H), 4.47 – 4.42 (m, 1H), 4.39 (dd, J = 9.9, 7.5 Hz, 1H), 4.24 (t, J = 8.1 Hz,
1H), 4.01 (d, J = 5.7 Hz, 2H), 3.66 – 3.38 (m, 20H), 2.96 (dd, J = 15.0, 2.7 Hz, 1H), 2.76 (dd, J = 15.0,
7.2 Hz, 1H). 13C NMR (300 MHz, Chloroform-d) δ 171.49, 156.00, 143.93, 143.78, 141.28, 134.54,
127.73, 127.14, 125.25, 125.18, 119.97, 117.40, 72.18, 70.51, 70.34, 70.30, 70.18, 69.95, 69.37,69.17,
67.14, 50.87, 47.09, 39.63, 37.91.
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5. Macrocyclization for Stabilizing Proteins with Coiled Coil Tertiary Structure
Zachary B. Jones contributed to the synthesis and purification of GCN4 monomers 22’-c0, 27-c2, 27-c4, 13e-4, 15’c0, 20-c4, and 22’-c0; GCN4 heterodimers d20e/22g’-40, and sd27e/29g’-DL-c004; and CD experiments on GCN4
heterodimers d13e/15g’-c40 and d20e/22g-c40. Dallin S. Ashton contributed to the synthesis and purification of GCN4
monomers 27e-2, 29e’-0, 6e-4, 8e’-0, 24b-4, and 25c’-0. Samantha Hatfield contributed to the synthesis of GCN4 monomers
27e-2, 29g’-0, 6e-4, 8g’-0, 24b-4, 25c’-0, 22e’-0, 27e-2, and 27e-4. Cody Dyer contributed to the synthesis of native affibody
WTA, GCN4 monomer 27e-0. Nicolas Dalley contributed to the synthesis and purification of GCN4 monomer 24b-4. Colby
Baron contributed to the synthesis of GCN4 monomers 24b-4 and 25c’-0.

5.1 Introduction
Please refer to the introductory chapter for detailed background of macrocyclization of
peptides/proteins.
α-Helical coiled coils are among the most prevalent and best understood tertiary/quaternary
structures within proteins. The primary sequence of a coiled-coil system comprises a seven-residue
repeating unit called a heptad, with each successive residue denoted with the letters a through g (Figure
1). Prior research has thoroughly illustrated that canonical coiled coils are stabilized by burying the
hydrophobic residues (from a- and d-positions) at the interhelical interface via “knobs-into-holes” packing;
with charged residues (from e- and g- positions) flanking the interhelical interface and engaged in
complementary electrostatic interactions.1-4 However, there are no structure- or sequence-based guidelines
for the incorporation of interhelical cross-linkers or staples within coiled coils; the length of an interhelical
staple is either arbitrarily chosen5-6 or requires significant optimization.7-8 Furthermore, current effort to
install a staple within coiled coils have been limited to on-resin functionalization5,

7

which is not

convenient for modification of more complicated peptides/proteins. Here we present our investigation of
interhelical staples of different lengths and at various solvent-exposed locations within a heterodimeric
coiled coil. We focus on the impact of interhelical stapling on both the conformational stability and
proteolytic resistance of the resulting stapled constructs relative to their non-stapled counterparts. We
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investigated the efficacy of staples between different solvent-exposed positions within the heptad repeat;
the impact of distance between the staple and an existing disulfide bridge; the length of PEG staple; and
α-carbon stereochemistry of the stapled amino acid. Additionally, we employed copper catalyzed azidealkyne cycloaddition (CuAAC)-based two component stapling to provide a more convenient way to install
an interhelical staple within well-folded coiled-coil structures, and making further functionalization of the
PEG staple much easier. Finally, we applied this stapling strategy to increase the conformational stability
of a HER-2 Affibody.
5.2 Results and discussion
We previously showed that macrocyclization , or stapling, can be combined with the desolvationbased stabilizing effect derived from polyethylene glycol (PEG)9-10 to enhance the conformational stability
of the WW domain, a small β-sheet-rich domain from the human protein Pin1.11 Within the WW domain,
we found that the most important criteria for PEG staple-based stabilization is ensuring that the stapled
side chains are distant in primary sequence but close in tertiary structure. We applied this PEG-stapling
criterion to another β-sheet-based protein, the SH3 domain of chicken Src protein, and to a disulfidebonded parallel coiled-coil heterodimer derived from the yeast transcription factor GCN4.12 In both cases,
the conformational stability is enhanced after macrocyclization via PEG stapling.
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Figure 1. A) Sequences of GCN4-derived peptides A and B, along with ribbon diagram of the parallel disulfidebonded coiled-coil heterodimer AB (PDB code:1kd9) that they form. g-position residues within A are numbered
and highlighted in orange; e-position residues within B are numbered and highlighted in blue. Bonds between αand β-carbons at these positions are shown as sticks to facilitate comparison of distances between various e- and
g-positions, which are shown as dashed lines. with positions of interest labeled with numbers. The dashed lines
and the associated numbers indicate the distances between the β-carbon of certain residues. B) Helical wheel
diagram of parallel disulfide-bonded coiled-coil heterodimer AB from the C-terminal end of the assembly. gposition residues within peptide A are highlighted in orange; e-positions within peptide B are highlighted in blue;
nonpolar a- and d-position residues are highlighted in gray.

For the GCN4 variant s27e/29g’-40 described in chapter 4, we found that stapling an Asn-linked
aizdo-group-terminated four-unit PEG at e-position 27 in peptide B with a Propargylglycine (Pra) at gposition 29’ in peptide A stabilizes the disulfide-bound GCN4 heterodimer system by -0.65 ± 0.01
kcal/mol relative to its non-stapled disulfide-bonded counterpart 27e/29g’-40 (Table 1). Positions 27 and
29’ of the GCN4 heterodimer are located close to the disulfide bond at the C-terminus (Figure 2). Because
this chapter will focus on comparing the impact of stapling at different heptad positions, we will hereafter
refer to stapled variant s27e/29g’-40 from Chapter 4 as sd27e/29g’-40. The two numbers immediately
following the hyphen describe the nature of the PEG staple. The first number, 4, indicates that an fourunit azide-terminated AsnPEG occupies e-position 27 (hereafter called position 27e). The second number,
0, indicates that Pra occupies g-position 29 (hereafter called position 29g). We have dropped the c
immediately after the hyphen because all the variants described in this chapter were stapled via CuAAC,
such that there was no need to distinguish between variants stapled via CuAAC vs. olefin metathesis (as
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was the case in Chapter 4). Similarly, we will hereafter refer to non-stapled variant 27e/29g’-40 from
Chapter 3 as d27e/29g’-40.
In the crystal structure of disulfide-bonded coiled-coil heterodimer AB, Glu27 is involved in a salt
bridge with Lys22’ (and not Lys29), whereas Lys29’ is involved in a salt bridge with Glu34. The distance
between the β-carbons of Glu27 and Lys22’ is 9.1 Å, which is similar to that between Glu27 and
Lys29’(9.7 Å) (Figure 1A). We wondered whether PEG stapling at salt-bridged positions 27e and 22g’
would enhance the conformational stability of this coiled coil to a similar extent as we observed in chapter
4 for stapling of non-salt-bridged positions 27e and 29g’. Accordingly, we prepared variant sd27e/22g’40, in which we used CuAAC to install a staple between an azide-terminated four-unit AsnPEG at position
27e and a Pra residue at position 22g’, stapled variant sd27e/22g’-40 is -2.02 ± 0.02 kcal/mol more stable
than its non-stapled counterpart d27e/22g’-40 (Table 1), a much greater level of stabilization than we
observed previously at positions 27e and 29g’.
We wondered whether the stabilizing impact of stapling at positions 27e/29g’ and 27e/22g’ would
depend similarly on staple length. To explore this possibility, we shortened the length of the staple from
a four-unit PEG to a two-unit PEG. We found that the resulting variant sd27e/29g’-20 is 0.19 ± 0.01
kcal/mol less stable than its non-stapled counterpart d27e/29g’-20, an effect driven by unfavorable
enthalpy (Table 1), potentially indicating that the two-unit PEG disrupts favorable contacts or introduces
unfavorable contacts within the coiled coil. In contrast, stapled variant sd27e/22g’-20 is -2.04 ± 0.04
kcal/mol more stable than d27e/22g’-20, an effect driven similarly by enthalpy (ΔΔHf = -1.5 ± 0.6
kcal/mol), with a nominally favorable entropic contribution (-TΔΔSf = -0.6 ± 0.6 kcal/mol). These
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observations suggest that installing a PEG staple in place of salt-bridged e/g’ residues provides superior
stabilization v.s. a PEG staple in place of non-salt-bridged e/g’ residues.
Other than the fact that 27e/22g’ are salt-bridged residues, and 27e/29g’ are non-salt-bridged
residues, position 22g’ is two helical turns farther away from the disulfide bond than position 29g’, which
makes us wonder whether the distance to the terminal disulfide bond would make a difference for
interhelical PEG stapling. To test this possibility, we placed a PEG staples at the opposite end of the
disulfide bond, between a salt-bridged 6e/1g’ positions, and non-salt-bridged positions 6e/8g’ of the
GCN4 heterodimer. Positions 6e and 1g’ are directly analogous to positions 27e and 22g’, whereas
positions 6e and 8g’ are directly analogous to positions 27e and 29g’ described above but farther away
from the C-terminal disulfide bond. (Figure 1). The impact of stapling at non-salt-bridged positions 6e
and 8g’ was -1.51 ± 0.06 kcal/mol (Table 1), whereas the impact of stapling at salt-bridged positions 6e
and 1g’ was -1.99 ± 0.03 kcal/mol. The difference in the stabilization associated with the 6e/1g’ vs. 6e/8g’
staples (-1.99 ± 0.03 kcal/mol vs. -1.51 ± 0.06 kcal/mol) is not as large as we observed for the 27/22’ vs
27/29’ staples (-2.02 ± 0.02 kcal/mol vs. -0.65 ± 0.02 kcal/mol), indicating that farther distance from
disulfide can make up for much but not all of the differences of stapling between the salt-bridge e/g’
residues and non-salt-bridged e/g’ residues. However, comparing the stapling effects from stapling at
positions 6e/8g’ with 27e/29g’, there is a nearly three-fold increase over the impact of stapling at positions
27e and 29g’. This result is congruent with our previous conclusions in the context of the WW and SH3
domains: a PEG staple yields the greatest energetic benefit when placed between two residues close in
tertiary structure, but distant from each other in primary sequence or (in this case) from the nearest existing
disulfide crosslink. The origin of this energetic benefit appears to be entropic in nature (-TΔΔS = 8.0 ±
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0.6 kcal/mol; Table 1), presumably due to preorganization of the protein into a conformation more closely
resembling the folded ensemble.
To further validate the this conclusion, we stapled positions 20e/22g’ with the same four-unit PEG
staple as for positions 6e/8g’ and 27e/29g’. Positions 20e/22g’ are analogous to positions 6e/8g’ and
27e/29g’ but located between those stapling sites. Compared with non-stapled counterpart d20e/22g’-40,
the stapled variant sd20e/22g’-40 is -1.02 ± 0.05 kcal/mol more stable. And sd13e/15g’-40 is -1.33 ± 0.02
kcal/mol more stable than its non-stapled counterpart d13e/15g’-40. We then plotted the impact of PEG
stapling (ΔΔGs) from positions 6e and 8g’, 13e and 15g’, 20e and 22g’, and 27e and 29g’, with the their
distances (numbers of amino acids away) to the disulfide bond, and the linear relationship (with R2 value
of 0.9978) further consolidates the conclusion that positions with further distance to the disulfide bond
can gain the coiled coil more stability upon PEG stapling.

Figure 2. Plot of the impact of PEG stapling (ΔΔGs) from positions 06/08’, 20/22’,
and 27/29’ with their distances (number of amino acids) to the disulfide bond. Slope
= 0.0413, intercept = 0.4876, R2 = 0.9783.
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Table 1. Structural identification and folding free energies of PEG-stapled GCN4 variants and their
unstapled counterparts. a
Impact of Stapling
Protein

Structural Identification

Tm (°C)

d27e/29g’
-40

41.1 ± 0.2

sd27e/29g
’-40

48.2 ± 0.1

d27e/29g’
-20

33.8 ± 0.2

sd27e/29g
’-20

31.1 ± 0.2

d27e/22g’
-40

43.2 ± 0.2

sd27e/22g
’-40

63.6 ± 0.1

d27e/22g’
-20

43.4 ± 0.2

sd27e/22g
’-20

64.9 ± 0.1

d6e/8g’40

34.3 ± 0.1

sd6e/8g’40

66.7 ± 0.7

d24b/25c’
-40

44.9 ± 0.1

sd24b/25c
’-40

33.0 ± 0.2

d7f/10b’40

40.0 ± 0.2

sd7f/10b’40

47.1 ± 1.1
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ΔΔG
(kcal/mol)

ΔΔH
(kcal/mol)

-TΔΔS
(kcal/mol)

-0.65 ± 0.02

1.3 ± 0.6

-1.9 ± 0.6b

0.19 ± 0.01

1.8 ± 0.6

-1.6 ± 0.6

-2.02 ± 0.02

-2.6 ± 0.5

0.6 ± 0.5

-2.04 ± 0.04

-0.6 ± 0.6

-1.5 ± 0.6

-1.51 ± 0.06

6.5 ± 0.6

-8.0 ± 0.6

0.74 ± 0.02

12.6 ± 0.6

-11.8 ± 0.6

-0.41 ± 0.07

8.6 ± 1.8

-9.1 ± 1.7

d27e/29g’
-00

34.7 ± 0.2

sd27e/29g
’-004

47.2 ± 0.2

-0.76 ± 0.02

3.7 ± 0.6

-4.5 ± 0.6

ysd27e/29
g’-004

49.3 ± 0.2

-0.99 ± 0.02

1.4 ± 0.6

-2.4 ± 0.6

d24b/25c’
-44

43.5 ± 0.6

sd24b/25c
’-44

40.9 ± 0.6

0.19 ± 0.06

0.3 ± 1.8

-0.1 ± 1.8

d7f10b’44

45.9 ± 0.2

sd7f10b’44

55.7 ± 0.1

-0.8 ± 0.02

2.3 ± 0.5

-3.1 ± 0.5

d20e/22g’
-40

41.8 ± 0.2

sd20e/22g
’-40

54.5 ± 0.5

-1.02 ± 0.05

3.6 ± 0.9

-4.7 ± 0.8

d27e/29g’
-DL-c00

33.1 ± 0.5

sd27e/29g
’-DL-00

42.2 ± 0.2

-0.73 ± 0.02

-1.6 ± 0.5

0.9 ± 0.5

d13e/15g’
-40

42.4 ± 0.1

sd13e/15g
’-40

57.7 ± 0.1

-1.33 ± 0.02

2.1 ± 0.5

-3.4 ± 0.5

d6e/1g’40

45.1 ± 0.5

sd6e/1g’40

74.9 ± 0.2

-1.99 ± 0.03

6.4 ± 0.3

-8.4 ± 0.3

Folding free energies for each variant are given ± std. error in kcal/mol at the melting temperature of its non-stapled nonPEGylated counterpart. GCN4 disulfide-bound heterodimers and their triazole-stapled counterparts were analyzed at 15 μM
protein concentration in 20 mM sodium phosphate buffer (pH 7) + 4.0 M GdnHCl. bVariants d27e/29g’-40 and sd27e/29g’40 were synthesized and characterized previously.
a
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Figure 3. GCN4 dimer with b/c’ (24/25’) positions and b/f’ positions highlighted; the
dashed lines with associated numbers indicate the distance between the β-carbons of
residues of interest.

Next we investigated the effect of stapling between other solvent-exposed positions within the
disulfide-bonded coiled-coil heterodimer, including b/f’and b/c’ staples. Residues at b- and f’- or b- and
c’- positions generally are farther apart in space and oriented away rather than toward the interface
between helices (Figure 1B). We wondered whether this increased distance might attenuate the impact of
stapling. Accordingly, we prepared variant d24b/25c’-40 (four-unit azide-terminated Asn-PEG at bposition 24; Pra at c-position 25’) and its stapled counterpart sd24b/25c’-40. Stapled sd24b/25c’-40 is
0.74 ± 0.02 kcal/mol less stable than its non-stapled counterpart, possibly because the four-unit PEG might
be too short to span the distance between b-position 24 and c-position 25’ (~15 Å, see Figure 3). To
explore this possibility, So we doubled the length of 24/25’ staple by preparing variant d24b/25c’-44
(four-unit azide-terminated Asn-PEG at b-position 24; four-unit propargyl-terminated Asn-PEG at cposition 25’) and its stapled counterpart sd24b/25c’-44. Stapled variant sd24b/25c’-44 is 0.19 ± 0.05
kcal/mol less stable than its non-stapled counterpart; apparently, increased staple length can overcome
some but not all of the destabilization associated with the b/c’ staple.
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We also evaluated the four-unit PEG staple at f-position 7 and b’-position 10’ (Figure 3). We found
the stapled variant sd7f/10b’-40 (four-unit azide-terminated Asn-PEG at f-position 7; Pra at b-position
10’) is -0.41 ± 0.07 kcal/mol more stable than the non-stapled variant d7f/10b’-40. This is a much smaller
level of stabilization than we observed for the 6e/8g’ and 6e’/1g’ staples, which are similarly distant from
the disulfide bridge, suggesting that b/f’ staples are less stabilizing than e/g’ positions. As with the
b/c’staple described above, we wondered whether a longer staple might better span the large distance
between f-position 7 and b’-position 10’. Accordingly, we prepared stapled variant sd7f/10b’-44 (fourunit azide-terminated Asn-PEG at f-position 7; four-unit propargyl-terminated Asn-PEG at b’-position
10’), along with its non-stapled counterpart. Stapled variant sd07f/10b’-44 is -0.68 ± 0.01 kcal/mol more
stable than its non-stapled counterpart d7f/10b’-44, indicating longer PEG staple is more favorable
stapling at f/b’ positions.
As described in chapter 4, we incorporated the four-unit azido- or propargyl-terminated Asn-PEG
residues into the variants described by solid phase peptide synthesis, which is much less convenient for
larger proteins. Propargylglycine13 and propargyloxyphenylalanine14 are genetically encodable; we
wondered whether stapling of two Pra residues with a bis-azido PEG would recapitulate the staple-based
stabilization we observed for staples between Pra and azide-terminated Asn-PEGs (Figure 5). If so, this
approach would be much more convenient to apply to expressed proteins. We prepared stapled variant
sd27e/29g’-040 by incorporating Pra at e-position 27 and g-position 29, followed by stapling via CuAAC
using a four-unit bis-azido PEG. Stapled sd27e/29g’-040 is -0.76 ± 0.02 kcal/mol more stable than its
non-stapled counterpart d27e’/29g’-00, which is comparable to what we observed for the Asn-PEG/Pra
27e/29g’ staple (-0.65 ± 0.02 kcal/mol). We can safely conclude that a two-component staple is at least as
favorable to or even slightly more favorable than a one-component PEG staple at the same location.
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Figure 5. Two component stapling strategy based on Click chemistry.

For monomeric helical peptide stapling crossing one helical turn or two, application of heterochiral
residues can further enhance the stabilizing effect from stapling on α-helices, since the heterochiral
residues are oriented toward to each other, adopting a more favorable geometry for crosslinking. The
favorable geometry derived from the heterochiral residues has been applied to disulfide-bond-based
stapling15-16 and metathesis-based stapling17-18 on monomeric helical peptides. We found that both the
residue 27e and 29g’ are oriented toward the same N-terminus direction of the GCN4 heterodimer from
the crystal structure. We wondered whether heterochiral residues at position 27e and 29g’ will be more
favorable for interhelical PEG stapling. Accordingly, we incorporated D-Pra at positions 27e on one
monomer, and L-Pra at position 29’ on another monomer to get a GCN4 heterodimer d27e/29g’-DL-00
and its stapled counterpart sd27e/29g’-DL-004. The stapled variant sd27e/29g’-DL-004 is -0.73 ± 0.02
kcal/mol more stable than its non-stapled counterpart d27e/29g’-DL-00, which is similar to that of
d27e/29g’-00 v.s. sd27e/29g’-004, in which L-Pra was incorporated at both position 27e and 29g’,
indicating that the heterochiral residues dose not contribute much stabilization to the interhelical PEG
stapling.
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Figure 6. Proteolysis of selected unstapled and stapled GCN4 variants by proteinase K (17 mg/mL) at 50 mM protein
concentration in 20 mM sodium phosphate buffer (pH 7) as monitored by HPLC. (A) – (F) represent proteolysis runs
contrasting unstapled variants (cyan) and corresponding stapled variants (magenta). Data points represent the average
of three replicate experiments. Solid lines represent fits of the data to a mono-exponential decay function, which was
used to determine apparent proteolysis rate constants. (G) Plot of the impact of PEGylation or PEG stapling on
proteolytic resistance (as assessed by the natural logarithm of r, the ratio of apparent proteolysis rate constant of PEGstapled GCN4 variants relative to their non-stapled PEGylated counterparts) vs. the impact of PEG stapling on GCN4
conformational stability (ΔΔG). Dotted line represents fit of the ln r vs. ΔΔG data to a linear equation. Slope = 1.31 ±
0.27; intercept = -0.01 ± 0.38; R2 = 0.8544.

One potential application of the interhelical PEG stapling is that it can be combined with cleavable
PEGylation to improve the pharmacokinetic properties of peptide and small protein therapeutics that are
sensitive to conventional PEGlyation. Multiple cleavable linkers have been developed to facilitate
reversible PEGylation,19 but none of them has been approved as an effective strategy for modification of
small proteins/peptides, possibly due in part to the rapid serum proteolysis of small proteins once the PEG
chains are cleaved. We hypothesize that this challenge can be addressed if a staple remains intact within
the small protein after cleavage of the PEG; presumably the increased conformational stability associated
with stapling would increase the proteolytic resistance of the resulting PEG-free protein. Accordingly, we
functionalized the four-unit PEG staple, in which the middle oxygen was replaced with a nitrogen as
linking atom, with an additional four-unit PEG chain through a cleavable carbamate linkage, resulting a
branched Y-shape PEG chain, as described in Figure 5. Two-component stapling strategy with the
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CuAAC reaction produced the Y-shape PEG stapled variant ysd27e/29g’-040, which is -0.99 ± 0.02
kcal/mol more stable than its non-stapled counterpart d27e/29g’-00 and -0.23 ± 0.03 kcal/mol more stable
than the PEG stapled variant sd27e/29g’-c040, which indicates that the benefits of PEG stapling can be
enhanced by additional modification of the staple.
Table 2. Structural identification and folding free energies of wide type affibody, PEG-stapled affibody
mutant, and its unstapled counterparts. a
Impact of Stapling
Protein

WTA
a8e/42g’00
sa8e/42g’040

Structural Identification

Tm (°C)

ΔΔG

ΔΔH

-TΔΔS

(kcal/mol)

(kcal/mol)

(kcal/mol)

60.9 ± 0.1

0.64 ± 0.01

-2.2 ± 1.0

2.8 ± 1.0

76.1 ± 0.1

-1.09 ± 0.02

3.5 ± 1.2

-4.5 ± 1.2

66.4 ± 0.2

Folding free energies for each variant are given ± std. error in kcal/mol at the melting temperature of its non-stapled nonPEGylated counterpart. Affibody variants were analyzed at 15 μM protein concentration in 20 mM sodium phosphate buffer
(pH 7).
a

We previously showed that PEG staple-based increases in WW conformational stability are
associated with increased levels of protection from proteolysis. We wondered whether this would be true
for PEG-stapled GCN4 variants. We explored this possibility by exposing 15 μM solutions of GCN4
variants d27e/29g’-40, sd27e/29g’-40; d27e/29g’-00, sd27e/29g’-004; d27e/29g’-20, sd27e/29g’-20;
d24b/25c’-40, sd24b/25c’-40; d6e/8g’-c40, sd6e/8g’-40; d27e/22g’-20, sd27e/22g’-20; d27e/22g’-40,
sd27e/22g’-40 to proteinase K (17 μg mL−1) and monitoring the amount of full-length protein remaining
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in solution at regular intervals by analytical HPLC. We fit the resulting data to a monoexponential decay
function to obtain apparent proteolysis rate constants k. The results of this analysis are shown in Figure
6A-F. All the PEG stapled variants with improved thermodynamic stability showed enhanced proteolytic
resistance. PEG-stapled variants with compromised conformational stability, such as sd24b/25c’-40, were
more vulnerable to proteolysis (Figure 6C). For each variant, we calculated a proteolytic resistance
factor r, which is the ratio between the apparent rate constant k for a PEG-stapled variant relative to the
non-stapled variant. Variants with smaller values of r are more resistant to proteolysis than the
corresponding parent variant. We then plotted the natural logarithm of r against the corresponding
difference in free energy for the compound relative to its non-stapled parent variant (Figure 6G). ln r varies
linearly with ΔΔG as indicated by least-squares regression (R2 = 0.854), indicating that more stabilized
GCN4 variants experience greater levels of proteolytic resistance.

Figure 7. A) Sequence and structure of HER-2 affibody (PDB code: 3mzw) with E08 and A40 mutated to
propargylglycine (Pra); Click chemistry based two component stapling between 08Pra and 40Pra; The yellow
colored residues indicate HER-2 binding area, and the black colored residues indicated the hydrophobic patch that
are from a-, d- positions of heptad repeat. B) Proteolytic rate constants k of the crosslinked affibody sa8e42g-040
and its non-crosslinked counterpart a8e42g’-00 as well as their wild type affibody WTA.
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We further applied the two-component stapling strategy to a therapeutic relevant protein HER-2
affibody. We chose the e/g’ (A42/E08) positions as stapling sites, since e/g’ positions should provide the
optimal stabilizing effect for interhelical staple, and E08 is located at the terminus of one helix and close
to A42 from another helix. (Figure 7A) Also, those positions are not involved in the binding interface
between the affibody and HER-2 (residues important for binding are colored in orange in Figure 7A). We
would expect that the mutations of A42 and E08 to propargylglycine far from the binding interface would
have minimal impact on target binding affinity, and further installation of PEG staple to those
propargylglycines will enhance the thermodynamic stability as well as target binding affinity. Compared
to the native affibody, the affibody mutant a8e42g’-00 (A42Pra/E08Pra) is 0.64 ± 0.01 kcal/mol less stable.
However, the PEG-stapled affibody variant sa8e42g’-040 is -1.09 ± 0.02 kcal/mol more stable than the
native affibody, and -1.60 ± 0.03 kcal/mol more stable than its non-stapled counterpart a8e42g’-00. As
indicated in Figure 7B, the stapled affibody mutant sa8e42g’-040 is nine-times more resistant to
proteolysis than the wide type affibody (WTA), and seventeen-times more resistant than its non-stapled
counterpart a8e42g’-00.
5.3 Conclusions
We thoroughly investigated the positional effect of 4-unit PEG staple stabilizing GCN4
heterodimer, including comparison of different distances to another covalent linkage (disulfide bond) and
comparison of different solvent exposed positions (e/g; b/c; b/f). We conclude that stapling at e/g’
positions provide superior stabilization than other solvent exposed positions, and PEG staple at saltbridged e/g’ positions stabilize the coiled coil more than non-salt-bridged e/g’ positions. We also conclude
that farther distance to the disulfide bond provides more conformational stability upon PEG stapling. We
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also showed that heterochiral residues did not further enhance the stabilizing effect from interhelical PEG
staple. We further applied this interhelical two-component stapling strategy to a therapeutic protein HER2 affibody, and found that the stapled variant is -1.6 kcal/mol more stable and 17-times more resistant to
proteolysis compared to its non-stapled counterpart. We believe this interhelical PEG staple strategy is
transferable to other proteins containing coiled-coil motifs for increasing conformational stability and
proteolytic resistance.
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5.5 Supporting Information
5.5.1 Structure of GCN4 variants
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Figure S1. A) Acidic GCN4 monomer, basic GCN4 monomer, noncovalent GCN4 heterodimer, and their triazole-stapled
counterpart. B-J) Disulfide-bound GCN4 heterodimers, their triazole-stapled counterparts, and their components including
cysteine-containing acidic GCN4 monomers and basic GCN4 monomers. 27e/29g’-40 and s27e/29g’-40 were previously
published structures by us.12 X represents propargyl glycine; Z represents a PEG-modified Asn residue with Alkyne as
terminus (as reported in previous publication 12); N represents a PEG-modified Asn residue with azido group as terminus; the
PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings.
Parentheses indicate notebook numbers.

5.5.2 Global Fitting of Variable Temperature CD Data
The conformational stability of stapled and unstapled GCN4 variants was assessed by variabletemperature circular dichroism spectropolarimetry. Data from three replicate variable temperature CD
experiments were each fit globally to a model for a two-state thermally induced unfolding transition
using the program Mathematica (Wolfram Research).
We used a model based on two-state monomer folding for GCN4 variants d27e/29g’-40, sd27e/29g’-40;
d27e/29g’-00, sd27e/29g’-004; d27e/29g’-20, sd27e/29g’-20; d24b/25c’-40, sd24b/25c’-40; d6e/8g’40, sd6e/8g’-40; 27e/22g’-20, s27e/22g’-20; 27e/22g’-40, s27e/22g’-40; d7b/10f’-40, sd7b/10f’-40;
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ysd27/29’-c040; 24b/25c’-44, s24b/25c’-44; d7b/10f’-44, sd7b/10f’-44; d13e/15g’-40, sd13e/15g’-40;
d20e/22g’-40, sd20e/22g’-40; d06/01’-c40, sd06/01’-c40; d27e/29g’-DL-004, sd27e/29g’-DL-004;
WTA, a8e/42g’-00, sa8e/42g’-004. This model is described in equation S1:
[θ] =

[K∙(an +bn ∙T)+(cn +dn ∙T)]

,

1+K

(S1)

where T is temperature in Kelvin, an is the y-intercept and bn is the slope of the pre-transition baseline
for melt n (a1 and b1 for replicate 1, a2 and b2 for replicate 2, a3 and b3 for replicate 3, etc.); cn is the yintercept and dn is the slope of the post-transition baseline for replicate n (c1 and d1 for replicate 1, c2 and
d2 for replicate 2, c3 and d3 for replicate 3, etc.); and K is the temperature-dependent folding equilibrium
constant. K is related to the temperature-dependent free energy of folding ΔG according to the following
equation:
𝐾𝐾 = exp �–

ΔG
RT

(S2)

�,

where R is the universal gas constant (0.0019872 kcal/mol/K). ΔG is a function of temperature, as
shown in the following equation:
Δ =

ΔΗ0 ∙(Tm −Τ)
Tm

+ ΔCp ∙ (T − Tm − T ∙ ln �

T

Tm

�),

(S3)

where Tm is the midpoint of the unfolding transition and the temperature at which ΔGf = 0; ΔH0 is the
change in enthalpy upon folding at T = Tm; and ΔCp is the change in heat capacity upon folding.
In some cases, we found that some fit parameters had sufficiently high standard errors as to
render them indistinguishable from zero and therefore not essential to the fit (as judged by their pvalues). When this occurred, we repeated the fitting process without the non-essential parameters. We
used the fit parameters for each variant to calculate the ΔG values given in the main text; we calculated
the uncertainty for each ΔG value by propagation of error using the standard errors of the fit parameters.
CD spectra and variable temperature CD data for GCN4 variants 27e/29g’-40, s27e/29g’-40;
27e/29g’-00, s27e/29g’-004; 27e/29g’-20, s27e/29g’-20; 24b/25c’-40, s24b/25c’-40; d6e/8g’-40,
sd6e/8g’-40; 27e/22g’-20, s27e/22g’-20; 27e/22g’-40, s27e/22g’-40; d7b/10f’-40, sd7b/10f’-40;
ysd27/29’-c040; 24b/25c’-44, s24b/25c’-44; d7b/10f’-44, sd7b/10f’-44; d13e/15g’-40, sd13e/15g’-40;
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d20e/22g’-40, sd20e/22g’-40; d06/01’-c40, sd06/01’-c40; d27e/29g’-DL-004, sd27e/29g’-DL-004;
WTA, a8e/42g’-00, sa8e/42g’-004. are shown in Figures S2–S28, along with the fit parameters ±
standard error. Standard parameter errors were used to estimate the uncertainty in the thermodynamic
values given in the main text by propagation of error.

Figure S2. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound GCN4 heterodimer
27e/29g’-00 (QX2271) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear
in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 307.85 K, with the indicated standard errors.

394

Figure S3. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant s27e/29g’-004 (QX2283) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 307.85 K, with the indicated standard errors.

Figure S4. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound GCN4 heterodimer
27e/29g’-20 (QX2289) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear
in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 306.95 K, with the indicated standard errors.
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Figure S5. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant s27e/29g’-20 (QX2289s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 306.95 K, with the indicated standard errors.

Figure S6. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound GCN4 heterodimer
24b/25c’-40 (QX2291) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear
in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 318.05 K, with the indicated standard errors.
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Figure S7. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant s24b/25c’-40 (QX2291s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 318.05 K, with the indicated standard errors.

Figure S8. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound GCN4 heterodimer
d6e/8g’-40 (QX2292) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in
the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 307.45 K, with the indicated standard errors.
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Figure S9. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant sd6e/8g’-40 (QX2292s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 307.45 K, with the indicated standard errors.

Figure S10. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound GCN4 heterodimer
27e/22g’-40 (QX2293) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear
in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 316.55 K, with the indicated standard errors.
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Figure S11. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant s27e/22g’-40 (QX2293s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 316.55 K, with the indicated standard errors.

Figure S12. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound GCN4 heterodimer
27e/22g’-20 (QX2294) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear
in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 316.35 K, with the indicated standard errors.
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Figure S13. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant s27e/22g’-40 (QX2294s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 316.35 K, with the indicated standard errors.

Figure S14. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound GCN4 heterodimer
d7b/10f’-40 (QX2295) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear
in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 313.15 K, with the indicated standard errors.
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Figure S15. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant sd7b/10f’-40 (QX2295s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 313.15 K, with the indicated standard errors.

Figure S16. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant s27e/29g’-004 (QX3079) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 307.85 K, with the indicated standard errors.
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Figure S17. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant 24b/25c’-44 (QX3096) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 316.65 K, with the indicated standard errors.

Figure S18. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant s24b/25c’-44 (QX3096s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 316.65 K, with the indicated standard errors.
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Figure S19. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant d7b/10f’-44 (QX3101) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 316.65 K, with the indicated standard errors.

Figure S20. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant sd7b/10f’-44 (QX3101s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 316.65 K, with the indicated standard errors.
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Figure S21. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant d20e/22g’-40 (ZJ10511) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 315.00 K, with the indicated standard errors.

Figure S22. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant sd20e/22g’-40 (ZJ10511s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 315.00 K, with the indicated standard errors.
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Figure S23. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant d01/06’-c40 (QX31172) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 318.25 K, with the indicated standard errors.

Figure S24. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant sd01/06’-c40(QX31172s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 318.25 K, with the indicated standard errors.
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Figure S25. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide bound triazole-stapled
GCN4 variant d13e/15g’-40 (QX31171) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations
S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 318.25 K, with the indicated standard errors.

Figure S26. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM native affibody variant Native
Affibody (CD1054) in 20 mM sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do
calculated values for ΔGf, ΔHf, and -TΔSf at 339.6 K, with the indicated standard errors.
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Figure S27. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM affibody variant Affibody08/42c00 (QX3102) in 20 mM sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated
values for ΔGf, ΔHf, and -TΔSf at 339.6 K, with the indicated standard errors.

Figure S28. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM affibody variant Affibody08/42c004 (QX3106) in 20 mM sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated
values for ΔGf, ΔHf, and -TΔSf at 339.6 K, with the indicated standard errors.
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Figure S29. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 7.5 μM disulfide bound triazole-stapled
GCN4 variant d27e/29g’-DL-00 (QX3118) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from
equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 306.25 K, with the indicated standard
errors.

Figure S30. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 7.5 μM disulfide bound triazole-stapled
GCN4 variant d27e/29g’-DL-00 (ZJ1056) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from
equations S1–S3 appear in the table, as do calculated values for ΔGf, ΔHf, and -TΔSf at 306.25 K, with the indicated standard
errors.

408

5.5.3 Synthesis of GCN4 variants
Peptide Synthesis: GCN4 monomers 27-c0 (notebook number QX22711), 29’-c0 (notebook number
QX22712), 27-c2 (notebook number DA10813), 29’-c0 (notebook number DA10796), 24-c4 (notebook
number DA10811), 25’-c0 (notebook number DA10792), 06-c4 (notebook number DA10812), 08’-c0
(notebook number DA10794), 27-c20 (notebook number ZJ10313), 22’-c0 (notebook number
ZJ10312), 27-c40 (notebook number ZJ10311), 22’-c0 (notebook number ZJ10312), 07-c4 (notebook
number QX22951), 10’-c0 (notebook number QX22952) were prepared as C-terminal amides on and
Rink amide MBHA LL resin (EMD Biosciences), by microwave-assisted solid phase peptide synthesis
using a standard Fmoc Nα protection strategy as described previously.9 Fmoc-protected amino acids
were purchased from Advanced Chem Tech, except for the PEGylated asparagine derivatives, which
were synthesized as described in section 7 below. GCN4 monomers were cleaved from resin and
purified by preparative reverse-phase high-performance liquid chromatography (HPLC) on a C18
column using a linear gradient of water in acetonitrile with 0.1% v/v trifluoroacetic acid. Peptide
identity was confirmed by electrospray ionization time- of-flight mass spectrometry.
Disulfide formation in the GCN4 heterodimer: We prepared the disulfide-bonded GCN4 heterodimer
27e/29g’-00 (notebook number QX2271), 27e/29g’-20 (notebook number QX2289), 24b/25c’-40
(notebook number QX2291), d6e/8g’-40 (notebook number QX2292), 27e/22g’-20 (notebook number
QX2293), 27e/22g’-40 (notebook number QX2294), d7b/10f’-40 (notebook number QX2295) by
mixing its purified cysteine-containing precursors in a 1:1 ratio in an aqueous solution of ammonium
bicarbonate (8 mg/mL) with exposure to air for 3 hrs. Reaction completeness was monitored by
analytical HPLC; GCN4 heterodimers were then purified by preparative HPLC and characterized by
ESI-TOF MS.
Stapling via copper-catalyzed azide/alkyne cycloaddition (CuAAC): We prepared triazole-stapled
variants s27e/29g’-20 (notebook number QX2289s); s24b/25c’-40 (notebook number QX2291s);
sd6e/8g’-40 (notebook number QX2292s); s27e/22g’-20 (notebook number QX2293s); s27e/22g’-40
(notebook number QX2294s); sd7b/10f’-40 (notebook number QX2295s) by stirring their purified nonstapled precursors in 2:1 (v/v) water/tert-butanol with 10 eq. copper sulfate pentahydrate and 10 eq.
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sodium ascorbate at 40 Celsius degree for 2 hours. The reaction was monitored by analytical HPLC,
where we observed small changes in retention time upon stapling. The triazole-stapled variants were
purified via preparative HPLC.
Two-component stapling via copper-catalyzed azide/alkyne cycloaddition (CuAAC): We prepared
triazole-stapled variants s27e/29g’-004 (notebook number QX2283) sd27e/29g’-DL-004 (notebook
number ZJ1056) and ys27e/29g’-004 (notebook number QX3079) by stirring their same purified nonstapled precursors 27e/29g’-00 (notebook number QX2271) or d27e/29g’-DL-00 (notebook number
QX3118) in 2:1 (v/v) water/tert-butanol with 1.5 eq. of 4-unit PEG chain (Y-shape PEG chain) with 2
azido group as terminuses, 10 eq. copper sulfate pentahydrate and 10 eq. sodium ascorbate at 40 Celsius
degree for 2 hours. The reaction was monitored by analytical HPLC, where we observed small changes
in retention time upon stapling. The triazole-stapled variants were purified via preparative HPLC.
Since the CuAAC reaction does not change the mass of the monomeric triazole-stapled variants
s27e/29g’-20 (notebook number QX2289s); s24b/25c’-40 (notebook number QX2291s); sd6e/8g’-40
(notebook number QX2292s); s27e/22g’-20 (notebook number QX2293s); s27e/22g’-40 (notebook
number QX2294s); sd7b/10f’-40 (notebook number QX2295s); s27e/29g’-004 (notebook number
QX2283); ys27e/29g’-004 (notebook number QX3079); s24b/25c’-44 (notebook number QX3096s);
sd7b/10f’-44 (notebook number QX3101s); sd13e/15g’-40 (notebook number QX31171s); sd22/22’c40 (notebook number ZJ10511s); sd06/01’-c40 (notebook number QX31172s) relative to their nonstapled azide/alkyne precursors 27e/29g’-20 (notebook number QX2289), 24b/25c’-40 (notebook
number QX2291), d6e/8g’-40 (notebook number QX2292), 27e/22g’-20 (notebook number QX2293),
27e/22g’-40 (notebook number QX2294), d7b/10f’-40 (notebook number QX2295), 27e/29g’-00
(notebook number QX2271), 24b/25c’-44 (notebook number QX3096), d7b/10f’-44 (notebook number
QX3101); d13e/15g’-40 (notebook number QX31171); d22/22’-c40 (notebook number ZJ10511);
d06/01’-c40 (notebook number QX31172). To confirm the completion of the CuAAC reaction, we
subjected each azide-containing unstapled variant and its triazole-stapled counterpart separately to a
solution of dithiothreitol (DTT, 15 mg) in 100 μL water, followed by incubation at room temperature for
8 hours. In all cases, the unstapled variants were reduced to their corresponding monomers with/without
DTT addition, for the triazole-stapled variants, the dimer still existed as dimer after the DTT treatment,
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indicating the formation of covalent linkage between helices of those dimers. The detailed results of this
analysis are shown below in Figures S29–S41.
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Figure S29. ESI-TOF MS data for GCN4 variant QX2271 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 8h. Expected [M+8H+]/8 = 1032.434 Da for QX2271 prior to reduction. Following reduction, QX2271
splits into its component peptides: QX22712 with expected mass [M+4H+]/4 = 1108.495 Da, representing the alkyne reduced
to an alkene and the addition of two DTT adducts, and QX22711, which does not appear in the spectra perhaps due to
difficulty for the monomer to become charged. For QX22712, the exposed cysteine has likely formed a disulfide bond with
DTT. Additionally, the alkyne has likely undergone reduction to an alkene and covalently linked to DTT, forming a vinyl
thioether. Also shown are ESI-TOF MS data for doubly triazole-stapled QX2283 before (B) and after (D,F) exposure to
reduction conditions for at least 8h. Expected [M+8H+]/8 = 1062.950 Da for doubly triazole-stapled QX2283 before
reduction and [M+8H+]/8 = 1063.202 Da after reduction.
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Figure S30. ESI-TOF MS data for GCN4 variant QX2289 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 8h. Expected [M+8H+]/8 = 1048.942 Da for QX2289 prior to reduction. Following reduction, QX2289
splits into its component peptides: DA10813 with expected mass [M+4H+]/4 = 1066.768 Da, and DA10796 with expected
mass [M+4H+]/4 = 1031.620 Da. Also shown are ESI-TOF MS data for triazole-stapled QX2289s before (B) and after (D,F)
exposure to reduction conditions for at least 8h. For QX2289s, expected [M+8H+]/8 = 1048.942 Da before reduction, and
[M+8H+]/8 = 1049.192 Da after reduction of the disulfide bond to cysteine residues.
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Figure S31. ESI-TOF MS data for GCN4 variant QX2291 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 8h. Expected [M+8H+]/8 = 1063.698 Da for QX2291 prior to reduction. Following reduction, QX2291
splits into its component peptides: DA10792 with expected mass [M+4H+]/4 = 1101.491 Da having two DTT adducts, and
DA10811 with expected mass [M+4H+]/4 = 1103.282 (does not appear on spectra, likely has difficulty becoming charged).
For DA10792, the exposed cysteine has likely formed a disulfide bond with DTT. Additionally, the alkyne has likely
undergone reduction to an alkene and covalently linked to DTT, forming a vinyl thioether. Also shown are ESI-TOF MS data
for triazole-stapled QX2289s before (B) and after (D,F) exposure to reduction conditions for at least 8h. For QX2289s,
expected [M+8H+]/8 = 1063.698 Da before reduction, and [M+8H+]/8 = 1063.948 Da after reduction of the disulfide bond to
cysteine residues.
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Figure S32. ESI-TOF MS data for GCN4 variant QX2292 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 8h. Expected [M+8H+]/8 = 1059.948 Da for QX2292 prior to reduction. Following reduction, QX2292
splits into its component peptides: DA10812 with expected mass [M+4H+]/4 = 1088.781 Da, and DA10794 with expected
mass [M+4H+]/4 = 1031.620 Da (does not appear on spectra, likely has difficulty becoming charged). Also shown are ESITOF MS data for triazole-stapled QX2292s before (B) and after (D,F) exposure to reduction conditions for at least 8h. For
QX2292s, expected [M+8H+]/8 = 1059.948 Da before reduction and [M+8H+]/8 = 1060.200 Da after reduction.
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Figure S33. ESI-TOF MS data for GCN4 variant QX2293 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 8h. Expected [M+8H+]/8 = 1048.942 Da for QX2293 prior to reduction. Following reduction, QX2293
splits into its component peptides: ZJ10313 with expected mass [M+4H+]/4 = 1066.768 Da, and ZJ10312 with expected
mass [M+4H+]/4 = 1031.620 Da. Also shown are ESI-TOF MS data for triazole-stapled QX2293s before (B) and after (D,F)
exposure to reduction conditions for at least 8h. For QX2293s, expected [M+8H+]/8 = 1048.943 Da before reduction and
[M+8H+]/8 = 1049.195 Da after reduction.
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Figure S34. ESI-TOF MS data for GCN4 variant QX2294 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 8h. Expected [M+8H+]/8 = 1059.948 Da for QX2294 prior to reduction. Following reduction, QX2294
splits into its component peptides: ZJ10311 with expected mass [M+4H+]/4 = 1088.781 Da, and ZJ10312 with expected
mass [M+4H+]/4 = 1031.620 Da (does not appear on spectra, likely has difficulty becoming charged). Also shown are ESITOF MS data for triazole-stapled QX2294s before (B) and after (D,F) exposure to reduction conditions for at least 8h. For
QX2294s, expected [M+8H+]/8 = 1059.948 before reduction, and [M+8H+]/8 = 1060.073 Da after reduction of disulfide
bond to cysteine residues.
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Figure S35. ESI-TOF MS data for GCN4 variant QX2295 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 8h. Expected [M+8H+]/8 = 1067.081 Da for QX2295 prior to reduction. Following reduction, QX2295
splits into its component peptides: QX22951 with expected mass [M+4H+]/4 = 1103.282 Da, and QX22952 with expected
mass [M+4H+]/4 = 1031.383 Da. Also shown are ESI-TOF MS data for triazole-stapled QX2295s before (B) and after (D,F)
exposure to reduction conditions for at least 8h. For QX2295s, expected [M+7H+]/7 = 1219.233 before reduction, and
[M+7H+]/7 = 1219.809 Da after reduction of disulfide bond to cysteine residues.
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Figure S36. ESI-TOF MS data for GCN4 variant QX2271 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 8h. Expected [M+8H+]/8 = 1032.434 Da for QX2271 prior to reduction. Following reduction, QX2271
splits into its component peptides: QX22712 with expected mass [M+4H+]/4 = 1108.495 Da, representing the alkyne reduced
to an alkene and the addition of two DTT adducts, and QX22711, which does not appear in the spectra perhaps due to
difficulty for the monomer to become charged. For QX22712, the exposed cysteine has likely formed a disulfide bond with
DTT. Additionally, the alkyne has likely undergone reduction to an alkene and covalently linked to DTT, forming a vinyl
thioether. Also shown are ESI-TOF MS data for doubly triazole-stapled QX3079 before (B) and after (D,F) exposure to
reduction conditions for at least 8h. For doubly triazole-stapled QX3079, expected [M+8H+]/8 = 1092.090 Da before
reduction and [M+8H+]/8 = 1092.342 Da after reduction.
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Figure S37. ESI-TOF MS data for GCN4 variant QX3096 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 4h. Expected [M+8H+]/8 = 1092.839 Da for QX3096 prior to reduction. Following reduction, QX3096
splits into its component peptides: QX3095 with expected mass [M+4H+]/4 = 1082.900 Da, and ND1095 with expected mass
[M+4H+]/4 = 1103.282 Da. Also shown are ESI-TOF MS data for triazole-stapled QX3096s before (B) and after (D,F)
exposure to reduction conditions for at least 8h. For QX3096s, expected [M+8H+]/8 = 1092.839 before reduction, and
[M+8H+]/8 = 1093.091 Da after reduction of disulfide bond to cysteine residues.
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Figure S38. ESI-TOF MS data for GCN4 variant QX3101 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 4h. Expected [M+8H+]/8 = 1096.211 Da for QX3101 prior to reduction. Following reduction, QX3101
splits into its component peptides: QX30982 with expected mass [M+4H+]/4 = 1089.664 Da, and QX30984 with expected
mass [M+4H+]/4 = 1103.282 Da. Also shown are ESI-TOF MS data for triazole-stapled QX3101s before (B) and after (D,F)
exposure to reduction conditions for at least 8h. For QX3101s, expected [M+7H+]/7 = 1252.680 before reduction, and
[M+8H+]/8 = 1096.2211 Da after reduction of disulfide bond to cysteine residues.

420

A

B

C

D

E

F

Figure S39. ESI-TOF MS data for GCN4 variant ZJ10511 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 4h. Expected [M+8H+]/8 = 1059.948 Da for ZJ10511 prior to reduction. Following reduction, ZJ10511
splits into its component peptides: ZJ10492 with expected mass [M+4H+]/4 = 1088.781 Da, and ZJ10452 with expected
mass [M+4H+]/4 = 1031.620 Da. Also shown are ESI-TOF MS data for triazole-stapled ZJ10511s before (B) and after (D,F)
exposure to reduction conditions for at least 8h. For ZJ10511s, expected [M+7H+]/7 = 1211.225 before reduction, and
[M+7H+]/7 = 1211.513 Da after reduction of disulfide bond to cysteine residues.
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Figure S40. ESI-TOF MS data for GCN4 variant QX31172 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 4h. Expected [M+8H+]/8 = 1059.948 Da for QX31172 prior to reduction. Following reduction, QX31172
splits into its component peptides: QX31101 with expected mass [M+4H+]/4 = 1088.781 Da, the other monomer QX31102
was not detected. Also shown are ESI-TOF MS data for triazole-stapled QX31172s before (B) and after (D,F) exposure to
reduction conditions for at least 8h. For QX31172s, expected [M+7H+]/7 = 1211.225 before reduction, and [M+7H+]/7 =
1211.291 Da after reduction of disulfide bond to cysteine residues.
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Figure S41. ESI-TOF MS data for GCN4 variant QX3118 before (A) and after (C,E) exposure to reducing conditions (1M
DTT) for at least 4h. Expected [M+8H+]/8 = 1032.434 Da for QX3118 prior to reduction. Following reduction, QX3118
splits into its component peptides: QX22712 with expected mass [M+4H+]/4 = 1031.620 Da, and monomer ZJ10551 with
expected mass [M+4H+]/4 = 1033.752 Da. Also shown are ESI-TOF MS data for triazole-stapled ZJ1056 before (B) and
after (D,F) exposure to reduction conditions for at least 8h. For ZJ1056, expected [M+8H+]/8 = 1062.950 before reduction,
and [M+8H+]/8 = 1063.202 Da after reduction of disulfide bond to cysteine residues.

A

B

C

D

Figure S42. A) ESI-TOF MS data for Affibody variant QX3102, expected [M+5H+]/5 = 1339.102 Da for QX3102. B) ESITOF MS data for triazole-stapled Affibody QX3106, expected [M+5H+]/5 = 1387.927 for QX3106. C) PEG linker with two
azido groups as termini get reduced to amines with the DTT/DIEA reduction condition. D) ESI-TOF MS data for triazolestapled Affibody QX3106 after exposure to DTT/DIEA reduction conditions for at least 8h.
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5.5.4 Proteolysis of GCN4 variants
15 μM protein solutions in 20 mM sodium phosphate buffer (pH 7) were incubated at ambient
temperature with 17 μg/mL proteinase K respectively for up to 5 hours. At each of the several time
points, the proteolysis reaction was quenched by adding 40 μL of aqueous trifluoroacetic acid (1% v/v)
to 40 uL of the reaction mixture. The quenched mixture was then analyzed in triplicate by reverse phase
HPLC analytical column, monitored by a UV-Vis detector at 220 nm. The degradation of the proteins
was assessed using the integrated HPLC peak area to account for how much of the full-length protein
remained at each time point. The protein half-lives were calculated by fitting the integrated peak areas as
a function of time to a mono exponential decay equation:
Area(t) = A • exp [-kt],
where t is time in minutes, A is a constant corresponding to relative integrated peak area at t = 0, and τ is
the decay time, which is related to the protein half-life t1/2 (t1/2 = τ ln 2). Decay traces for proteins
GCN4 variants, 27e/29g’-00 (QX2271), s27e/29g’-004 (QX2283); 27e/29g’-20 (QX2289), s27e/29g’20 (QX2289s); 24b/25c’-40 (QX2291), s24b/25c’-40 (QX2291s); d6e/8g’-40 (QX2292), sd6e/8g’-40
(QX2292s); 27e/22g’-20 (QX2293), s27e/22g’-20 (QX2292s); 27e/22g’-40 (QX2294), s27e/22g’-40
(QX2294s) affibody variants Affibody08/42-c00 (QX3102) and Affibody08/42-c004 (QX3106) are
shown in Figures S43– S57.
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Figure S43. Proteolysis of QX2271 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX2271 are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

Figure S44. Proteolysis of QX2283 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX2283 are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

Figure S45. Proteolysis of QX2289 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX2289 are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.
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Figure S46. Proteolysis of QX2289s (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17μg/mL) as monitored by HPLC. Data points for QX2289s are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

Figure S47. Proteolysis of QX2291 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX2291 are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.
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Figure S48. Proteolysis of QX2291s (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17μg/mL) as monitored by HPLC. Data points for QX2291s are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

Figure S49. Proteolysis of QX2292 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX2292 are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.
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Figure S50. Proteolysis of QX2292s (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17μg/mL) as monitored by HPLC. Data points for QX2292s are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

Figure S51. Proteolysis of QX2293 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX2293 are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.
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Figure S52. Proteolysis of QX2293s (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17μg/mL) as monitored by HPLC. Data points for QX2293s are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

Figure S53. Proteolysis of QX2294 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX2294 are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.
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Figure S54. Proteolysis of QX2294s (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase
K (17μg/mL) as monitored by HPLC. Data points for QX2294s are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

Figure S55. Proteolysis of QX3102 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX3102 are shown as blue circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

430

Figure S56. Proteolysis of CD1054 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for CD1054 are shown as green circles, and each represents the average of
three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which was used
to calculate the indicated half-lives.

Figure S57. Proteolysis of QX3106 (15 μM protein concentration in 20 mM sodium phosphate buffer, pH 7) by proteinase K
(17μg/mL) as monitored by HPLC. Data points for QX3106 are shown as dark magenta circles, and each represents the
average of three replicate experiments. The dashed line represents fit of the data to a mono exponential decay function, which
was used to calculate the indicated half-lives.
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5.5.5 ESI-TOF MS data for GCN4 variants
Table S1. Summary of mass spectrum data for all synthesized GCN4 and Affibody variants.
Name

Notebook
Number

Molecular Formula

z

Expected
[M+z∙H]/z

Observed
[M+z∙H]/z

27-c0

QX22711

C178H277N46O64S

4

1033.752

1033.757

29’-c0

QX22712

C187H324N56O46S

4

1031.620

1031.624

27e/29g’-00

QX2271

C365H597N101O110S2

8

1032.434

1032.442

s27e/29g’-004

QX2283

C373H613N107O113S2

8

1062.950

1062.952

27-c2

DA10813

C181H287N51O68S

4

1066.768

1066.763

29’-c0

DA10796

C187H324N56O46S

4

1031.620

1031.622

27e/29g’-20

QX2289

C368H605N105O114S2

8

1048.942

1048.940

s27e/29g’-20

QX2289s

C368H605N105O114S2

8

1048.942

1048.942

06-c4

DA10812

C185H295N51O68S

4

1088.781

1088.783

08’-c0

DA10794

C186H319N55O48S

4

1031.620

1031.619

d6e/8g’-40

QX2292

C372H613N105O114S2

8

1059.948

1059.948

sd6e/8g’-40

QX2292s

C372H613N105O114S2

6

1412.928

1412.937

24-c4

DA10811

C187H297N51O70S

4

1103.282

1103.268

25’-c0

DA10792

C186H319N53O48S

4

1024.618

1024.605

24b/25c’-40

QX2291

C374H615N103O116S2

8

1063.698

1063.705

s24b/25c’-40

QX2291s

C374H615N103O116S2

8

1063.698

1063.697

27-c2

ZJ10313

C181H287N51O68S

4

1066.768

1066.769

22’-c0

ZJ10312

C187H324N56O46S

4

1031.620

1031.613

27e/22g’-20

QX2293

C368H605N105O114S2

8

1048.942

1048.948

s27e/22g’-20

QX2293s

C368H605N105O114S2

8

1048.942

1048.948

27-c4

ZJ10311

C185H295N51O68S

4

1088.781

1088.781

22’-c0

ZJ10312

C187H324N56O46S

4

1031.620

1031.613
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27e/22g’-40

QX2294

C372H613N105O114S2

8

1059.948

1059.953

s27e/22g’-40

QX2294s

C372H613N105O114S2

8

1059.948

1059.953

07-c4

QX22951

C187H297N51O70S

4

1103.282

1103.298

10’-c0

QX22952

C188H329N57O44S

4

1031.383

1031.397

d7b/10f’-40

QX2295

C374H615N105O116S2

8

1067.081

1067.088

sd7b/10f’-40

QX2295s

C374H615N105O116S2

6

1422.438

1422.428

s27e/29g’-004

QX3079

C383H632N108O118S2

8

1092.090

1092.075

24-c4

ND1095

C187H297N51O70S

4

1103.282

1103.277

25’-c4

QX3095

C197H343N55O51S

4

1082.900

1082.906

24b/25c’-44

QX3096

C384H634N104O121S2

8

1092.839

1093.064

s24b/25c’-44

QX3096s

C384H634N104O121S2

8

1092.839

1093.072

07-c4

QX30984

C187H297N51O70S

4

1103.282

1103.282

10’-c4

QX30982

C198H348N58O49S

4

1089.664

1089.671

d7b/10f’-44

QX3101

C385H639N107O119S2

8

1096.221

1096.447

sd7b/10f’-44

QX3101s

C384H634N104O121S2

7

1252.680

1253.046

20-c4

ZJ10492

C185H295N51O68S

4

1088.781

1088.770

22’-c0

ZJ10452

C187H324N56O46S

4

1031.620

1031.596

d20e/22g’-40

ZJ10511

C372H613N105O114S2

8

1059.948

1060.067

sd20e/22g’-40

ZJ10511s

C372H613N105O114S2

8

1059.948

1060.086

06-c4

QX31101

C185H295N51O68S

4

1088.781

1088.789

01’-c0

QX31102

C187H324N56O46S

4

1031.620

1031.629

d06/01-c40

QX31172

C372H613N105O114S2

8

1059.948

1060.088

sd06/01-c40

QX31172s

C372H613N105O114S2

7

1121.225

1121.387

27-D-c0

ZJ10551

C178H277N46O64S

4

1033.752

1033.751

d27e/29g’-DL00

QX3118

C365H597N101O110S2

8

1032.434

1032.541
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sd27e/29g’-DL004

ZJ1056

C373H613N107O113S2

8

1062.950

1063.073

WTA

CD1054

C296H471N87O89S1

5

1341.103

1341.106

Affibody08/42c00

QX3102

C298H469N87O87S1

5

1339.102

1339.123

Affibody08/42c004

QX3106

C306H485N93O90S1

5

1387.927

1387.915

Figure S58. ESI-TOF spectrum for GCN4 variant QX22711. Expected [M+4H+]/4 = 1033.752 Da. Observed [M+4H+]/4 =
1033.757 Da.

Figure S59. ESI-TOF spectrum for GCN4 variant QX22712. Expected [M+4H+]/4 = 1031.620 Da. Observed [M+4H+]/4 =
1031.624 Da.
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Figure S60. ESI-TOF spectrum for GCN4 variant QX2271. Expected [M+8H+]/8 = 1032.434 Da. Observed [M+8H+]/8 =
1032.442 Da.

Figure S61. ESI-TOF spectrum for GCN4 variant QX2283. Expected [M+8H+]/8 = 1062.950 Da. Observed [M+8H+]/8 =
1062.952 Da.
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Figure S62. ESI-TOF spectrum for GCN4 variant DA10813. Expected [M+4H+]/4 = 1066.768 Da. Observed [M+4H+]/4=
1066.763 Da.

Figure S63. ESI-TOF spectrum for GCN4 variant DA10796. Expected [M+4H+]/4 = 1031.620 Da. Observed [M+4H+]/4 =
1031.622 Da.

Figure S64. ESI-TOF spectrum for GCN4 variant QX2289. Expected [M+8H+]/8 = 1048.942 Da. Observed [M+8H+]/8 =
1048.940 Da.
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Figure S65. ESI-TOF spectrum for GCN4 variant QX2289s. Expected [M+8H+]/8 = 1048.942 Da. Observed [M+8H+]/8 =
1048.942 Da.

Figure S66. ESI-TOF spectrum for GCN4 variant DA10812. Expected [M+4H+]/4 = 1088.781 Da. Observed [M+4H+]/4 =
1088.783 Da.
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Figure S67. ESI-TOF spectrum for GCN4 variant DA10794. Expected [M+4H+]/4 = 1031.620 Da. Observed [M+4H+]/4 =
1031.619 Da.

Figure
S68. ESI-TOF spectrum for GCN4 variant QX2292. Expected [M+8H ]/8 = 1059.948 Da. Observed [M+8H ]/8 = 1059.948
Da.
+
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Figure S69. ESI-TOF spectrum for GCN4 variant QX2292s. Expected [M+6H+]/6 = 1412.928 Da. Observed [M+6H+]/6 =
1412.937 Da.

Figure S70. ESI-TOF spectrum for GCN4 variant DA 10811. Expected [M+4H+]/4 = 1103.282 Da. Observed [M+4H+]/4 =
1103.268 Da.

Figure S71. ESI-TOF spectrum for GCN4 variant 10792. Expected [M+4H+]/4 = 1024.618 Da. Observed [M+4H+]/4 =
1024.605 Da.
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Figure S72. ESI-TOF spectrum for GCN4 variant QX2291. Expected [M+8H+]/8 = 1063.698 Da. Observed [M+8H+]/8 =
1063.705 Da.

Figure S73. ESI-TOF spectrum for GCN4 variant QX2291s. Expected [M+8H+]/8 = 1063.698 Da. Observed [M+8H+]/8 =
1063.697 Da.
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Figure S74. ESI-TOF spectrum for GCN4 variant ZJ10313. Expected [M+4H+]/4 = 1066.768 Da. Observed [M+4H+]/4 =
1066.769 Da.

Figure S75. ESI-TOF spectrum for GCN4 variant ZJ10312. Expected [M+4H+]/4 = 1031.620 Da. Observed [M+4H+]/4 =
1031.613 Da.
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Figure S76. ESI-TOF spectrum for GCN4 variant QX2293. Expected [M+8H+]/8 = 1048.942 Da. Observed [M+8H+]/8 =
1048.948 Da.

Figure S77. ESI-TOF spectrum for GCN4 variant QX2293s. Expected [M+8H+]/8 = 1048.942 Da. Observed [M+8H+]/8 =
1048.948 Da.
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Figure S78. ESI-TOF spectrum for GCN4 variant ZJ10311. Expected [M+4H+]/4 = 1088.781 Da. Observed [M+4H+]/4 =
1088.781 Da.

Figure S79. ESI-TOF spectrum for GCN4 variant QX2294. Expected [M+8H+]/8 = 1059.948 Da. Observed [M+8H+]/8 =
1059.953 Da.

Figure S80. ESI-TOF spectrum for GCN4 variant QX2294s. Expected [M+8H+]/8 = 1059.948 Da. Observed [M+8H+]/8 =
1059.953 Da.
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Figure S81. ESI-TOF spectrum for GCN4 variant QX22951. Expected [M+4H+]/4 = 1103.282 Da. Observed [M+4H+]/4 =
1103.298 Da.

Figure S82. ESI-TOF spectrum for GCN4 variant QX22952. Expected [M+4H+]/4 = 1031.383 Da. Observed [M+4H+]/4 =
1031.397 Da.
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Figure S83. ESI-TOF spectrum for GCN4 variant QX2295. Expected [M+8H+]/8 = 1067.081 Da. Observed [M+8H+]/8 =
1067.088 Da.

Figure S84. ESI-TOF spectrum for GCN4 variant QX2295s. Expected [M+6H+]/6 = 1422.438 Da. Observed [M+6H+]/6 =
1422.428 Da.
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Figure S85. ESI-TOF spectrum for GCN4 variant QX3079. Expected [M+8H+]/8 = 1092.090 Da. Observed [M+8H+]/8 =
1092.075 Da.

Figure S86. ESI-TOF spectrum for GCN4 variant QX3095. Expected [M+4H+]/4 = 1082. 900 Da. Observed [M+4H+]/4 =
1082.906 Da.
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Figure S87. ESI-TOF spectrum for GCN4 variant ND1095. Expected [M+4H+]/4 = 1103.282 Da. Observed [M+4H+]/4 =
1103.277 Da.

Figure S88. ESI-TOF spectrum for GCN4 variant QX3096. Expected [M+8H+]/8 = 1092.839 Da. Observed [M+8H+]/8 =
1093.064 Da.

Figure S89. ESI-TOF spectrum for GCN4 variant QX3096s. Expected [M+8H+]/8 = 1092.839 Da. Observed [M+8H+]/8 =
1093.072 Da.
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Figure S90. ESI-TOF spectrum for GCN4 variant QX30983. Expected [M+4H+]/4 = 1088.781 Da. Observed [M+4H+]/4 =
1088.793 Da.

Figure S91. ESI-TOF spectrum for GCN4 variant QX30984. Expected [M+4H+]/4 = 1103.282 Da. Observed [M+4H+]/4 =
1103.282 Da.
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Figure S92. ESI-TOF spectrum for GCN4 variant QX30982. Expected [M+4H+]/4 = 1089.664 Da. Observed [M+4H+]/4 =
1089.671 Da.

Figure S93. ESI-TOF spectrum for GCN4 variant QX30981. Expected [M+4H+]/4 = 1031.383 Da. Observed [M+4H+]/4 =
1031.404 Da.

449

Figure S94. ESI-TOF spectrum for GCN4 variant QX3100. Expected [M+8H+]/8 = 1059.830 Da. Observed [M+8H+]/8 =
1060.067 Da.

Figure S95. ESI-TOF spectrum for GCN4 variant QX3101. Expected [M+8H+]/8 = 1096.221 Da. Observed [M+8H+]/8 =
1096.447 Da.

Figure S96. ESI-TOF spectrum for GCN4 variant QX3101s. Expected [M+7H+]/7 = 1252.680 Da. Observed [M+7H+]/7 =
1253.046 Da.
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Figure S97. ESI-TOF spectrum for GCN4 variant ZJ10492. Expected [M+4H+]/4 = 1088.781 Da. Observed [M+4H+]/4 =
1088.770 Da.

Figure S98. ESI-TOF spectrum for GCN4 variant ZJ10452. Expected [M+4H+]/4 = 1031.620 Da. Observed [M+4H+]/4 =
1031.596 Da.
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Figure S99. ESI-TOF spectrum for GCN4 variant ZJ10511. Expected [M+8H+]/8 = 1059.948 Da. Observed [M+8H+]/8 =
1060.067 Da.

Figure S100. ESI-TOF spectrum for GCN4 variant ZJ10511s. Expected [M+8H+]/8 = 1059.948 Da. Observed [M+8H+]/8 =
1060.086 Da.

Figure S101. ESI-TOF spectrum for GCN4 variant ZJ10493. Expected [M+4H+]/4 = 1088.781 Da. Observed [M+4H+]/4 =
1088.763 Da.
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Figure S102. ESI-TOF spectrum for GCN4 variant ZJ10494. Expected [M+4H+]/4 = 1031.620 Da. Observed [M+4H+]/4 =
1031.601 Da.

S103. ESI-TOF spectrum for GCN4 variant QX31101. Expected [M+4H+]/4 = 1088.781 Da. Observed [M+4H+]/4 =
1088.789 Da.
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Figure

Figure S104. ESI-TOF spectrum for GCN4 variant QX31102. Expected [M+4H+]/4 = 1031.620 Da. Observed [M+4H+]/4 =
1031.629 Da.

Figure S105. ESI-TOF spectrum for GCN4 variant QX31172. Expected [M+8H+]/8 = 1059.948 Da. Observed [M+8H+]/8 =
1060.088 Da.

Figure S106. ESI-TOF spectrum for GCN4 variant QX31172s. Expected [M+7H+]/7 = 1211.225 Da. Observed [M+7H+]/7 =
1211.388 Da.
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Figure S107. ESI-TOF spectrum for GCN4 variant QX31171. Expected [M+8H+]/8 = 1059.948 Da. Observed [M+8H+]/8 =
1060.086 Da.

Figure S108. ESI-TOF spectrum for GCN4 variant ZJ10551. Expected [M+4H+]/4 = 1033.752 Da. Observed [M+4H+]/4 =
1033.751 Da.
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Figure
S109. ESI-TOF spectrum for GCN4 variant QX3118. Expected [M+8H+]/8 = 1032.434 Da. Observed [M+8H+]/8 = 1032.541
Da.

Figure S110. ESI-TOF spectrum for GCN4 variant ZJ1056. Expected [M+8H+]/8 = 1062.950 Da. Observed [M+8H+]/8 =
1063.073 Da.
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Figure S111. ESI-TOF spectrum for Affibody variant CD1054. Expected [M+5H+]/5 = 1341.102 Da. Observed [M+5H+]/5 =
1341.106 Da.

Figure S112. ESI-TOF spectrum for Affibody variant QX3102. Expected [M+5H+]/5 = 1339.102 Da. Observed [M+5H+]/5 =
1339.123 Da.

Figure S113. ESI-TOF spectrum for Affibody variant QX3106. Expected [M+5H+]/5 = 1387.927 Da. Observed [M+5H+]/5 =
1387.915 Da.
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5.5.6. Analytical HPLC data

Figure S114. Analytical HPLC Data for GCN4 variant QX2271. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S115. Analytical HPLC Data for GCN4 variant QX2283. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S116. Analytical HPLC Data for GCN4 variant QX2289. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S117. Analytical HPLC Data for GCN4 variant QX2289s. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

459

Figure S118. Analytical HPLC Data for GCN4 variant QX2291. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S119. Analytical HPLC Data for GCN4 variant QX2291s. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S120. Analytical HPLC Data for GCN4 variant QX2292. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S121. Analytical HPLC Data for GCN4 variant QX2292s. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S122. Analytical HPLC Data for GCN4 variant QX2293. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S123. Analytical HPLC Data for GCN4 variant QX2293s. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S124. Analytical HPLC Data for GCN4 variant QX2294. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S125. Analytical HPLC Data for GCN4 variant QX2294s. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S126. Analytical HPLC Data for GCN4 variant QX2295. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S127. Analytical HPLC Data for GCN4 variant QX2295s. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure
S128. Analytical HPLC Data for GCN4 variant QX3079. Protein solution was injected onto a C18 analytical column and
eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S129. Analytical HPLC Data for GCN4 variant QX3096. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S130. Analytical HPLC Data for GCN4 variant QX3096s. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S131. Analytical HPLC Data for GCN4 variant QX3100. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S132. Analytical HPLC Data for GCN4 variant QX3101. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S133. Analytical HPLC Data for GCN4 variant QX3101s. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S134. Analytical HPLC Data for GCN4 variant ZJ10511. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S135. Analytical HPLC Data for GCN4 variant ZJ10511s. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes,
followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S136. Analytical HPLC Data for GCN4 variant QX31171. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes,
followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S137. Analytical HPLC Data for GCN4 variant QX31172. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes,
followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S138. Analytical HPLC Data for GCN4 variant QX31172s. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes,
followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S139. Analytical HPLC Data for GCN4 variant QX3118. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by
a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S140. Analytical HPLC Data for native affibody variant CD1054. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes,
followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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Figure S141. Analytical HPLC Data for affibody mutant QX3102. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes,
followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S142. Analytical HPLC Data for stapled affibody mutant QX3106. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50
minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

Figure S143. Analytical HPLC Data for stapled affibody mutant ZJ1056. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A = H2O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes,
followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.
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5.5.7 Synthesis of PEGylated Asn derivative and branched Y-shape PEG.
Oxybis(ethane-2,1-diyl) dimethanesulfonate (QX2227)

Methanesulfonyl chloride (14.3 g, 125 mmol) was added dropwise to a stirred solution of 2,2'oxybis(ethan-1-ol) (5.3 g, 50 mmol) and TEA (15.2 g, 150 mmol) in dichloromethane (200 mL) at 0 °C.
After the addition was complete, the resulting mixture was stirred at r.t. for 12 hrs. Water was added to
quench the reaction. The organic phase was separated, and the aqueous phase was extracted with
dichloromethane (2 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL),
dried with anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation to
afford 13.1 g of colorless oil, which was used in the next step without purification. Yield quantitative.
MS(ESI-TOF) m/z calc. for C6H15O7S2+ 263.03, found 263.02 [M+H+]; calc. for C6H18NO7S2+
280.05, found 280.05 [M+NH4+].
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1-Azido-2-(2-azidoethoxy)ethane (QX2228)
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To a solution of NaN3 (9.7 g, 150 mmol) in DMF (200 mL) was added QX2227 (13.1 g, 50 mmol) at
room temperature. The reaction mixture was heated to 70 Celsius degree and stirred for 12 hours. The
crude mixture was diluted with 400 mL of water and extracted with DCM (200 mL) for 3 times. The
combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate,
filtered, and the solvent was removed by rotary evaporation to afford 8.32 g of yellow oil. Yield
quantitative. The crude product was used in the next step without further purification. The product was
confirmed by Crude NMR: 1H-NMR (300 MHz, Chloroform-d) δ 3.71 (t, J = 4.8 Hz, 4H), 3.44 (t, J =
4.8 Hz, 4H). 13C-NMR (126 MHz, Chloroform-d) δ 70.10, 50.76.
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2-(2-Azidoethoxy)ethan-1-amine (QX2229)
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Triphenylphosphine (11 g, 45 mmol, 0.9 eq.) dissolved in ether (80 mL) was added to a solution of
QX2228 (8.32 g, 50 mmol) in Ether/THF/ 1M aqueous HCl (50 mL/100 mL/50mL). Addition was
performed over a period of 3 hours at room temperature and the reaction was stirred overnight. Phases
were separated by a separation funnel and the organic layer was washed with 4M HCl aqueous solution.
The combined aqueous layer was adjusted to pH 14 with sodium hydroxide powder. Product was then
extracted with DCM (3 × 80 mL). Combined organic layer was dried over anhydrous sodium sulfate and
filtered. After removal of the solvent under reduced pressure, a yellow oil was afforded (4.3 g, yield
66%), which was used in the next step without purification. MS(ESI-TOF) m/z calc. for C4H11N4O+
131.09, found 131.09 [M+H+ ].
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tert-Butyl N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(2-(2-azidoethoxy)ethyl)-L-asparaginate
(QX2230)

To N-Fmoc-O-tBu Asp (4.9 g, 12 mmol) dissolved in dry DMF (60 ml) was added HATU (7.4 g, 18
mmol), HOBT (2.4 g, 18 mmol), DIPEA (6.3 ml, 36 mmol). Then the mixture was stirred for 15 minutes
at room temperature. Then compound QX2229 (1.9 g, 15 mmol, dissolved in 10 ml DMF) was added to
the mixture and the mixture was stirred for another 2 hours at room temperature. Upon completion of the
reaction monitored by TLC, 120 ml water was added to the flask and extracted 3 times with ethyl acetate
(50 mL). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate
and evaporated to dryness. The crude was purified by chromatography (EA/Hexane 1:1 to 1:0);
MS(ESI-TOF) m/z calc. for C27H34N5O6+ 524.25, found 524.25 [M+H+]; 1H NMR (500 MHz,

Chloroform-d) δ 7.75 (d, J = 7.5 Hz, 2H), 7.60 (dd, J = 7, 3.5 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.30 (t, J
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= 7.5 Hz, 2H), 6.25 (br.s., 1H), 6.15 (d, J = 8 Hz, 1H), 4.52-4.48 (m., 1H), 4.39 (t, J = 7.5 Hz, 1H), 4.31
(t, J = 7.5 Hz, 1H), 4.22 (t, J = 7.5 Hz, 1H), 3.58 (t, J = 5 Hz, 2H), 3.50 (t, J = 5 Hz, 2H), 3.44 (d, J =
4.5 Hz, 2H), 3.29 (t, J = 4 Hz, 2H), 2.87 (dd, J = 15.5, 4.5 Hz, 1H), 2.72 (dd, J = 15.5, 4.5Hz, 1H), 1.47
(s, 9H). 13C NMR (500 MHz, Chloroform-d) 170.15, 170.01, 156.24, 143.93, 143.81, 141.25, 127.71,
127.10, 127.08, 125.25, 125.20, 119.96, 82.29, 70.05, 69.59, 67.14, 51.42, 50.49, 47.10, 39.19, 37.91,
27.91.
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N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-(2-(2-azidoethoxy)ethyl)-L-asparagine (QX2232)
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Compound QX2230 (1.0 g, 1.9 mmol) was dissolved in a mixture of TFA (3 ml) and water (150 uL).
Then the reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction,
TFA and water were removed by rotary evaporation. Yield quantitative. The crude was used directly for
peptide synthesis without purification. MS(ESI-TOF) m/z calc. for C23H27N5O6+ 469.20, found
469.19 [M+H+].
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2,5-Dioxopyrrolidin-1-yl (2,5,8,11-tetraoxatridecan-13-yl) carbonate (QX3065)

To a solution of 2,5,8,11-tetraoxatridecan-13-ol (2.08 g, 10 mmol), and bis(2,5-dioxopyrrolidin-1-yl)
carbonate (3.84 g, 15 mmol), was added 4.16 mL (30 mmol) TEA. The resulting solution was stirred at
r.t. for 3 hours. After the reaction was completed, monitored by TLC, the ACN solvent was removed and
100 mL DCM was added. Then the solution was washed with 5% sodium bicarbonate (50 mL× 3) then
with water (50 mL × 2). The organic layer was then dried over sodium sulfate, filtered, and evaporated
with reduced pressure to give us the crude product as colorless oil. Yield quantative. The crude was used
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in the next step without purification. MS(ESI-TOF) m/z calc. for C14H24NO9+ 350.14, found 350.15
[M+H+]; calc. for C14H27N2O9+ 367.17, found 367.17 [M+NH4+].
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2,2'-((Azanediylbis(ethane-2,1-diyl))bis(oxy))bis(ethan-1-ol) (QX3061)

Add a solution of 2-(2-chloroethoxy)ethanol (6.4 mL, 60 mmol) in toluene(15 mL) dropwise to a stirred
refluxing mixture of 2-(2-aminoethoxy)ethanol (24 mL, 240 mmol) and Na2CO3 (7 g, 66 mmol) in
toluene (150 mL) in a flask fitted with Dean-Stark apparatus. Then the mixture was heated to 120
Celsius degree for 4 days. The solids were removed by filtration after the mixture was cooled to room
temperature. The residue was washed by ether and the combined filtrates were concentrated in vacuo.
The crude residue was purified by distillation. MS(ESI-TOF) m/z calc. for C8H20NO4+ 194.14, found
194.14 [M+H+]. 1H NMR (300 MHz, Chloroform-d) δ 3.72 (t, J = 4 Hz, 4H), 3.66-3.60 (m, 8H), 2.86
(t, J = 5.1 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) 72.71, 69.79, 61.63, 48.94.
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15-Oxo-16-(2-(2-(tosyloxy)ethoxy)ethyl)-2,5,8,11,14,19-hexaoxa-16-azahenicosan-21-yl 4methylbenzenesulfonate (QX3072)
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QX3065 (525 mg, 1.5 mmol) was added to a mixture of QX3061 (193 mg, 1.0 mmol) and TEA (415 uL,
3.0 mmol) in DCM (5 mL) at room temperature. Then the mixture was stirred at room temperature for
12 hours. Then additional TEA (276 uL, 2.0 mmol) was added to the mixture followed by 762 mg of
TsCl (4.0 mmol). The reaction was stirred at room termperature for another 18 hours. Then the reaction
was quenched with water, and the organic layer was further washed with sodium bicarbonate (5%) and
brine. The crude was purified by chromatography (pure EA as mobile phase). MS(ESI-TOF) m/z calc.
for C32H52N2O14S2+ 753.29, found 753.29 [M+NH4+]. 1H NMR (300 MHz, Chloroform-d) δ 7.82 (t, J

= 8.1 Hz, 4H), 7.37 (t, J = 8.1 Hz, 4H), 4.23 (t, J = 5.1 Hz, 2H), 4.16 (t, J = 4.5 Hz, 4H), 3.71-3.65 (m,
16H), 3.58-3.52 (m, 6H), 3.42 (t, J = 5.4 Hz, 4H), 3.40 (s, 3H) 2.47 (s, 6H). 13C NMR (126 MHz,
Chloroform-d) 156.05, 144.90, 132.93, 129.91, 127.97, 71.94, 70.61, 70.59, 70.54, 70.44, 70.01, 69.72,
69.51, 69.24, 68.44, 68.34, 67.45, 59.07, 48.20, 47.75, 21.69.
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2,5,8,11-Tetraoxatridecan-13-yl bis(2-(2-azidoethoxy)ethyl)carbamate (QX3075)

To a solution of NaN3 (77 mg, 1.2 mmol) in DMF (2 mL) was added QX3072 (219 mg, 0.29 mmol) at
room temperature. The reaction mixture was heated to 70 Celsius degree and stirred for 12 hours. The
crude mixture was diluted with 4 mL of water and extracted with DCM (2 mL) for 3 times. The
combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate,
filtered, and the solvent was removed by rotary evaporation to afford 138 mg of product as colorless oil.
Yield quantitative. MS(ESI-TOF) m/z calc. for C18H39N8O8+ 495.29, found 495.29 [M+NH4+]. 1H

NMR (300 MHz, Chloroform-d) δ 4.23 (t, J = 5.1 Hz, 2H), 3.69 (t, J = 4.5 Hz, 2H), 3.66-3.61 (m, 18H),
3.55-3.54 (m, 6H), 3.38 (s, 3H), 3.37-3.35 (m, 4H),. 13C NMR (126 MHz, Chloroform-d) 156.05, 71.93,
70.61, 70.53, 70.44, 69.92, 69.86, 69.78, 69.66, 69.53, 64.41, 59.03, 50.77, 48.37, 47.94.
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6. Conclusions
We investigated the impact of PEG on the strength of vicinal salt bridges in chapter 2. We placed
4-unit-PEG-chain functionalized amino acids near salt bridges within different peptides, including GCN4
dimer, WW domain, 1CW trimer to explore the impact from PEG on the strength of salt bridges whose
residues are from the same helix, from a β-turn, from an adjacent β-strand, from an opposite helix, and
from two different helices. Strength of salt bridges were enhanced by PEG chain in some cases, whereas
in other cases, the PEG chain had no impact on the nearby salt bridges, leading us to conclude that the
PEG chain can enhance its nearby salt bridges though its effect is not universal. The precise structural
prerequisite is not a simple function of secondary structure context. The crystal structure of PEGylated
GCN4 variant, within which the PEG chain enhanced the strength of a nearby salt bridge, indicated the
PEG chain increase the salt bridge interaction via desolvation effect. One potential explanation for the
diverse effect of PEG-based salt-bridge enhancement is that the linker we used for each case is different
from one to the other, and we have previously shown that the linker choice did make a difference for PEG
based conformational stability. Different orientation of PEG chain from different linkers for PEGylation,
combined with salt bridges from different structural contexts may lead to the PEG chain pose different
proximities to its nearby salt bridge. One potential future direction could be locking the PEG chain near
the salt-bridge residues via macrocyclization so that the proximity of PEG chain to the vicinal salt bridges
can be fixed from case to case. The same approach can also be applied to the impact from PEG on other
non-covalent interactions.
In chapter 3 and chapter 4, we combined the PEG-based conformational enhancement with
macrocyclization-based conformational constraint to increase the conformational stability of WW domain.
We found that the PEG staple can combine the stabilization effect from both PEGylation and
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macrocyclization to increase the conformational stability of WW domain. We also found that five-unit
PEG staple can stabilize a β-turn to the largest extent and PEG staples longer than that are not optimal
presumably due to the limited constraint the PEG staple can apply to the β-turn. And the stapling effect
became unfavorable when the PEG staple is too short (3- or 4- unit PEG), which is likely because the short
PEG staple might limit those sidechains to adopt their native conformations. We also found that stapling
effect was more significant when the PEG staple is placed at positions that are far away in primary
sequence but close in tertiary structure compared with the stapling effect from PEG staple crossing a βturn. The rationale for the increased stabilization effect from long-ranged PEG staple is that the freedom
degree can be much more limited when sites are far away from each other are fixed via stapling, leading
to a less entropy penalty over the process of folding. The stapling effect from long-range PEG staple is
independent of PEG stabilizing effect, suggesting that sites that are far away from each other in primary
sequence but close in tertiary structure is the most important criteria for long-range PEG stapling. The
guideline for PEG stapling β-sheet-based structure is that 1) stapling inter-strand sites that are far away
from each other in primary sequence but close in tertiary structure is the most important criteria; 2) the
amount of stapling effect from PEG staple crossing a single β-turn is marginal. 3) sites that are from two
different loops in a β-sheet based tertiary structure also meet the long-range criteria and can also be
favorable sites for PEG stapling; 4) Olefin-metathesis and Click chemistry can be used interchangeably
for PEG stapling.
In chapter 5, we investigated the impact of PEG staple on the stability of coiled-coild tertiary
structure. We concluded that e/g’ positions are more favorable for inter helical PEG stapling than other
solvent-exposed positions, including b/c’ and f/b’ positions, which is because residues from e/g’ positions
are flanking the interhelical interface and more proximate to each other than other solvent-exposed
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residues. We also concluded that salt-bridged e/g’ positions are more favorable than non-salt-bridged e/g’
positions, which is likely because PEG staple crossing non-salt-bridged positions might shift the two
helical monomers in a way that the other interhelical salt bridges get compromised. We also concluded
that for non-salt bridges e/g’ position stapling, sites that are far from the terminal disulfide bond are more
favorable for interhelical PEG stapling due to the same reason for long-range PEG stapling on β-sheet,
which is the freedom of the two helical dimers can be more limited when the staple and the disulfide bond
are located at the two termini of the coiled coil dimer. We also concluded that longer PEG chain is more
favorable for f/b’ stapling. Besides, two-component stapling strategy is more convenient for PEG staple
engineering and can stabilize coiled coil similarly to the intramolecular stapling. Y-shape PEG staple that
combines PEGylation and PEG stapling can gain the coiled coil more conformational stability compared
to the linear shape PEG staple, which is likely because of the desolvation effect of PEG chain on the
adjacent interhelical salt bridges. The interhelical PEG staple with heterochiral chemistry stabilize the
coiled coil similarly to that of PEG staple with homochiral chemistry, which is because the D-amino acid
itself is not favorable for the stabilization of helical structure. A coiled-coil-based small protein HER-2
affibody can get stabilized with interhelical PEG staple at e/g positions. The guidelines for interhelical
PEG stapling can be summarized as 1) salt-bridged e/g’ positions that are farther away to another covalent
linkage within the coiled coil are optimal; 2) non-salt-bridged e/g’ positions can also significantly stabilize
the coiled coil if there is no salt-bridged e/g’ positions within a given coiled coil; 3) two-to four-unit PEG
chain is ideal for salt-bridged e/g’-position stapling; 4) longer PEG chain (ideally more than eight-unit
PEG chain) are more favorable for stapling f/b’ positions; 5) Y-shape branched PEG staple can gain the
coiled coil more stability than linear shape PEG staple; 6) interhelical PEG staple can be used
independently to stabilize coiled coil without the presence of disulfide bond. The future directions could
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be 1) testing the target binding affinity of PEG stapled HER-2 affibody since theoretically, target binding
affinity should also get improved with enhanced conformational stability; 2) replacing the disulfide bond
with another interhelical PEG staple since the low abundance of interhelical disulfide bond in nature; 3)
placing PEG chain between two terminal interhelical PEG staple to further constrain the conformational
stability and desolvate the salt bridges in between, which should maximize the stabilization effect from
both stapling and PEG-based desolvation.
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